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Ankle foot orthoses (AFO’s) are prescribed to patients who have ankle 
impairments causing difficulty walking following stroke. The evidence regarding the 
benefit of prescribing AFO’s, particularly with regard to type of AFO and timing of 
intervention, is unclear.  There are few studies that investigate the effect of AFO’s in 
the subacute phase following stroke and few studies that compare different types of 
AFO. There is little evidence regarding the effect of AFO’s on the gait of normal 
healthy individuals. This study aimed to compare the effects on walking in different 
AFO’s, of varying degrees of rigidity, in participants in the early stages of stroke 
walking recovery and in healthy individuals.   
Thirteen participants (ten male) in the subacute phase of stroke recovery, 
aged 23-71 years (M=52.3+13.9), and thirteen age and gender matched healthy 
participants, aged 26-70 years (M=52.2 +13.1), were recruited to the study. Stroke 
participants were included if they had a unilateral hemiparesis, were less than 20 
weeks post stroke, able to walk with or without supervision and had a motor deficit of 
the ankle dorsiflexors. 
Temporal distance gait measures were collected using the GAITRite mat (CIR 
Systems GRG-24, United States, 80Hz) and knee angles throughout the stance 
phase, were collected using  Silicon Coach Pro software™ (version 7, Silicon Coach 
Pty Ltd, Dunedin, New Zealand). Stroke participants were tested across three 
consecutive days, whilst the healthy participants were tested on a single occasion in 
barefoot, shoes, and three AFO types of varying rigidity: push aequi brace, spring 
leaf AFO and in a fibreglass cast Each group of participants were familiarised to 
walking in each AFO. Group differences across the five conditions were assessed 
using the Friedman’s Test. The ‘smallest real difference’ measure was used to 
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determine the degree of individual improvement with use of the AFOs compared to 
the shod walking 
The results indicated the healthy participants walking performance exceeded 
that of the stroke participants for velocity, cadence, double limb support, step length, 
single support phase, single support symmetry, but not swing phase or knee angle at 
initial contact, midstance or terminal stance for each of conditions tested. Group 
analysis demonstrated that use of an AFO did not improve walking for the stroke 
participants: who walked at 46.0 cm/sec (SD: 25.9) in shoes, compared with 46.9 
cm/sec (SD: 24.4) in an AFO (p= 0.507).  However it caused deterioration in walking 
in the healthy participants, as demonstrated by a 11.9cm/sec deterioration in a AFO 
(120.1cm/sec +14.2)  in comparison to shoes (132.0cm/sec +16.1) (p=0.002) with 
similar deteriorations in cadence (shoe: 113.1 steps/minute +7.1; AFO: 102.2 +30.7; 
p=0.009), step length (shoe: 69.9cm +7.9; AFO: 66.0 +7.2; p=0.002), single stance 
phase (shoe: 37.1% +1.3; AFO 36.0 +1.3; p=0.009), swing phase (shoe: 37.2% +1.4; 
AFO: 37.7 +1.1; p=0.039), stance symmetry (shoe: -0.63 +2.9; AFO: -4.9 +3.1; 
p=0.004) and knee angle at initial contact (shoe: 1.92 degrees +3.9; AFO:3.6 +2.6; 
p=0.049). The results demonstrating the more rigid the AFO the greater the 
deterioration for the healthy participants. The smallest real differences of the stroke 
group indicated that for five participants at least one type of AFO improved their 
walking. 
The findings of this study do not support the routine prescription of AFO’s 
following stroke to patients with ankle impairment. As the walking of the healthy 
participants deteriorated, there is the suggestion that the application of an AFO may 
be detrimental. As AFO’s have been demonstrated to improve walking performance 
by increasing velocity, step length or affected leg stance percentage of the gait cycle 
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for some participants the prescription of an AFO should not be discounted. Prior to 
prescription of an AFO to a stroke patient careful assessment should occur. 
Following the prescription of an AFO ongoing assessment is required to examine 
whether the   AFO yields a benefit.  Future research should consider the analysis of 







Table of Contents 
Cover/Title page          i 
Statement of Source          ii 
Abstract            iii 
Table of contents          vi 
List of Figures          xiv 
List of Tables          xvi 




















Table of Contents 
1.0 Chapter One            1 
1.0 Introduction and overview of project      2 
1.1 Ankle Foot Orthosis        3 
1.2 General Objectives         5 
1.3 Research Hypotheses        6 
1.4 Summary          8 
2.0 Chapter Two           9 
2.0 Literature Review         10 
2.1 Stroke          10 
2.1.1 Causes of stroke       11 
2.1.2 Consequences of stroke      14 
2.1.3 Recovery following stroke      17 
 2.1.3.1 Neuroplasticity/Recovery of function  
from stroke       17 
2.1.4 Treatment approaches following stroke    21 
2.1.5 Walking        23 
2.1.5.1Normal gait       23 
2.1.5.2 Measuring walking      29 
2.1.6 Walking in stroke       31 
2.1.6.1 Ankle Impairments in stroke    35 
2.2 Ankle Foot Orthosis        37 
2.2.1 Biomechanics of AFO’s      37 
2.2.2 Effect of AFO’s       38 
2.2.2.1 Prescription of AFO’s     40 
viii 
 
2.2.2.2 AFO’s in stroke      41 
 2.2.2.2.1 Type of AFO’s     66 
 2.2.2.2.2 The effect of ankle impairment on 
       on response to AFO’s    67 
 2.2.2.2.3 The duration following stroke at which the 
       the AFO was assessed    68 
 2.2.2.2.4 The walking ability of participant’s at  
                 assessment     69 
2.2.3 Summary of considerations regarding AFO 
 prescription                  69 
2.3 Summary        70 
3.0 Chapter Three           72 
3.0 Methods          73 
3.1 Research Design        74 
3.2 Participants         74 
3.2.1 Recruitment of Stroke Participants     74 
3.2.2 Recruitment of Healthy Participants    75 
3.2.3 Inclusion/Exclusion Criteria      76 
3.2.3.1 Inclusion/Exclusion Criteria  
Stroke Participants      76 
3.2.3.2 Inclusion criteria Healthy participants   78 
  3.2.4 Participant Groups       79 
   3.2.4.1 Stroke Group      79 




3.3 Measures         80 
 3.3.1Spatiotemporal measures of gait     80 
 3.3.2 Kinematic measures       82 
 3.3.3 Demographics       84 
 3.3.4 Physical assessment tests      84 
3.3.4.1 Range of movement     84 
3.3.4.2 Tone        84 
3.3.4.3 Active motor control     86 
3.3.4.4 Sensation and proprioception    88 
 3.4 Interventions - AFO’s        89 
   3.4.1 Push Aequi Brace (PAB)     89 
   3.4.2 Spring Leaf AFO (SLAFO)     90 
   3.4.3 Fibreglass Cast (FGC)     90 
3.5 Procedures         91 
3.5.1 Physical Assessment      93 
 3.5.1.1 Demographics assessment    93 
 3.5.1.2 Range of Movement     98 
 3.5.1.3 Tone        96 
 3.5.1.4 Active motor control     96 
  3.5.1.4.1 Quadriceps     97 
  3.5.1.4.2 Tibialis Anterior     98 
 3.5.1.5 Sensation and Proprioception    100 
3.5.2 Gait assessment procedure      101 
 3.5.2.1 Reliability procedure     105 
3.5.3 Spatiotemporal data       105 
x 
 
3.5.4 Kinematic data       105 
3.5 Data Analysis         107 
4.0 Chapter Four            112 
4.0 Results          113 
4.1 Reliability sub-study        114 
 4.1.1 Test retest reliability       114 
 4.1.2 Interrater reliability       115 
4.2 General characteristics of the stroke and healthy participants  117 
4.3 Shod walking compared to barefoot walking    124 
 4.3.1 Stroke participants compared to healthy participants  124 
 4.3.2 Shod walking compared to barefoot walking of stroke  
  participants         129 
 4.3.3 Shod walking compared to barefoot walking of healthy 
  participants        129 
4.4 Shod walking compared to all AFO’s      130 
 4.4.1 Stroke participants compared to healthy participants  130 
 4.4.2 Shod walking compared to walking in all AFO’s of  
  stroke participants       135 
 4.4.3 Shod walking compared to walking in all AFO’s of  
  healthy participants       135 
4.5 Shod walking in comparison to AFO’s of varying rigidity   136 
 4.5.1 Stroke participants compared to healthy participants  136 
  4.5.1.1 Comparison of the push aequi brace between 
   stroke and healthy participants    137 
   
xi 
 
4.5.1.2 Comparison of the spring leaf AFO between 
   stroke and healthy participants    138 
  4.5.1.3 Comparison of the fibreglass cast between 
   stroke and healthy participants    139 
 4.5.2 Comparison of shod walking and AFO’s of varying  
  rigidity in stroke participants     150 
 4.5.3 Comparison of shod walking and AFO’s of varying  
  rigidity in stroke participants     150 
4.6 Smallest real differences of the stroke group    152 
 4.6.1 Stroke participants’ smallest real differences   152 
 4.6.2 Stroke participants Individual Responses    154 
  4.6.2.1 Shod versus barefoot for individual participants 154 
  4.6.2.2 Shod versus PAB      155 
  4.6.2.3 Shod versus SLAFO     155 
  4.6.2.4 Shod versus FGC      155 
  4.6.2.5 Differences between AFO conditions   156 
 4.6.3 Stroke participants’ identification of responders and  
  non-responders       164 
 4.6.4 Case Studies        165 
  4.6.4.1 Stroke Participant Two     166 
  4.6.4.2 Stroke Participant Six     167 
  4.6.4.3 Stroke Participant Seven     168 
4.7 Smallest real differences of the healthy participant group   169 
 4.7.1 Individual responses       171 
  4.7.1.1 Shod versus barefoot     171 
xii 
 
  4.7.1.2 Shod versus PAB      172 
  4.7.1.3 Shod versus SLAFO      172 
  4.7.1.4 Shod versus FGC      172 
  4.7.1.5 Differences between AFO conditions   173 
5.0 Chapter Five           179 
5.0 Discussion         180 
5.1 The effects of AFO’s on spatiotemporal variable of gait 
 following stroke        180 
5.2 The effects of AFO’s on healthy participants    190 
5.3 The effects of AFO’s of varying rigidity     191 
5.4 Other considerations knees analysis      193 
 5.4.1 Reliability of the kinematic data     193 
 5.4.2 Knee analysis of the stroke group     198 
 5.4.3 Knee analysis of the healthy group     195 
5.5 Potential indicators of responders to AFO’s     196 
5.6 Issues regarding variability in study design in the AFO literature  196 
 5.6.1 Inclusion/Exclusion Criteria      196 
  5.6.1.1 Walking ability      197 
  5.6.1.2 Ankle impairment      198 
  5.6.1.3 Previous AFO use      198 
  5.6.1.4 Duration of stroke      199 
5.7 Limitations of the study        201 
5.8 Implications for further research      205 





References            208 
List of Appendices         220 
Appendix A  Ethics approval from St. Vincent’s Health   221 
Appendix B  Reciprocal ethics approval from Australian  
Catholic University       223 
Appendix C  Stroke participant consent forms                                           224 
 Appendix D  Healthy participant consent forms              230 
Appendix E  Summary of the Tardieu Scale     232 
Appendix F  Box Plot – Individual stroke group velocity   235 
Appendix G  Box Plot – Individual stroke group double limb support  236 
Appendix H  Smallest Real difference bar graph– Individual  
stroke group        237 
Appendix I  Box Plot - Affected leg single support phase   238 
Appendix J  Box Plot – Individual stroke group stance  
symmetry ratio       239 
Appendix K  Box Plot – Individual stroke group affected leg  
step length        240 
Appendix L  Smallest Real difference bar graph –  
Individual stroke group affected leg swing phase  241 
Appendix M  Box Plot – Individual stroke group affected leg  
swing phase        242 
Appendix N  Smallest Real difference bar graph –  
Individual stroke group cadence     243 




Appendix P  Box Plot – Individual stroke group knee angle  
at initial contact       245 
Appendix Q  Box Plot – Individual stroke group knee angle  
at midstance        246 
Appendix R  Box Plot – Individual stroke group knee angle  
at terminal stance       247 
Appendix S  Box Plot – Individual healthy group velocity   248 
Appendix T  Box Plot – Individual healthy group double limb support 249 
Appendix U  Smallest Real difference bar graph – Individual  
healthy group matched leg single support phase  250 
Appendix V  Box Plot – Individual healthy group matched  
leg single support phase      251 
Appendix W  Box Plot – Individual healthy group stance symmetry ratio 252 
Appendix X  Box Plot – Individual healthy group matched leg  
step length        253 
Appendix Y  Smallest Real difference bar graph – Individual  
healthy group matched leg swing phase    254 
Appendix Z  Box Plot – Individual healthy group matched leg  
swing phase        255 
Appendix AA Smallest Real difference bar graph – Individual  
healthy group cadence      256 
Appendix AB Box Plot – Individual healthy group cadence   257 
Appendix AC Smallest Real difference bar graph – Individual  




Appendix AD Box Plot – Individual healthy group knee angle  
at initial contact       259 
Appendix AE Smallest Real difference bar graph – Individual  
healthy knee angle at midstance     260 
Appendix AF Box Plot – Individual healthy group knee angle  
at midstance        261 
Appendix AG Box Plot – Individual healthy group knee angle at  




List of Figures 
Figure 2.1   Outline of the subsections of stroke    11 
Figure 2.2   Pathogenesis and pathophysiology of stroke   13 
Figure 2.3   Schematic representation of the phases              19 
of recovery following stroke  
Figure 2.4   Phases of the gait cycle      26 
Figure 2.5   Spring leaf AFO components     38 
Figure 3.1  Photograph of the GAITRite ® Mat used in this study   82 
Figure 3.2    AFO’s used in the study      89 
Figure 3.3   Flowchart of examination and testing     92 
Figure 3.4  ROM assessment in prone, knee extended   94 
Figure 3.5   ROM assessment in prone, knee flexed    95 
Figure 3.6   ROM assessment, position of the goniometer   95 
Figure 3.7  Assessment of spasticity      96 
Figure 3.8  Assessment of quadriceps strength    98 
Figure 3.9  Assessment of tibialis anterior strength    99 
Figure 3.10  STREAM Assessment      100 
Figure 3.11  Flowchart of testing procedure for stroke participants  103 
Figure 3.12  GAITRite ® and video camera set-up    106 
Figure 3.13  Example of the SiliconCoach output    107 
Figure 4.1   Stroke group bar graph demonstrating mean difference 
   of velocity        157 
Figure 4.2   Stroke group bar graph demonstrating mean difference 




Figure 4.3   Stroke group bar graph demonstrating mean difference 
   of single stance symmetry ratio     159 
Figure 4.4   Stroke group bar graph demonstrating mean difference 
   of affected leg step length      160 
Figure 4.5  Stroke group bar graph demonstrating mean difference 
   of knee angle at initial contact     161 
Figure 4.6  Stroke group bar graph demonstrating mean difference 
   of knee angle at midstance     162 
Figure 4.7  Stroke group bar graph demonstrating mean difference 
   of knee angle at terminal stance     163 
Figure 4.8  Healthy group bar graph demonstrating mean difference 
   of velocity        174 
Figure 4.9   Healthy group bar graph demonstrating mean difference 
   of double limb support      175 
Figure 4.10  Healthy group bar graph demonstrating mean difference 
   of single stance symmetry ratio     176 
Figure 4.11   Healthy group bar graph demonstrating mean difference 
   of matched leg step length      177 
Figure 4.12  Healthy group bar graph demonstrating mean difference 





List of Tables 
Table 2.1   Description of the phases of recovery     20 
following stroke          
Table 2.2   Description of the phases of gait     27 
Table 2.3   Hemiplegic gait       32 
Table 2.4   Summary of normative values for spatiotemporal 
parameters of people with stroke      34 
Table 2.5  A summary table of the types of AFO’s    43 
Table 2.6   Studies identified which assess or compare AFO’s  46  
Table 3.1   Inclusion criteria for the stroke participants   76 
Table 3.2   Exclusion criteria for the stroke participants   77 
Table 3.3   Inclusion criteria for the healthy participants   78 
Table 3.4   Summary of the dependent variables    83 
Table 3.5  Modified Tardieu Scale      85 
Table 3.6  STREAM        87 
Table 3.7  Oxford Scale        88 
Table 3.8  Method of applying the FGC     104 
Table 3.9  Categorisation of ankle impairments for responders 
   and non-responders      109 
Table 4.1  Test retest reliability       115 
Table 4.2  Interrater reliability       116 
Table 4.3   Demographic description of the stroke group   118 




Table 4.5  Comparison between the demographics of the stroke  
and healthy participant groups      121 
Table 4.6   Comparison of the physical characteristics of the  
                      stroke and healthy participant groups                                 121 
Table 4.7  Results of the pre-testing screening for the stroke group        122 
Table 4.8  Results of the pre-testing screening for the healthy group 123 
Table 4.9  Comparison of velocity and cadence for the stroke and 
   healthy participants in shoes and barefoot   125 
Table 4.10  Comparison of double limb support and affected/matched 
leg step length for the stroke and healthy participants in shoes 
and barefoot         126 
Table 4.11 A comparison of affected/matched leg single support stance, 
affected/matched leg swing and single stance time symmetry 
ratio in shoes and barefoot for the stroke and healthy  
participants        127 
Table 4.12  A comparison of knee angle at initial contact, midstance  
   and terminal stance in shoes and in barefoot for the 
   stroke and healthy participants     128 
Table 4.13 A comparison of velocity and cadence of shod walking and 
walking in all AFO’s for the stroke and healthy 
 participants        131 
Table 4.14 A comparison of double limb support and affected/matched leg 
step length of shod walking and walking in all AFO’s for the  





Table 4.15 A comparison of affected/matched leg single support, 
affected/matched leg swing and single stance time symmetry 
 of shod walking and walking in all AFO’s for the stroke and 
healthy participants       133 
Table 4.16  A comparison of knee angle at initial contact, midstance 
   and terminal stance of shod walking and walking in 
   all AFO’s for the stroke and healthy participants  134 
Table 4.17  A comparison of walking velocity of the stroke and healthy 
   participants in shoes and each of PAB, SLAFO and FGC 140 
Table 4.18  A comparison of cadence of the stroke and healthy 
   participants in shoes and each of PAB, SLAFO and FGC 141 
Table 4.19  A comparison of double limb stance of the stroke and healthy 
   participants in shoes and each of PAB, SLAFO and FGC 142 
Table 4.20 A comparison of affected/matched leg step length of the stroke 
and healthy participants in shoes and each of PAB, SLAFO  
and FGC        143 
Table 4.21 A comparison of affected/matched leg single support stance of 
the stroke and healthy participants in shoes and each of PAB, 
SLAFO and FGC       144 
Table 4.22 A comparison of affected/matched leg swing phase of the stroke 
and healthy participants in shoes and each of PAB, SLAFO  





Table 4.23  A comparison of single stance time symmetry of the stroke  
and healthy participants in shoes and each of PAB, SLAFO  
and FGC        146 
Table 4.24  A comparison of the knee angle at initial contact of the  
stroke and healthy participants in shoes and each of PAB, 
SLAFO and FGC       147 
Table 4.25  A comparison of the knee angle at midstance of the  
stroke and healthy participants in shoes and each of PAB, 
SLAFO and FGC       148 
Table 4.26  A comparison of the knee angle terminal stance of the  
stroke and healthy participants in shoes and each of PAB, 
SLAFO and FGC       149 
Table 4.27  Stroke participants’ values indicating the smallest real 
   difference at a 95% confidence level for each 
   spatiotemporal parameter      153 
Table 4.28  Categorisation of ankle impairments of stroke participants 
   of those who demonstrated a positive response and those 
   that did not (non responder)     165 
Table 4.29  Healthy participants’ values indicating the smallest real 
   difference at a 95% confidence level for each 
   spatiotemporal parameter      170 






I would like to take the opportunity to acknowledge and thank the following people for 
contributions to this study. 
 
To the staff and patients of the rehabilitation wards of St Vincent’s Health, 
Melbourne. Your willingness to assist and participate allowed this study to occur. 
Also to my colleagues who supported me during periods of data collection, writing 
and revising. 
 
My three supervisors, Elizabeth Bradshaw, Vanessa Rice and Kim Brock, who have 
all happily provided me with their time and advice. Without whom, none of this study 
would have occurred.  
 
And lastly, special thanks and love to my beautiful wife Amy for her support and love 
during this process and love to Paddy, Molly and Ella for being who they are. Paddy 















1.0 Introduction and overview of project 
Stroke is one of the most common diseases of the cardiovascular 
system in the western world. In 2003, over 40,000 stroke events occurred and 
there were over 340,000 Australians whom had suffered a stroke at some 
point in their lives (AIHW: Senes, 2006). A stroke occurs when the blood 
supply to the brain is interrupted (National Stroke Foundation, 2008) resulting 
in irreversible cell damage. A stroke can affect all physical and cognitive 
domains including strength, sensation, proprioception, muscle tone, vision, 
the ability to swallow, attention, concentration, memory, orientation, language 
and executive functions such as initiation and inhibition of behaviours, 
planning and problem solving (National Stroke Foundation, 2005). The 
consequences of stroke can bring about changes in an individuals’ ability to 
carry out basic tasks of day to day living. 
The loss of the ability to walk is a common consequence of stroke. Fifty 
to 80% of patients will regain some level of walking function following stroke 
(Skilbeck, Wade, Hewer, & Wood, 1983), with 62% of patients being able to 
walk independently six months post stroke (Kollen, Kwakkel, & Lindeman, 
2006). It is the aim of health professionals to limit the deleterious effects of 
stroke by maximising an individual’s functional level in the physical, cognitive 
and social domains (AIHW: Senes, 2006). The prescription of an ankle foot 
orthosis (AFO) is one intervention used to address physical function; 
specifically for those patients who have ankle impairments resulting in 
difficulty walking after a stroke. An AFO provides assistance to the affected 
leg through the stance and swing phases of gait in order to improve the 
performance in walking. 
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The use of AFO’s in stroke is widespread (Teasell, McRae, Foley, & 
Bhardwaj, 2001), however there is little evidence regarding the efficacy of 
AFO’s in the literature (Condie, 2003), particularly in the early stages of 
walking recovery following stroke. Due to the limited research regarding the 
use of AFO’s in stroke it remains unclear if specific AFO’s are suitable for 
particular patient groups. There are many types of AFO, each having different 
effects on the biomechanics of the foot/ankle complex or lower limb in general 
during gait. There is little gait research specific to early stroke recovery, and 
less examining AFO’s with different biomechanical purposes. Therefore, the 
current clinical recommendations are inadequate due to the lack of research 
studies. The aim of this study was to identify differences in walking 
performance using different AFO’s. 
 
1.1 Ankle Foot Orthosis 
AFO’s can allow stroke patients more independence or greater 
efficiency in their walking by assisting the swing and/or stance phases of gait. 
These benefits can reduce the burden of care and everyday task participation 
restriction, which can be significant following stroke. Specifically AFO’s have 
been found to improve walking velocity (Franceschini, Massucci, Ferrari, 
Agosti, & Paroli, 2003; Gok, Kucukdeveci, Altinkaynak, Yavuzer, & Ergin, 
2003; Hesse, Luecke, Jahnke, & Mauritz, 1996; Leung & Moseley, 2003; 
Pavlik, 2008; Wang, Lin, Lee, & Yang, 2007; Wang et al., 2005), step length 
(Gok et al., 2003; Hesse, et al., 1996; Leung & Moseley, 2003; Wang et al., 




There are many AFO options available to prescribe, as is evidenced by 
the variety that have been examined and reported in the literature (Chen, 
Yeung, Wang, Chu, & Yeh, 1999; Corcoran, Jebsen, Brengelmann, & Simons, 
1970; de Wit, Buurke, Nijlant, MJ, & Hermens, 2004; Diamond & Ottenbacher, 
1990; Dieli, Ayyappa, & Hornbeak, 1997; Fatone & Hansen, 2007; 
Franceschini et al., 2003; Gok et al., 2003; Hesse et al., 1996; Wang et al., 
2005). These include custom-made and mass produced AFO options. Whilst 
there is evidence that AFO’s can be of benefit, there is also a belief that 
AFO’s could reduce the ultimate recovery of volitional muscle activity of the 
ankle by limiting the movement available at that joint (Leung & Moseley, 
2003). The impact of AFO use on recovery of volitional muscle activity at the 
ankle has not yet been fully investigated.  
Clinical markers used to assist in prescribing AFO’s in stroke have not 
been established. Prescription is currently based on the clinical experience of 
the clinician, without a sound evidence base established to guide practice 
(Condie, 2003). The clinician should assess the impairments of their patient 
and decide on the characteristics of the AFO which will effectively address 
these impairments. Relationships between impairments and brace 
characteristics have not been established. A need has been identified to 
further understand the timing of the application of AFO’s and the type of 
AFO’s prescribed (including comparing pre-fabricated AFO’s with custom-
made AFO’s) (National Stroke Foundation, 2005; Tyson & Kent, 2009).   
Most studies compare walking with and without a single type of AFO in 
the chronic stage post stroke (Chen et al., 1999; Danielsson & Stibrant, 2004; 
de Wit et al., 2004; Dieli et al., 1997; Fatone & Hansen, 2007; Franceschini et 
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al., 2003; Hesse et al., 1996; Hesse et al., 1999; Mojica et al., 1988; Tyson & 
Thornton, 2001; Wang et al., 2005). The current study focused on patients in 
the early stages of recovery following stroke and examined AFO’s of varying 
rigidity. This was considered significant as no study has described a similar 
methodology and the outcomes of such a methodology might allow more 
accurate prescription of AFO’s and may improve outcomes for people with 
stroke.  
The current literature regarding AFO prescription, particularly in the 
early stages of walking recovery following stroke, leaves a significant number 
of unanswered questions. These questions include; are certain populations of 
patients likely to benefit from an AFO? Do differences in the type of AFO used 
alter walking performance? Further to this, do specific physical impairments 
indicate a particular type of AFO to be more appropriate? These questions 
could be answered via a scientific investigation into the use of AFO’s in 
patients in the early stages of recovery following stroke. 
 
 
1.2 General Objectives 
The questions mentioned above, positioned this study to be of 
significance and unique. This formed the objectives of the study, which are: 
 
1. To compare walking performance of patients in the early stages of 




2. To compare walking performance in this target population under 




1.3 Research Hypotheses 
The following hypotheses were proposed to measure the effect of 
different AFO’s use on walking performance in comparison to walking in 
shoes in the early stages of walking recovery following stroke. The study 
also considered the effect of different AFO’s on an age and aged matched 
normative comparison group. AFO’s with differing levels of rigidity and 
ankle support were utilised in the study. A comparison between shod 
walking and barefoot walking will also be considered as walking in 
barefoot may also influence performance due to direct contact to the 
ground, which may increase kinaesthetic feedback. Analysis of symmetry 
in walking is necessary as stroke commonly cause unilateral deficits, 
resulting in differing performances between the left and right sides of the 
body. Symmetrical gait can be considered to be left and right sided 
performance not differing by more than ten percent (Balasubramanian, 
Bowden, Neptune, & Kautz, 2007).  
 
 By using an AFO’s a sample of patients in the early stages of walking 
recovery following stroke will improve in their walking performance as 
measured by GAITRite ™. 
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 By using an AFO a sample of patients in the early stages of walking 
recovery following stroke will be more symmetrical in spatial and 
temporal parameters of walking as measured by GAITRiteTM. 
 Participants with a greater degree of ankle impairment will improve in 
their walking performance as measured by GAITRite ™ when using 
more rigid bracing.  
 Normative participants will deteriorate in the walking performance as 
measured by GAITRite ™ when using AFO’s.  
 Normative participants will be less symmetrical in spatial and temporal 
parameters of walking as measured by GAITRiteTM when using AFO’s 
 Normative participants will show greater deterioration in their walking 
















1.4  Summary 
Ankle foot orthoses can be used to improve walking performance in 
certain patients following stroke. AFO’s have been demonstrated to assist 
in various parameters of walking performance (Leung & Moseley, 2003). 
These parameters have not been well described in patients with stroke in 
the early stages of their walking recovery, nor have ankle impairments 
been used to better describe which AFO’s may be of benefit. Studies have 
not controlled for the impairment of the ankle, and few have controlled for 
the acuity of the stroke.  
This study is of scientific merit as it aims to answer gaps within the 
scientific literature. The gaps in knowledge pertaining to the use of AFO’s 
are: the immediate effects of AFO’s in the early stages of walking 
recovery, the effects of ankle impairment on the use of AFO’s and the 
effects of the application of varying types of AFO’s in the early stages of 
walking recovery. This study was unique as it focused on patients in the 
early stages of walking recovery, controlled for three different types of 























2.0  Literature Review 
This section reviews the prevalence and aetiology of stroke. The 
consequences of stroke are discussed followed by the impact of these 
consequences.  The impact of alterations in the capacity to walk is highlighted 
as one such consequence. Ankle foot orthoses (AFO’s) are introduced as one 
method to assist in limiting the impact of stroke on walking. Areas requiring 
further research into the prescription of AFO’s are identified. Following this, a 




Stroke is one of the most common diseases of the cardiovascular 
system in the western world. The overall cost of stroke to Australia is 
estimated to be $2.14 billion a year (National Stroke Foundation, 2010). 
These figures indicate that stroke is a significant disease affecting many 
individuals and the community at large. A stroke occurs when the blood 
supply to the brain is interrupted (National Stroke Foundation, 2008), resulting 
in irreversible cell damage as the neural cells that make up the brain do not 
store their own energy (Durukan & Tatlisumak, 2007). A stroke can affect all 
physical and cognitive domains, including: strength, sensation, proprioception, 
muscle tone, vision, the ability to swallow, attention, concentration, memory, 
orientation, language and executive functions such as initiation and inhibition 
of behaviours, planning and problem solving (National Stroke Foundation, 
2005). These consequences can bring about changes in an individual’s ability 




2.1.1 Causes of Stroke 
Stroke is categorized into ischaemic and haemorrhagic infarctions, and 
these subsets are further divided according to their aetiology (Figure 2.1). 
Infarctions account for 87% of all strokes, with haemorrhagic strokes 
accounting for the remainder (Rosamond et al., 2007). Whilst the 
pathophysiology of both types of strokes is different, the ensuing neurologic 
deficits are the same, however the mortality associated with haemorrhagic 
strokes is much greater than infarction (Rosamond et al., 2007). Fatality within 
the first thirty days following infarction is 10% and for intracerebral 
















Thrombotic Embolic Intracerebral Subarachnoid 
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The two subsets of an ischaemic infarction are thrombotic or embolic. 
A thrombotic stroke occurs when a thrombus, or blood clot, develops within 
the cerebral circulation usually due to turbulent blood flow (Figure 2.2). 
Turbulent blood flow occurs due to atherosclerosis or where the artery 
bifurcates.  In both instances the change in the lumen of the artery causes the 
turbulence which in turn allows clots to form or lodge.  An embolic stroke 
occurs when an embolus, from a distant thrombus, is dislodged and travels to 
the cerebral circulation where it lodges causing a blockage. Risk factors for 
both thrombotic and embolic infarction are cumulative and include age (Thrift, 
Dewey, Macdonell, McNeil, & Donnan, 2000; Wolf, D'Agostino, Belanger, & 
Kannel, 1991), gender (Kelly-Hayes et al., 2003; Thrift et al., 2000), family 
history (National Stroke Foundation, 2005), smoking (Wolf, D'Agostino, 
Kannel, Bonita, & Belanger, 1988), atrial fibrillation (Wolf, Abbott, & Kannel, 
1991; Wolf, D'Agostino et al., 1991), hypertension (Seshadri et al., 2006), high 
cholesterol, diabetes, and obesity (Wolf, D'Agostino et al., 1991). The 
presence of more than one risk factor increases the risk of stroke 



















Figure 2.2. Pathogenesis and pathophysiology of stroke. (a) Turbulent flow 
due to atherosclerosis (fissure and rupture of plaque) that develops into a 
thrombus. (b) Complications of a thrombus; the development of an embolus, 
from a distant thrombus that can cause an (c) occluded (blocked) artery. 
Diagrams from www.strokecenter.com 
 
 
A haemorrhagic stroke is a reduction in blood supply to the brain due to  
the splitting or bursting of a cerebral artery due to changes in the arterial wall 
or malformations of the arterio-venous system within the brain. Haemorrhagic 
strokes can be classified into two main categories: intracerebral and 
subarachnoid haemorrhage. Intracerebral haemorrhages are usually the 
result of arterial hypertension causing a rupture in the arterial wall and 
bleeding into the surrounding tissue. This has a two-fold effect. The disruption 
of blood supply starves the cerebral tissue, the artery supplies of oxygen and 
nutrients, and the bleeding into the cerebral tissue raises the pressure within 





subarachnoid haemorrhage is a rupture of an artery within the subarachnoid 
space, a small space between the outer covering of the brain and the two 
outer layers of the brain (dura mater and arachnoid mater) and is usually filled 
with cerebrospinal fluid. Subarachnoid haemorrhages may result from a 
rupture of an aneurysm of an artery within the subarachnoid space, an 
extension of an intracerebral haemorrhage or vascular malformation. 
One factor that can increase the risk of stroke is age (Thrift et al., 2000; 
Wolf, D'Agostino et al., 1991). Therefore as the population is ageing 
(Australian Bureau of Statistics, 2008) the incidence of stroke is expected to 
rise. Over 100,000 strokes per year are expected to occur in Australia by 
2030, an increase from over 40,000 in 1997 (AIHW: Senes, 2006). The 
incidence of the burden of stroke on individuals and their families can also be 
expected to rise. Resources from both within hospitals and the community can 
be expected to be further stretched as demand increases.  
 
2.1.2 Consequences of Stroke 
Many survivors of stroke experience disability following stroke. 
Disability is best described by the classification system outlined by the World 
Health Organisation (WHO) which provides a framework for explaining the 
affect of illness and disability. The International Classification of Functioning, 
Disability and Health (ICF) includes all factors which influence disability, 
recognizing that the interaction between factors such as environment, 
personal and physical factors influence their ability to participate in activity 
(WHO, 2001).   
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The WHO describes difficulties an individual has in executing activities 
as an activity limitation and a problem an individual experiences in 
involvement in life situations as a participation restriction (2001). Following 
stroke a large number of survivors are unable to complete activities that 
formed the basis of their pre-stroke lives, reporting difficulties with living 
independently, such as requiring assistance with mobility, personal and 
household tasks (Paul et al., 2005). This category of survivors can be defined 
as having activity limitations and participation restrictions which can 
significantly reduce the quality of their lives (Sturm et al., 2004). The findings 
of Paul et al. (2005) can be extrapolated to include difficulties in maintaining a 
career or providing assistance to other family members. The range of 
activities that can be negatively influenced by stroke is endless, from the most 
basic to the highest functional level possible. In 2003 81% of stroke survivors 
had a disability of some form (AIHW: Senes, 2006). Seventy-three percent of 
those survivors were moderately to profoundly limited in core activities, such 
as communication, mobility and self care (AIHW: Senes, 2006). The cost of 
addressing activity limitations is great, both in monetary terms (Dewey et al., 
2001) and in the time and the emotional burden placed on family members 
who become carers (Dewey et al., 2002).  
The outcome following stroke is of great interest to patients, their 
families and those health professionals providing their care. One in five 
people die as a result of stroke within one month, and one in three within 12 
months (Thrift et al., 2000). Fifty percent of three-day survivors survive five 
years (Hankey, Jamrozik, Broadhurst, Forbes, & Anderson, 2002). Nearly all 
people are disabled to some degree immediately following their stroke (AIHW: 
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Senes, 2006). The prevalence of disability following stroke has been 
measured between 36% to 81%, (AIHW: Senes, 2006; Hankey et al., 2002).  
Sixty-six percent of cases surveyed reported an incomplete recovery at 12 
months, the greatest limitations being in physical independence and being 
able to engage in personally important occupations (Sturm, Dewey et al., 
2002). At the end of 12 months about half of all survivors are dependent on 
others for activities of daily living (Hankey et al., 2002). Of the stroke survivors 
with disability, half needed help with health care, mobility, household chores 
and transport and a quarter needed help with self care and cognitive tasks 
(Senes, 2004).   
A study which evaluated quality of life following stroke found a normally 
distributed result where some participants reported that the stroke did not 
change the quality of their life at all, and another participant reported that 
having a stroke resulted in a quality of life worse than death (Sturm, Osborne 
et al., 2002). The awareness of the effect of depression post-stroke, and other 
psychological disorders on quality of life and the ability to participate in 
activities of importance is increasing (Paolucci et al., 1999).    It is the aim of 
health professionals to limit the deleterious effects of stroke by maximising an 
individual’s functional level in the physical, cognitive and social domains 
(AIHW: Senes, 2006). Maximising an individual’s functional level can reduce 
activity limitations and increase participation levels. This could limit the 






2.1.3 Recovery following stroke 
Reduction of disability following stroke is due to the recovery of 
function due to neuroplasticity (Ward & Cohen, 2004) and the adoption of 
compensatory strategies to mitigate for the loss of movement and function.  
 
2.1.3.1 Neuroplasticity/Recovery of Function from Stroke 
Recovery in function following injury to the central nervous system 
(CNS) such as from stroke is thought to be due to a reorganization of the CNS 
(Ward & Cohen, 2004). Recovery is improved in the therapeutic setting (Kalra 
& Ratan, 2008) and both are influenced by behavioural experience (Nudo, 
2007). Recovery and re-organisation of the brain occurs in the very early 
stages following stroke as demonstrated in an animal (mouse) model by 
Brown, Wong and Murphy (2008). This suggests that the reorganization of the 
brain can be influenced by behavioural or environmental exposure during the 
acute phase post stroke. There is however limited research into the early 
recovery following stroke in humans (Hodics, Cohen, & Cramer, 2006), with 
many of the conclusions in regards to recovery in the early stages drawn from 
studies on animals (Cramer & Riley, 2008; Nudo, 2007). These results may or 
may not be entirely applicable to humans. 
A number of cellular changes  occur within the brain to aid recovery 
(Cramer, 2008).  Neuroplasticity can be maximised by utilising experience of 
the environment to direct the neuronal plastic recovery process towards 
functional and meaningful activities. It has been shown that providing demand 
through forced use of the paretic upper limb increases cerebral activity and 
size (Nudo, 2007). Conversely, a lack of demand results in reduced cerebral 
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representation (Nudo, 2007). Areas of the brain that are involved in the 
reorganisation are task related areas within the affected hemisphere, peri-
infarct regions, regions of the affected hemisphere linked (but distant to) the 
infarct area and homologus areas of the unaffected hemisphere (Kreisel, 
Bazner, & Hennerici, 2006; Rijntjes, 2006). The reorganisation is highly 
dynamic in the early stages of recovery (Van Peppen et al., 2004) and poorly 
understood (Kreisel, Hennerici, & Bazner, 2007). The pathophysiological 
process of recovery commences seconds following the initial insult and 
continue for days or weeks (Kreisel et al., 2006). There are five phases of 
recovery following stroke; a hyperacute phase (less than 6 hours post stoke), 
an acute phase (up to four days post stroke), a subacute phase (two to three 
weeks post stroke), a consolidation phase (months post stroke) and a chronic 
phase  (several months post stroke (Kreisel et al., 2006) ;see Figure 2.3). 
Each phase overlaps and represents different processes in the function of 








Figure 2.3: Schematic representation of the five phases of recovery following 
stroke (Kreisel et al., 2006), 
 
As the subacute phase is a period of great neuroplastic recovery 
(Kreisel et al., 2006) it is of great importance to clinicians because there is the 
potential for significant recovery to occur, which could be harnessed to 
maximise function. This must be utilised carefully as there is also potential for 
reorganisation to occur which is inappropriate and may be negative in effect 
(Huitema et al., 2004). It is unclear how the intrinsic recovery processes 
interact with the recovery processes driven by extrinsic factors such as the 
environment, treatment and remaining motor activity (Forrester, Wheaton, & 
Luft, 2008; Krakauer, 2006; Kreisel et al., 2006; Nudo, 2007). The evidence 
for the effects of experience and environmental interaction suggest that the 
extrinsic processes play a significant role (Liepert, Graef, Uhde, Leidner, & 
Weiller, 2000; Nudo, 2007; Rijntjes, 2006; Ward & Cohen, 2004). If it is 
accepted that extrinsic processes are of great significance, care must be 





Table 2.1: Description of the phases of recovery following stroke. 
Phase Summary of neural recovery occurring 
Hyperacute Lesion core does not participate in the network.   
Acute Lesion core does not participate in the network.   
Penumbra contributes to resolution (positively or negatively 
depending if the penumbra is recruited to the affected network).  
Subacute Network highly active, adapting to internal changes (the lesion) and 
external mechanisms (compensating for loss of function). Highly 
plastic phase 
Consolidation Slowing of the subacute phase,  
Chronic Recovery of function is due to compensation 
 
 
Recovery of function can also occur due to compensatory changes 
established by the body in response to the original loss of function 
(Bensoussan, Mesure, Viton, & Delarque, 2006; Kerrigan, Bang, & Burke, 
1999; Kerrigan, Frates, Rogan, & Riley, 2000). These compensations can be 
useful in restoring function but some clinicians believe that they can interfere 
in optimal movement being attained (Pollock, Baer, Langhorne, & Pomeroy, 
2007). There are currently no clinical guidelines or direction from the scientific 
literature as to when compensatory techniques should be instituted in the 
treatment of patients with stroke, if at all. It is accepted that the most rapid 
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neuroplastic changes occur within three months (Boake et al., 2007), although 
this is currently being challenged in the literature (Fritz, Pittman, Robinson, 
Orton, & Rivers, 2007; Page, Gater, & Bach-y-Rita, 2004). Individuals 
certainly continue to make gains in function after the three month point 
(Paolucci et al., 2001).  Whether this is mediated via neuroplastic processes 
or via compensatory processes is unclear (Bensoussan et al., 2006; Page et 
al., 2004). This does highlight the potential for patients to improve. Clinical 
interaction, or treatment, with the patient has the potential for positive and 
negative effects. Therefore, the clinician must take care to ensure they do not 
limit their patients’ outcome. AFO’s can be thought to be a compensatory 
strategy as they mitigate impaired stance or swing phases of gait. However 
people with stroke attempting to walk without ankle control may also adopt 
maladaptive intra and interlimb compensatory strategies (Chen, Chen, Tang, 
Wu, Cheng & Hong, 2003). Using the principles of neuroplasticity, 
constraining the ankle in an AFO may reduce the environmental demand on 
the ankle and limit motor recovery. This limitation in recovery may in turn 
impact on the ultimate functional outcome due to the lack of demand on 
recovery. 
 
2.1.4 Treatment Approaches Following Stroke 
The importance of maximising the capacity to bring about recovery of 
movement and therefore improving functional outcome in the early stages of 
stroke is paramount. This has the potential to limit participation restrictions 
commonly suffered by individuals with stroke. Physiotherapists and other 
clinicians utilize a number of different strategies to address the changes in 
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gait patterns following stroke. Treatment techniques include ‘The Bobath 
Concept’, task specific training, proprioceptive neuromuscular facilitation and 
stretching. These techniques are all based upon neurophysiological concepts, 
as outlined earlier, and motor relearning principles (Hesse, 2003; Pollock et 
al., 2007). The goal of rehabilitation is to address impairments and restore 
functional abilities to limit or eliminate disability (Pomeroy & Tallis, 2002). No 
specific physiotherapy treatment has been identified to be more 
advantageous in the treatment of stroke, and all therapeutic approaches have 
been found to be better than no treatment at all (Pollock et al., 2007).  
Physiotherapists’ treat movement disorders by identifying how and why 
a movement differs from normal, before attempting to restore the missing 
element (Moseley, Wales, Herbert, Schurr, & Moore, 1993). Physiotherapists 
attempt to restore function without using compensatory techniques or 
encouraging compensatory movements. This is particularly important in the 
early stages of recovery when the neurological system is in its’ neuroplastic 
phase (Kreisel et al., 2006) as there is the potential to train compensatory 
movements to the detriment of overall outcome. Techniques that use 
compensation such as orthoses, walking aids or deliberately altering the way 
in which a patient moves in comparison to healthy need to be considered 
carefully in the subacute stage of recovery. Once the patient plateaus in their 
recovery, there is less concern about utilising compensation strategies to 







2.1.5 Walking  
Walking is a basic (fundamental) human activity. The loss of the ability 
to walk is commonly reported following stroke (National Stroke Foundation, 
2005). This limits an individual’s activities and restricts their ability to 
participate in home, work or recreational related tasks. The loss of the ability 
to walk can influence an individual’s capacity to participate in a broad range of 
activities. These activities can be as simple as walking to the toilet or playing 
in the park with grandchildren, maintaining a career or supporting other family 
members, potentially diminishing their family role and affecting their 
psychological wellbeing (Paul et al., 2005). 
 
2.1.5.1 Normal Gait 
Walking, whilst being highly individualized, has a number of elements 
consistently similar despite differences in its appearance (Norkin & Levange, 
1992). The motor control of gait is under the control of a number of the body 
systems that interact to modify the output (walking) to ensure that the task is 
completed in the manner in which it was originally being intended. There are 
three sensory systems involved in the control of balance and gait (Shumway-
Cook & Woollacott, 2007; Winter, 1995; Woollacott, 2000). The visual system 
(i) evaluates non-tactile information regarding the body’s position from the 
environment (Shumway-Cook & Woollacott, 2007; Woollacott, 2000), (ii) the 
vestibular system senses linear and angular acceleration of the body 
(Shumway-Cook & Woollacott, 2007; Winter, 1995); and (iii) the 
somatosensory system detects the position and velocity of all body segments 
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in relation to gravity and the environment (Shumway-Cook & Woollacott, 
2007; Winter, 1995). A continuous cycle of processing sensory information 
and executing motor responses, defined as a postural control strategy, occurs 
where: (i) sensory information from the cutaneous, proprioceptive and 
vestibular receptors are relayed to the CNS; (ii) within the CNS the 
information is interpreted, a movement strategy is formulated and initiated; 
and (iii) a movement response is executed in the periphery (Shumway-Cook & 
Woollacott, 2007). 
Walking is a complex activity that requires postural control in order to 
maintain balance. This is mediated by the sensory systems outlined above. 
As each step is taken a perturbation occurs which destabilises the individual. 
These perturbations are due to movements produced by the individual to 
propel themselves forwards (i.e. stepping their leg through). The perturbations 
are also caused by external influences such as those produced by the foot 
striking the ground.  Muscle activity is required for stabilisation to ensure an 
upright posture is maintained. Alterations in the ability to provide that 
stabilisation due to pathologic processes such as stroke limit the strategies 
available to produce that particular movement in response to the perturbation 
(Heiderscheit, Hamill, & van Emmerik, 2002).  This results in the reduced 
performance of walking.  This performance can be measured and reported in 
a number of ways.  
Walking can be measured, in simple terms, using a number of 
variables such as speed, the length of the step and the contact the foot makes 
with the ground, including any differences between the left and right sides. 
The way in which we walk can also be represented by the movements that 
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take place at each joint of the body as we walk (Winter, 1991). These 
movements can be better described by identifying the stage of the walking 
cycle which they occur. The phases of gait are traditionally divided into stance 
phase and swing phase, with further description within each phase (Lehmann, 
1993) (Figure 2.3). There are two conventions in describing the phases of 
gait, both phases have been outlined below (Table 2.2) and represent the 
same periods of the gait cycle. There are periods of overlap between each 
cycle for the left and right sides where both limbs are in contact with the 
ground. These periods are known as double limb support (DLS). Periods of 
DLS allow for a brief period of stabilisation, prior to the commencement of the 
next single leg stance period (Winter, 1995). The time spent in double limb 
support, as percentage of the gait cycle, is used to determine the control of 
balance in gait. For example, as the control of walking increases, the time 
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Figure 2.4. Phases of the gait cycle, from Norkin and Levange, ‘Joint 
Structure & Function: A comprehensive analysis’ 1993 pg 451. DLS = double 













Table 2.2: Description of the two phases of gait (from Norkin and Levange 
1993) 




Commencement of stance phase, and end of swing 
phase. Occurs the moment the heel of  the swinging leg 





When the foot is flat on the ground and the contralateral 
leg begins its swing phase 




The heel of the stance leg begins to leave the ground, 




Only the toe is in contact with the ground of the stance 
limb. The progression from heel off towards toe off 
  




Begins once the toe leave the ground and continues 
until maximal knee flexion has occurred and the limb is 
directly below the body 





The tibia progresses from its vertical position in 




There are accepted degrees of what constitutes “normal” values for the 
movements at each joint and parameters such as walking velocity. These 
variables can be affected by age, height, weight, body morphology, habit, 
psychological status and any disease process that is present (Norkin & 
Levange, 1992). A number of studies have identified what constitutes normal 
values for parameters such as velocity. Comfortable walking speed for men 
varies between 124 cm/sec to 146.2 cm/sec depending on age, whilst women 
varying between 112.5 cm/sec and 141.5 cm/sec (Bohannon, 1997; Chao, 
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Laughman, Schneider, & Stauffer, 1983). Small changes in gait speed can 
have significant functional implications. Being able to walk faster than 
40cm/sec is indicative of an individual being able to access the community in 
a limited fashion and being able to walk faster than 80cm/sec is indicative of 
being a “full” community walker (Perry, Garrett, Gronley, & Mulroy, 1995; 
Schmid et al., 2007). Potter, Evans and Duncan (1995) examined a sample of 
geriatric patients and reported that gait speeds of less than 25cm/sec 
indicated likely dependence in activities of daily living. Progression between 
these speeds can indicate substantial improvements in an individual’s ability 
to be active in the community.  
Normal values for time spent in single and double limb stance has 
been established and commonly reported as a percentage of the gait cycle 
(Goldie, Matyas, & Evans, 2001; Winter, 1991). Stance times of normal gait 
comprising 58-61% of the gait cycle and swing times 39-42% with double 
stance comprising 16-22% of the cycle (Chao et al., 1983; Norkin & Levange, 
1992; Winter, 1991).  Step length is another common parameter used to 
measure gait performance, both in raw measurements and in measurements 
of symmetry (Balasubramanian et al., 2007).  Further to this, more specific 
temporal measures of the gait cycle can be reported as a raw score (seconds) 
or expressed as a percentage of the gait cycle. Examples of such measures 
include time spent in single leg stance of a specific leg, time spent in double 
limb support or swing time of a specific leg. Comparison of each side of these 
values can be used to describe symmetry of the gait single. Normative gait 
tends to be symmetric (Kim & Eng, 2003) whilst gait following stroke tends to 
be asymmetric (Patterson et al., 2008). Examination of such specifics of the 
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gait cycle may enable greater description of the quality of walking. 
Furthermore, comparison of such parameters of performance of each leg in 
the gait cycle may describe the relative symmetry and asymmetry of walking 
and therefore indicate the presence of a pathological gait pattern (Goldie et 
al., 2001; Kim & Eng, 2003; Patterson et al., 2008). 
 
2.1.5.2 Measuring Walking 
Walking can be described and measured using a number of different 
measurement tools. These range from simple observational measurements 
(Eastlack, Arvidson, Snyder-Mackler, Danoff, & McGarvey, 1991; Williams, 
Morris, Schache, & McCrory, 2009) to complex laboratory based equipment 
including force platforms, three dimensional motion capture systems (e.g. 
Vicon), electromyography (EMG), contact/pressure mats (e.g. Gaitrite) and 
footswitch systems. These tools provide detailed information regarding 
walking performance, muscle activity, movements occurring at each joint, the 
pattern in which the foot contacts the ground and the amount of force 
produced when the foot contacts the ground. These factors are important to 
clinicians, however utilising such measures can be time consuming and not 
practical in regards to access. Gait laboratories require large areas and can 
often be distant to clinical areas or located at separate sites.   In the clinical 
setting, therapists use tools that allow instantaneous feedback to the clinician 
and patient.  
GAITRite ® is an electronic instrumented walkway system which 
measures spatiotemporal parameters of gait. GaitRite® has been shown to 
have strong concurrent validity and test-retest reliability across all 
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spatiotemporal parameters in healthy subjects (Bilney, Morris, & Webster, 
2003; van Uden & Besser, 2004), and older adults (Hollman et al., 2010; 
Menz, Latt, Tiedemann, Mun San Kwan, & Lord, 2004). However, GAITrite® 
has been demonstrated to have reduced reliability for variability measures in 
dual task walking conditions (Hollman et al., 2010). Validity has also been 
demonstrated in regards to averaged and individual step characteristics 
following knee replacement surgery (Webster, Wittwer, & Feller, 2005). Base 
of support and toe in/out angle have reduced reliability, possibly due to the 
spatial resolution of GaitRite ® or perhaps inherent variability of these 
parameters (Menz et al., 2004). GaitRite ® is easy to use, provides 
instantaneous feedback and is relatively portable. It provides more detailed 
information than gained by examining gait using a 10 m walk, which is a 
commonly used clinical tool.  
Laboratory testing is the ultimate method used to analyse walking for 
clinical purposes. It was decided not to use a full Gait Laboratory in this study. 
The reasons behind this decision were: (1) a gait laboratory was not co-
located with the patients; (2) the patients were admitted to a hospital whilst 
participating in the study; (3) to transport the patients to a gait laboratory over 
three consecutive days would negatively impact the patients’ availability for 
necessary routine rehabilitative therapies, therefore being potentially 
detrimental to their rehabilitation outcome; and (4) quantitative measurement 
devices which capture commonly reported gait data were available on site 
which have demonstrated reliability. While acknowledging the limitations of 
the gait analysis equipment in the clinical setting compared to a gait 
laboratory, the opportunity to capture the data of stroke survivors in the early 
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stages of walking recovery enabled analysis of a patient group which has had 
minimal attention.   
 
2.1.6 Walking post stroke 
It is difficult to determine why an individual loses their ability to walk 
following a stroke; nevertheless their ability to walk is a primary objective for 
recovery (Olney & Richards, 1996; Viosca et al., 2005).The ability to walk 
following a stroke varies throughout the recovery of the individual. Fifty to 80% 
of patients will regain some sort of walking ability following stroke (Skilbeck et 
al., 1983) with 62% of patients being able to walk independently six months 
post stroke (Kollen et al., 2006). The altered pattern of walking following a 
stroke is due to the primary neural lesion, adaptive changes as a result of 
impairments due to the lesion and the interaction of these factors with the 
motor control system or as a learned adaptive response (Moseley et al., 
1993). The degree of the change is partly dependent on the severity of the 
neurological insult (Olney & Richards, 1996).  
Hemiplegic gait has been well described in regards to the stance and 
swing phases at the pelvis, hip and knee (Moore, Schurr, Wales, Moseley, & 
Herbert, 1993; Moseley et al., 1993) (see Table 2.3) resulting in decreases in 
velocity, increases in stance time of the unaffected leg and decreases in 
stance time of the affected leg (Olney, Griffin, & McBride, 1994).  The 
kinematics of the ankle joint in stroke gait has had limited examination in the 
literature. The importance of the ankle and foot in walking has been well 
established in healthy subjects and a number of studies into elements of 
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hemiplegic walking have described the importance of the ankle and foot 
though there is limited supporting evidence to date. 
 
Table 2.3: Hemiplegic gait. The altered biomechanics during the stance and 
swing phases. (Moore et al., 1993; Moseley et al., 1993) 
Stance – Kinematic Deviation Swing – Kinematic Deviation 
Decreased hip extension in late 
stance 
Decreased peak hip flexion 
Decreased lateral pelvic 
displacement 
Decreased peak knee flexion 
Increased lateral pelvic 
displacement 
Decreased knee extension prior 
to knee strike 
Knee hyperextension Decreased dorsiflexion/toe 
clearance 
Increased knee flexion at midstance  




Walking speed and other spatiotemporal parameters are reduced in 
ambulant stroke populations when compared with normative data (Olney & 
Richards, 1996). Generally speaking, the more severe the hemiplegia, the 
greater the change in the parameters from normal (Hesse, 2003; Olney & 
Richards, 1996). However, more severely affected individuals can perform 
better than those less affected due to more efficient compensatory movement 
patterns (Bowden, Balasubramanian, Neptune, & Kautz, 2006). Olney and 
Richards (1996) reviewed 17 studies which reported the spatiotemporal 
parameters of hemiplegic subjects. Average walking speeds in hemiplegic 
subjects ranged from 0.23 m/s to 0.73 m/s. They reported that hemiplegic 
patients spent more time in double limb support than healthy subjects when 
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walking at comparable speeds. In comparison, comfortable walking speeds in 
healthy older adults have been reported at 1.41 m/s for men and 1.30 m/s for 
women (Bohannon, Andrews, & Thomas, 1996). Titianova, Pitkanen, 
Paakkonen, Sivenius and Tarkka (2007) found an average hemiparetic step 
length of 41.3 cm (SD 15.5cm), with a step length of 39.4cm for the non-
affected leg in comparison of 73cm in age matched controls. Reduced step 
length is related to reduced paretic leg propulsion and is not related to gait 
speed in patients with stroke (Balasubramanian et al., 2007). Put more simply, 
some stroke survivors will have a reduced step length irrespective of the 
speed at which they walk. (Goldie et al., 2001) found increases in time spent 
in DLS and unaffected single limb support of stroke patients in comparison to 
age and gender matched controls. Unfortunately data for these parameters 
was normalised (i.e. presented as a ratio) and cannot be reported as a 
meaningful value. Table 2.4 describes data regarding normative values of gait 












Table 2.4: Summary of  reported values for spatiotemporal parameters of 
people with stroke 
Gait Characteristic Value 
Velocity 
Normative value for older 
adults: 102-113 cm/sec 
(Hollman, McDade and 
Petersen, 2011) 
0.45 m/sec-1 +/- 0.21 (Olney & Richards, 1996) 
0.89 – 0.94 m/sec (Flansbjer, Holmback, 
Downham, Patten, & Lexell, 2005) 
44.5 cm/sec +/- 24.8 (Goldie et al., 2001) 
41 cm/sec +/- 18 (Lamontagne & Fung, 2004) 
46 cm/sec +/- 22.8 (Lord, McPherson, 
McNaughton, Rochester, & Weatherall, 2008) 
81 cm/sec +/- 18cm/sec  (Kim & Eng, 2003) 
DLS (%) 
26.3-30.3% (Hollman et al, 
2011) 
45% (Olney & Richards, 1996) 
31% (Evans, Goldie, & Hill, 1997) 
Unaffected SLS (sec) 
0.38-0.44 sec (Hollman et 
al, 2011) 
0.53 secs (Evans et al., 1997) 
0.49 +/- 0.11 (Kim & Eng, 2003) 
Affected SLS (sec) 0.43 secs (Evans et al., 1997) 
0.37 +/- 0.07 secs (Kim & Eng, 2003) 
Step Length Affected 
59-69cm (Hollman et al, 
2011) 
47.5cm (Kim & Eng, 2003) 
Step Length Unafffected 
(cm) 
48.5cm (Kim & Eng, 2003) 
 
As has been discussed earlier, asymmetry can be an indicator of 
pathological gait. Asymmetry has been demonstrated in the gait of stroke 
patients (Goldie et al., 2001; Kim & Eng, 2003; Patterson et al., 2008) and 
thus should be considered describe the quality of walking of patients following 
stroke. As normal walking is considered to be symmetrical, reductions in 
35 
 
asymmetry of gait parameters of stroke patients could be interpreted as 
indicators of improvement/recovery. 
 
2.1.6.1 Ankle Impairments in Stroke 
There is a lack of empirical data regarding specific impairments around 
the ankle. Most studies investigating mobility alterations following stroke 
comment on lower limb impairments as an inclusion criteria without describing 
specific impairments to the ankle. Alterations to strength, sensation, 
proprioception and tone affect the ankle as they do other regions of the body 
following stroke. These range from no impairment to significant degrees of 
impairment. More specifically to the ankle, in the following articles impairment 
criteria were used to recruit participants or  were reported as patient 
characteristics, however  defined parameters were not used. Examples of 
these are: reduced strength or motor control (Abe, Michimata, Sugawara, 
Sugaya, & Izumi, 2009; Burdett, Borello-France, Blatchly, & Potter, 1988; 
Chen et al., 1999; Danielsson & Stibrant, 2004; de Wit et al., 2004; Diamond 
& Ottenbacher, 1990; Fatone, Gard, & Malas, 2009;  Lehmann, Condon, 
Price, & DeLateur, 1987; Mojica et al., 1988; Ring, Treger, Gruendlinger, & 
Hausdorff, 2009; Roehrig & Yates, 2008; Wang et al., 2007), alterations in 
tone or spasticity (Beckerman, Becher, Lankhorst, & Verbeek, 1996; Burdett 
et al., 1988; Danielsson & Stibrant, 2004; Dieli et al., 1997; Franceschini et al., 
2003; Gok et al., 2003; Hesse, Brandl-Hesse, Bardeleben, Werner, & Funk, 
2001; Hesse et al., 1996; Mojica et al., 1988) and contracture or reductions in 
range of movement (Beckerman et al., 1996; Burdett et al., 1988; Dieli et al., 
1997; Fatone et al., 2009; Gok et al., 2003; Hesse et al., 1996; Iwata et al., 
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2003; Lehmann et al., 1987; Mojica et al., 1988; Ring et al., 2009; Roehrig & 
Yates, 2008; Tyson, Thornton, & Downes, 1998; Tyson & Thornton, 2001) 
Alterations to walking performance can be attributable to impairments 
of the joints and neuromuscular activity of the lower limbs. (Lamontagne, 
Malouin, Richards, & Dumas, 2002). Hsu, Tang and Jan (2003) found that 
reduced hip flexor strength accounted for the observed reductions in gait 
velocity, and plantar flexor spasticity accounted for the asymmetrical gait 
pattern. However they excluded participants with reduced ankle range of 
movement (ROM). Alterations in ankle function are one factor that can 
contribute to changes in walking ability following stroke (Lamontagne, 
Malouin, & Richards, 2000; Lin, Yang, Cheng, & Wang, 2006). The effect of 
ankle impairments on walking can be significantly disabling. Reduced dorsi 
flexor strength of the affected limb correlates highly with the reduction in gait 
velocity due to increasing swing time and reduced eccentric loading ability 
during midstance (Lin et al., 2006). Plantar flexor spasticity moderately 
correlated with the reduced ability to transfer the weight onto the affected leg 
through the stance phase and is highly correlated with a reduced step length 
of the unaffected side (Lin et al., 2006). Alterations in sensation or 
proprioception may also influence walking performance as impaired joint 








2.2 Ankle Foot Orthoses 
Ankle foot orthoses (AFO’s) are devices used to correct for 
abnormalities of ankle function through the  stance and swing phases of gait 
in a variety of clinical conditions including stroke (Leung & Moseley, 2003), 
multiple sclerosis (Sheffler et al., 2008), cerebral palsy (Brehm et al., 2008; 
Westberry et al., 2007) and poliomyelitis (Waring, Maynard, Grady, Grady, & 
Boyles, 1989) . The role of the AFO is to compensate for impaired or absent 
ankle movement which hinders the ability to walk. There is a suggestion, but 
limited evidence, that an AFO (Hesse et al., 1999) may reduce the muscle 
activity around the ankle (Leung & Moseley, 2003), thereby limiting the extent 
of a patients recovery.  
The literature describing the effect of AFO’s and the use of AFO’s 
following stroke is described in this section. The effects of AFO’s used in 
stroke on these parameters was discussed, as was the prescription of AFO’s 
to stroke patients. Subsequent to this a method which increases the 
knowledge regarding AFO prescription was proposed. 
 
2.2.1 Biomechanics of AFO’s 
An AFO is commonly prescribed in stroke to prevent unrestricted 
plantar flexion (foot drop) through the swing phase of gait. AFO’s are also 
thought to provide stability through the stance phase, although this may 
depend on the construct of the AFO. Using the spring leaf AFO as an 
example, the foot plate (Figure 2.4) holds the foot in a neutral position, whilst 
the upright (posterior shell) and strap (Figure 2.4) ensure the AFO is well 





Figure 2.5. A Spring Leaf AFO indicating its components 
 
The material by which an AFO is constructed will also affect function. 
Less rigid materials provide less resistance to unrestricted plantar flexion, 
whilst more rigid materials will provide more resistance. The majority of 
research into AFO’s has been regarding their functional effects such as gait 
parameters rather than biomechanical influences (Chu, 2001). Research into 
differences of AFO’s of different design or construction has not occurred. 
 
2.2.2 The effect of AFO’s on walking  
The prescription of an ankle foot orthosis (AFO) has been reported to 
be used around 22% of the time at discharge from an inpatient rehabilitation 
program (de Vries, 1991; Teasell et al., 2001). AFO’s are prescribed in stroke 
Footplate 




as they are considered to improve the quality and efficiency of walking, and 
thereby improve function (Hesse et al., 1996; Leung & Moseley, 2003). AFO’s 
are designed to improve walking by minimizing gait deviations caused by 
dysfunction around the ankle, providing stability through the stance phase and 
assistance in the swing phase improving temporal and kinematic parameters 
(Leung & Moseley, 2003) and by making walking more efficient (Danielsson & 
Stibrant, 2004). Specific parameters of the gait cycle that AFO’s that have 
been found to improve in stroke patients are walking speed (Gok et al., 2003; 
Hesse et al., 1996; Mojica et al., 1988; Wang et al., 2007; Wang et al., 2005), 
cadence (Gok et al., 2003; Wang et al., 2005), step length (Gok et al., 2003; 
Hesse et al., 1996;  Lehmann et al., 1987; Wang et al., 2007), ankle dorsi 
flexion in the swing phase (Gok et al., 2003), foot contact patterns (Hesse et 
al., 1996; Mojica et al., 1988; Pohl & Mehrholz, 2006), improved stance times 
(Hesse et al., 1999; Lehmann et al., 1987), and improved symmetry of the gait 
cycle (Pohl & Mehrholz, 2006).  
Whilst there is general agreement within the literature regarding the 
benefits of AFO’s in some stroke patients there is no clear consensus 
regarding which stroke patients will benefit. The work of Hesse et al. (1996) 
suggests that AFO’s will benefit stroke patients with spasticity of the plantar 
flexors. However, they excluded patients who were unable to attain a 
plantigrade ankle position. Most of the literature reported are suggestive of 
impaired ankle movements and or strength but do not define or quantify the 






2.2.2.1 Prescription of AFO’s 
The International Society of Prosthetist’s and Orthotist’s (ISPO) met in 
2003 to discuss AFO prescription in stroke and an in depth review of the 
literature resulted. The conference reached a consensus that AFO’s were of 
benefit, however, the proceedings of this conference indicated that there is 
little scientific evidence on the prescription of AFO’s in this patient population. 
Most of the guidelines developed for the prescription of AFO’s are justified by 
the following statement by Condie (2003) – “…recommended best practice 
based on clinical experience of the guideline development group”.  The 
prescription of AFO’s in stroke is controversial as clinicians and academics 
have been unable to reach a consensus on their use in stroke (Leung & 
Moseley, 2003). The beneficial effects of AFO’s on temporal and kinematic 
parameters of walking on a broad, undefined population of stroke patients is 
accepted; the effects of AFO use on muscle activity is unclear (Leung & 
Moseley, 2003). No evidence had been identified regarding the timing of the 
application of an AFO following stroke or the impairments suggestive towards 
the benefits of an AFO (Tyson & Kent, 2009). As such, there is no evidence 
regarding AFO prescription, much of it being based on clinical experience and 
knowledge (Condie, 2003; van Til, Renzenbrink, Dolan, & Ijzerman, 2008).  A 
Cochrane review by Tyson and Kent (2009) investigating the effect of AFO’s 
in stroke indicated that AFO’s have an immediate effect on walking 
performance. The effect of long term use of AFO’s is not clear, nor are the 
guidelines regarding their application, particularly in regards to the timing of 
application and which particular AFO should be applied. They identified the 
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areas which required further research as: the long term effects of AFO use, 
optimal timing and duration of use and optimal design of the AFO. Specifically 
off the shelf AFO’s require comparison with custom made AFO’s, and further 
studies are required to identify which AFO’s should be used and when.  
Patients in the early stages following stroke exhibit the same or similar 
impairments around the ankle as those patients in the chronic stages of stroke 
recovery. These impairments can change the ability of, and the quality of 
walking. An AFO can potentially correct some or all of these impairments. 
Therefore, the clinician needs to consider the effect that an AFO can have on 
the recovery of ankle function, and whether this could limit the final functional 
outcome of their patient (Hanna & Harvey, 2001). The need for functional 
restoration of the ankle as an outcome has to be balanced against the benefit 
of walking independently in the early stages of walking recovery.  Ideally, a 
balance between both philosophies’ is required. 
 
2.2.2.2 The use of AFO’s in stroke 
There is little consistency between the types of AFO used in the 
literature examining the use of AFO’s in stroke, other than authors with 
multiple publications utilising the same orthoses in their study design. AFO’s 
were fixed (Beckerman et al., 1996; Burdett et al., 1988; Chen et al., 1999; 
Danielsson & Stibrant, 2004; de Wit et al., 2004; Dieli et al., 1997; Gok et al., 
2003; Pohl & Mehrholz, 2006;  Tyson & Thornton, 2001; Wang et al., 2007; 
Wang et al., 2005), or articulated at the ankle (Beckerman et al., 1996; Hesse 
et al., 1996; Hesse et al., 1999; Tyson & Thornton, 2001). There are studies 
that have also examined custom-made (Beckerman et al., 1996; Chen et al., 
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1999; Dieli et al., 1997; Fatone & Hansen, 2007; Gok et al., 2003; Mojica et 
al., 1988; Pavlik, 2008; Pohl & Mehrholz, 2006; Tyson & Thornton, 2001) and 
off the shelf AFO’s (Burdett et al., 1988; de Wit et al., 2004; Hesse et al., 
1996; Hesse et al., 1999; Wang et al., 2007; Wang et al., 2005) of varying 
designs. Franceschini, Massucci, Ferrari, Agosti and Paroli (2003) did not 
adequately describe the design or construct of the AFO’s used in their study. 
Table 2.5 lists examples of types of AFO described in the literature, the 
biomechanical effects of each type of AFO and the clinical indications for each 
type. Although the scientific support of the clinical indication is weak, 
inadequate or absent (Condie, 2003; van Til et al., 2008). 
Further to the studies reported above there have been a number of 
studies have been identified, in addition to those reported by Leung and 
Moseley (2003), which compare the use of AFO’s in stroke. Each study 
involved comparisons of orthoses with other orthoses or unaided walking. A 
summary of these studies is provided in Table 2.6. Each study examined the 


















Type Example Biomechanical action Indication for prescription 




Provide mediolateral stability of the ankle 
Unrestricted plantar flexion and dorsi flexion 
Control inversion 
Less severe 
 (Burdett et al., 1988) 
 
 
Plastic Spring Leaf 
 
Prevent plantar flexion in swing phase 
Allow some dorsi flexion in stance phase 
Ankle and knee dysfunction  





Custom made Prevent plantar flexion in swing phase 
Allow some ankle movement in stance phase, 
but control the amount of movement 
Ankle and knee dysfunction 
Minimal tone 













Custom made Prevent plantar flexion in swing phase 
More stability in stance phase 
Ankle and knee dysfunction 
Reduced dorsiflexion range 
Moderate tone 
 (Condie, 2003; Gok et al., 2003) 
Ground 
Reaction 
Custom made Prevent plantar flexion in swing phase 
Assist stabilising the knee in the stance phase 
May allow ankle movement, depending on 
design 
Ankle and significant knee dysfunction 
Varying degrees of dorsiflexion range  
limitation 
Varying degrees of tone 




Of the studies identified in Table 2.6 only eight compare AFO’s of 
varying types. In each of these comparisons, the difference in the 
biomechanical properties of each AFO compared is limited. Gok et al., (2003) 
compared metallic and plastic AFO’s is a study designed to compare the 
effect of altering the construction material of AFO’s. Diamond and 
Otternbacher (1990) compared an AFO used to reduce the effects of tone and 
a standard AFO whilst Kitaoka et al., (2006) examined standard and 
articulated AFO’s on the gait of healthy participants. There has been no study 
comparing AFO’s with significantly different biomechanical properties. More 
specifically, comparisons of very restrictive AFO’s with less restrictive AFO’s 
in clinical populations have not occurred. The research of Kitaoka et al. (2006) 
on the effects of AFO’s in healthy participants is of use in examining the 
effects of AFO prescription. AFO’s are prescribed in order to improve gait, this 
is assessed by determining if gait becomes more normal. Kitaoka et al. (2006) 
found that AFO’s caused deterioration in gait in healthy individuals, but did not 
report on parameters such as velocity and step length commonly assessed in 
gait analysis. This raises that suggestion that AFO prescription could have a 
negative effect in some cases. 
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Table 2.6: Studies identified which assess or compare AFO’s 
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in barefeet 
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9 60 participants 
 
Average age: 

























More than one 
stroke 







ability to ambulate 
 







Clonus present in 
varying degrees 
in all participants 
Thermocoagulatio
























19 19 participants Not defined Inclusion criteria: 
Diagnosis of stroke 
 
Ambulate 
unassisted with or 




had  increased 
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Plastic AFO’s set 
at plantigrade or 
50 dorsiflexion 
 




















side step length 
using either Air 
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using either Air 





































support for 60 
seconds and shift 
weight forwards, 
backwards and to 
the sides 
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 Inclusion criteria: 
Stroke patients 
identified by their 
therapist as 
requiring an AFO 

























32 10 participants 
 












Stroke diagnosis  
 
At least 6 months post 
stroke 
 
Walk for 5 minutes ± gait 
aid 
 
Habituated to using a 
carbon composite AFO 
 
Exclusion criteria: 






Non – stroke gait 
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flexion muscles tone: 
4 (2-4) Modified 
Ashworth Scale 
 






VO2 – oxygen 
consumption 
 

































34 20 participants 
 
Average age 
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Diagnosis of stroke, 
MCA artery territory 
 
40-75 years of age 
 
At least 6 months 
post stroke 
 
Used and AFO daily 
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post 
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movements at the 














































38 3 participants  Inclusion criteria: 
Able to walk 10m 
without a gait aid 
 
Able to achieve 
plantigrade at the 
ankle 
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43 16 participants 
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No major 
involvement of the 
contralateral limb 
 
Wearing or had 
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Articulated AFO 
with 900 plantar 













No difference in 
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AFO’s created a 
knee extension 
moment in early 
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post stroke 
 
Used an AFO for at 
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110 4 participants 
 









Infarction, 6 months 
– 10 years post  
 
AFO  use for at 
least 6 months 
 





Co morbidities that 
affected  their 
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constructed short 
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No differences at 4 
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Improved stride 
time and swing 
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an extended steel 











141 4 participants 
reported as single 
case designs: 
 
65 year old female 
(1),  
 






52 yo man (3),  
 
 
24 yo man, ICH 8 
months ago (4),  
 
3 years post 
stroke (1) 
 
























Step the weak leg 
 
Plantigrade at both 
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Able to walk 
with/without AFO (1) 
 
 
Unable to walk 




Able to walk without 
the AFO (3) 
 
 
Assisted to walk (4) 











AFO not described, 











Improvements of 3 
participants in all 
aspects. No 


















142 25 participants 
 
49.9 ±1 years 
Average 
duration of 
lesion 8.3 ± 
5.5 months 




One month post 
fitting of a 
articulated AFO 
 
Able to weightbear 
and step the 
affected leg 
 


















































felt they walked  
better with an AFO 
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62.3 years ± 
11.8 years 
Group 1:  
101  ±53.3 
days 
 
Group 2:  
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support for 60 
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Walk 10m ± 
assistive device 
 
Able to follow 
commands 
 











eyes open and 





Limit of stability 














sway on foam, LOS 
to the affected and 
non-affected sides, 




AFO’s did not 
significantly 





There is little homogeneity in the methods of the studies identified in Table 2.6 
limiting the ability to compare the results. Aspects of the methods that particularly limit 
comparison are the types of AFO compared the point of recovery from stroke at which 
the AFO is compared, the impairments of the ankle, and their walking ability. Key 
methodological constraints of certain studies outlined in Table 2.6 will be discussed 
below. 
 
2.2.2.2.1 Type of AFO 
Of the 26 studies listed in Table 2.6, the majority (N =18) compared one type of 
AFO with walking in shoes and/or barefoot. For these studies, a variety of AFO’s were 
utilised, of either plastic, metal or carbon construction and off the shelf or custom made. 
Some studies involved individually prescribed AFO’s (Abe et al., 2009; Churchill et al., 
2003; Fatone & Hansen, 2007; Franceschini et al., 2003; Mojica et al., 1988; Pavlik, 
2008; Pohl & Mehrholz, 2006; Ring et al., 2009; Tyson & Thornton, 2001), without 
investigating differences between the types of AFOs utilised by participants. Two 
studies (Burdett et al., 1988; Gok et al., 2003) compared AFO’s of different construction 
materials (plastic and metal) both finding improvement in speed and/or step length 
between walking with either AFO and without but not between AFO’s. Burdett et al. 
(1988) also examined a minimally rigid air stirrup brace finding it equivocal to a plastic 
or metal AFO’s.  Five other studies (Diamond & Ottenbacher, 1990; Dieli et al., 1997; 
Fatone et al., 2009; Kitaoka et al., 2006;  Lehmann et al., 1987) compared different 
types of AFO. Kitaoka et al. (2006) found the more rigid the AFO the less movement at 
the ankle in healthy participants. Lehmann et al. (1987) determined that altering the 
setting of the ankle angle changed knee flexion through stance, but did not alter walking 
speed. Fatone et al.  (2009) found no difference in walking speed between an 
articulated and two heel height compensated AFO’s of varying footplate length, but that 
the longer the footplate the greater the plantar flexion moment. The construction of the 
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AFO’s in this study did not vary greatly, which may account for their results. Dieli et al. 
(1997) did not perform statistical analysis when comparing a polypropylene AFO with a 
dynamic AFO, whilst Diamond and Ottenbacher (1990) only assessed one participant in 
an polypropylene AFO or custom designed tone inhibiting AFO.   To date, no studies 
have attempted to match clinical characteristics of patients following stroke (e.g. 
presence of increased tone in calf muscles) with type of AFO.  
 
2.2.2.2.2 The effect of ankle impairments on response to AFO 
 Similarly there is a lack of consistency with regard to ankle impairments in 
inclusion and exclusion criteria in the listed studies. Differences in ankle impairment 
may account for differences in study outcomes. Wang et al.  (2007) did not control for 
ankle strength of their participants. The mean dorsiflexion strength of the participants 
was greater than 25 pounds (range: 12.95 – 45.19 pounds) in the affected leg of these 
subjects, indicating the availability of significant levels of ankle strength. An ankle that is 
able to produce over 25 pounds of strength may not be considered greatly impaired. 
The clinical appropriateness of prescribing an AFO to a patient with ankle movement 
and strength in the early stages of walking recovery, as in Wang et al. (2007) is difficult 
to justify.  
Hesse et al.  (1996) endeavoured to use ankle impairment as a determinant to 
prescribe an AFO by specifying that their participants had plantar flexor spasticity of at 
least three (Ashworth Scale) and were able to achieve a plantigrade position of the 
ankle. A Valens calliper (AFO) shoed and barefoot walking were compared. Walking 
with the calliper and shoes improved walking velocity and improved contact of the foot 
during roll-over. However there was no comparison of the Valens calliper in individuals 
with differing levels of ankle spasticity, nor a comparison with an AFO that was hinged. 
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Such comparisons may have allowed a conclusion that ankle impairment may be used 
to assist in AFO prescription. In a separate study, with the same inclusion criteria,  
Hesse et al.  (1999) looked at the effects of a Valens Caliper on balance 
parameters in people with stroke, finding that an AFO improves dynamic balance 
measures. This study also utilised surface EMG to compare the muscle activity when 
using an AFO. In particular they found that vastus lateralis activity increased with the 
use of an AFO and tibialis anterior activity decreased with an AFO. Additionally the use 
of the AFO contributed to premature muscle activity of gastrocnemius. This is the only 
study which provides evidence in support of the belief that an AFO may negatively 
influence tibialis anterior activity, although the long term effects are not established.  
Other than the two studies by Hesse et al, there is very little investigation into the 
relationship between ankle impairment and the effects of AFO’s. 
 
2.2.2.2.3 The duration following stroke at which an AFO was assessed 
 There is also disparity amongst the studies regarding the time point 
following stroke. In 15 of the 26 studies, the mean time from stroke for participants 
exceeded nine months. Thirteen of these studies found improvements in gait speed 
when an AFO was utilised. Due to the chronicity of their strokes these patients may 
have adapted to the use of an AFO and so would deteriorate in their walking without it.  
In these studies with participants with chronic stroke, 10 included participants who were 
already using an AFO, in 5 of these studies prior use of an AFO was unclear. Five 
studies included both those in the subacute and chronic phases of stroke (Abe et al., 
2009; Beckerman et al., 1996; Chen et al., 1999; Danielsson & Stibrant, 2004; 
Franceschini et al., 2003). In contrast Gok et al. (2003) compared two types of AFO with 
each other and walking without an orthosis in twelve participants, with most at an earlier 
stage of recovery (mean: 67 days; 30-270 day range). Another study with participants in 
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the consolidation stage of recovery was that of Pohl and Mehrholz (2006) whose 
participants had a mean duration of 2.6 months post stroke (range 1-6 months).  Similar 
to the studies of chronic stroke patients identified above, these two acute studies also 
found differences in walking velocity. In conclusion, few studies have focused on 
patients with stroke in the early stages of walking recovery who have not used an AFO 
prior to the study.   
 
2.2.2.2.4 The walking ability of participants at assessment 
 The walking ability of the participants may also influence the outcomes resulting 
from the application an AFO. Similarly to the influence that the duration of recovery may 
have on walking, the length of time that the participant had walked prior to assessment 
may have an effect. None of the studies identified in Table 2.6 considered or controlled 
for the length of time that the participant had been walking prior to assessment.  
 
2.2.3 Summary of gait variable considerations regarding AFO prescription 
Whilst there is evidence to suggest that an AFO can be of benefit in improving 
various parameters of gait performance following stroke there are few investigations in 
patients in the early stages of walking recovery. Most of the studies included 
participants in the chronic phase of recovery who have already been prescribed an 
AFO. Other than a reduction in tibialis anterior activation, identified by Hesse et al. 
(1999), and discussed in the systematic review of Leung and Mosley (2003), no study 
identifies potential risks of AFO prescription. There has also been limited comparison 
between differing types of AFO’s. The effect of AFO use on normal gait is not clear for 
walking velocity, step length, single stance phase, swing phase, stance symmetry and 
knee angle during the stance phase. 
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Using our understanding of the principles regarding recovery in stroke and the 
positive role that interacting with the environment has on recovery there is the potential 
that AFO’s may be deleterious in their effect, particularly more restrictive AFO’s. These 
potential negative effects need to be balanced by the positive effects that the 
prescription of an AFO can have on walking – as measured by gait velocity in the 
studies identified. Other benefits to gait parameters identified by the literature review 
include step length, stance time and double limb support percentages. There has been 
no examination of the effect on walking of various AFO’s in patients with stroke with an 
ankle impairment limiting walking performance who have not yet been prescribed an 
AFO. 
Despite the evidence supporting the use of AFO’s in stroke, questions remain 
regarding the application of AFO’s in stroke. It remains unclear if specific AFO’s are 




AFO’s can be prescribed to people who have had a stroke and have difficulty 
walking as a result of impairments around the ankle. There are many factors to consider 
when prescribing an orthosis, such as the type of orthosis and the timing of the 
application of the orthosis, for which there is little evidence.   
It is accepted that AFO’s are beneficial in terms of improving gait parameters 
such as velocity, step length and symmetry in stroke patients in the consolidation and 
chronic stages of recovery. The differences in effects on walking of AFO’s of varying 
rigidity is less clearly understood. It has been suggested that AFO prescription may limit 
potential recovery of ankle function in the early stages following stroke, as 
neuroplasticity is greatest at this time (Leung & Moseley, 2003).  It is important to have 
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objective evidence of the effects of various types of AFO when used in the early stages 
post stroke. 
 The objectives of this study were established to; (1) examine the walking 
performance in patients in the early stages of walking recovery following stroke ; (2)  to 
examine the effects of AFO’s of varying rigidity on walking performance in patients in 
the early stages of walking recovery following stroke; (3) to examine the effects of 
AFO’s on walking performance in healthy individuals; (4)  to determine differences on 
walking performance under the different AFO conditions between individuals in the early 
stages of walking recovery following stroke and healthy individuals.  
 This study was the first to compare AFO’s with varying biomechanical properties 
to determine differences in gait performance under each different AFO conditions in the 
early stages of walking recovery following stroke. By being the first study to compare 
AFO’s of differing properties  under the same conditions at the same functional stage of 
recovery it is anticipated that inferences can be drawn that can be used clinically to aid 
prescription of AFO’s in these patients.  Additionally, the examination of the effects on 
walking of these AFO’s on healthy participants will further describe the influence of 















This chapter describes the identification, selection, and recruitment of 
participants. Their assessment, intervention and follow-up procedures are also 
outlined. There are two sections to the study design: (1) a comparison of gait whilst 
walking under varying ankle foot orthoses (AFO) conditions in a group of people who 
have suffered a stroke, and (2) a comparison of gait whilst walking under various 
AFO conditions in a group of age and gender matched healthy (control) participants. 
In addition a sub study was conducted to examine the reliability of kinematic data. 
 
This chapter is divided into the following sections: 




3.5) Procedures  
3. 6) Data analysis 
 
 
This project received Human Research Ethics Committee approval from St Vincent’s 
Hospital Melbourne (HREC-A 028/08, refer to Appendix A) and from Australian 





3.1 Research Design 
The major component of this study was a within subject repeated measures 
design to analyse the effect of each AFO on walking  and a  case control group 
comparison design in order to identify differences between stroke and healthy 
participants. A sub-study examined the test-retest reliability and inter-rater reliability 
of the kinematic data relating to knee position in stance. 
 
3.2  Participants 
  
3.2.1  Recruitment of Stroke participants 
Patients with a diagnosis of stroke were recruited from the Rehabilitation Units 
of St Vincent’s Hospital Melbourne for this study. The selection process sought to 
identify patients with an ankle impairment which may have contributed to their altered 
walking performance. The consent forms for stroke participants can be found in 
Appendix C. 
Patients were recruited from the sub-acute wards of a large public hospital. All 
patients with a diagnosis of stroke were assessed by physiotherapy staff for 
alterations to their walking abilities. Physiotherapists within the hospital were briefed 
of the research project and informed of the inclusion criteria of the study. The treating 
physiotherapist informed the patient of the study if the patient met the inclusion 
criteria. If the patient expressed an interest in volunteering to participate in the study, 
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the investigator was then contacted. The investigator met with the patient to fully 
explain the study and the assessment procedure, and also provide a written 
information letter about the study. Each patient was given the opportunity to ask 




3.2.2  Recruitment of Healthy participants 
Thirteen healthy individuals were recruited from staff, family and friends of St 
Vincent’s Health to act as a control group. Healthy participants were age matched (+/- 
5 years) and gender matched to the previously recruited participants with a diagnosis 
of stroke. The consent form for the healthy participants can found in Appendix D. 
In order to recruit healthy participants the staff of St Vincent’s Hospital 
Physiotherapy Department were emailed to determine levels of interest. Potential 
participants were encouraged to contact the student investigator for further 
discussion. Potential participants were screened for their eligibility at that point. If they 
met the inclusion criteria (age and gender match, healthy and no history of stroke) 
they were provided with a Participant Information and Consent Form, and were 






3.2.3 Inclusion/Exclusion Criteria  
The inclusion and exclusion criteria are outlined below for the stroke 
participants (Tables 3.1 and 3.2) and the inclusion criteria for the healthy participants 
(Table 3.3).  
 
3.2.3.1 Inclusion/Exclusion Criteria Stroke Participants  
The criteria applied in order to determine eligibility for recruitment to the study are 
summarised in Tables 3.1 and 3.2 below. Following is a justification of these criteria. 
 
 
Table 3.1: Inclusion criteria for the stroke participants 
Inclusion Criteria 
Diagnosis of stroke 
Unilateral hemiparesis 
Less than 20 weeks post stroke 
Able to walk with or without supervision, with or without a gait aid 
Motor deficit of the ankle dorsiflexors (STREAM <2 and/or Oxford Scale <3) 







Table 3.2: Exclusion criteria of the stroke participants 
Exclusion Criteria 
Ataxia 
Orthopaedic impairment limiting mobility pre-morbidly 
Ankle dorsiflexor strength greater than or equal to three, as measured by the 
Oxford Scale 
Wounds or fragile skin on the hemiplegic lower limb that would preclude the 
application of a fibreglass cast 
 
 
Ataxia was considered to be exclusion criteria because it can negatively affect 
walking performance irrespective of alterations in ankle function. Not excluding 
patients with ataxia could misrepresent the effect of the AFO’s used. Similarly, 
impaired walking prior to their stroke could confound the effects of the AFO on 
walking performance. The premorbid walking impairment could produce a ceiling 
effect which would not enable accurate measurement of the effects of the AFO’s. 
Having ankle strength greater than grade three on the Oxford Scale indicates that the 
patient has the motor ability to be able to clear the foot during the swing phase of 
gait. AFO’s would not be indicated in this instance. Including such patients would be 
misrepresentative of the population of stroke patients who benefit most from AFO 
prescription. The application of a fibreglass cast can put fragile skin at risk of wounds 
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or pressure areas. Such incidents can significantly impact on a patients’ outcome. It 
was deemed unethical to put patients at such risk. 
Two hundred and twenty people were admitted to the sub acute wards of St 
Vincent’s Health with a diagnosis of stroke during the course of the study. Thirteen 
patients met the eligibility criteria as identified by their treating therapist and all 
consented to participate in the study after agreeing to discuss their participation with 
the student investigator.  No participant withdrew from this study. 
Of the 207 people with a diagnosis of stroke who were ineligible for this study 
the main reason for exclusion was either no difficulty walking, inability to walk without 
assistance, or minimal impairments around the ankle.  
 
3.2.3.2 Inclusion Criteria Healthy participants 
Healthy participants were eligible to participate if they met the inclusion criteria 
summarised in Table 3.3: 
 
Table 3.3: Inclusion criteria for the healthy participants 
Inclusion criteria 
No history of musculoskeletal abnormality of the foot and ankle 
No history of neurological conditions that affect balance or walking 
Do not use an ankle support device 




3.2.4 Participant Groups 
Thirteen participants were eligible for this study and were recruited. 
Accordingly, thirteen healthy participants were also recruited. Their demographic 
information is recorded below. 
 
3.2.4.1 Stroke Group 
The stroke group included ten males and three females (mean age 52.31 
years +13.9; mean height 1.74m +0.08; mean body mass 80.7kg +15.8). Eight 
participants had a haemorrhagic stroke whilst five had an infarct.  The mean duration 
of their stroke was 51.15 days (standard deviation 27.5 days). Seven participants 
were affected on the left side, whilst six were right side affected. 
 
3.2.4.2 Healthy Group 
The mean age of the healthy group was 52.2 years (standard deviation 13.1 
years); mean height was 1.72 m (standard deviation 0.06 m); and body mass was 










This section describes the methods in which the participant’s gait was 
assessed. It is divided into spatiotemporal measures and kinematic measures, which 
are summarised in Table 3.4 
 
3.3.1 Spatiotemporal measures of gait 
Spatio temporal gait characteristics collected were velocity, cadence,  
percentage of gait cycle in double limb support, affected leg single support phase,  
the symmetry between the affected and non-affected single leg stance times (Stance 
Symmetry Ratio),  affected leg  step length, and affected leg swing phase percentage 
of gait cycle. The single leg stance times between the affected and unaffected limb 
was determined using the Symmetry Index (SI) as proposed by Robinson, Herzog 
and Nigg (1987) and reported by Sadeghi, Allard, Prince and Labelle (2000; Equation 
3.1). Whilst this index has limitations (Sadeghi, Allard, Prince, & Labelle, 2000), it has 
been demonstrated to show improvements in gait symmetry following ankle fractures 









GAITRite®, as seen in Figure 3.1, is an electronic instrumented walkway 
system which measures spatiotemporal parameters of gait. It consists of a portable 
walkway, embedded with pressure sensitive sensors, positioned beneath a vinyl with 
square thread reinforced fabric walkway on a on an open cell rubber base. The 
walkway is linked to a compatible computer by a serial interface cable, which then 
records each footfall and analyses and stores the data to produce the spatiotemporal 
parameters. The walkway used measures 810cm long, 89cm wide and 0.625cm thick 
and has an active recording area of 720cm by 60cm (GAITRite ®, CIR Systems 
GRG-24, United States, 80Hz). Each sensor is pressure activated as each foot 
contacts the mat, triggering multiple sensors in pattern of the foot contact. Multiple 
foot contacts are analysed over a known time period (triggered by first foot contact to 
last foot contact over the active area of the walkway) to determine velocity, step 
length, cadence, time in single and double support among multiple other parameters.  
The degree of toe in or out of the foot can also be determined by the angle of the foot 
contact on the gait mat.  
 GaitRite® has strong concurrent validity and test-retest reliability across all 
spatiotemporal parameters in healthy subjects (Bilney et al., 2003; van Uden & 
Besser, 2004), as well as in older individuals (Menz et al., 2004). Its validity has also 
been established in regards to averaged and individual step characteristics following 
knee replacement surgery (Webster et al., 2005). Base of support and toe in/out 
angle have reduced reliability, possibly due to the spatial resolution of GaitRite® or 









3.3.2 Kinematic Measures 
 The angle of the knee joint was assessed through the stance phase of 
gait as occurs in clinical practice in which the effect on knee hyperextension after the 
application of an AFO is noted. Knee hyperextension is a common gait abnormality 
following a stroke, which puts the knee at risk of potential trauma. AFO’s have the 
potential to cause hyperextension, depending on their construction (Condie, 2003; 
Lehmann, 1993). The presence of knee hyperextension may indicate that an AFO is 
not appropriate (Condie, 2003). However, certain types of AFO may be utilised to 
prevent knee hyperextension, though there are no studies investigating this to date. 
Knee hyperextension analysis was required to ensure participant safety. Silicon 
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Coach Pro software™ (version 7, Silicon Coach Pty Ltd, Dunedin, New Zealand) was 
used to measure the angle of the knee through stance phase. Silicon Coach has 
been demonstrated to be a reliable kinematic technique for measuring ROM at the 
knee joint (Cronin, Nash, & Whatman, 2006), however there are no studies 
investigating the validity of the measure. The reliability has not been determined in 
regards to stroke. Although the SiliconCoach software lacks established reliability and 
validity research evidence, superior motion analysis tools such as Vicon, were not 
available. The resulting kinematic data was examined in order to determine if the 
application of an AFO caused knee hyperextension.  A summary of the dependent 
variables is outlined in Table 3. 8. 
 
Table 3.4: Summary of Dependent Variables 
Laboratory Tool Parameter Measure 
GAITRite Velocity cm/sec 
 Cadence Steps/minute 
 Affected/Matched leg 
step length 
cm 
 Double limb stance % of gait cycle 
 Affected/Matched leg 
single support phase 
% of gait cycle 
 Single leg stance 
symmetry 
Ratio (Equation 3.1) 
 Affected/Matched leg 
swing phase  
% of gait cycle 




3.3.3 Demographics Assessment 
The medical history of the participant was reviewed and in particular any 
radiological investigation that confirmed the diagnosis and location of the cerebral 
lesion.  
 
3.3.4  Physical Assessment Tests 
Alterations to the strength and movement of the ankle are common after 
stroke. A thorough examination of the neuromuscular performance of the ankle is 
routinely performed during the examination of patients following stroke. 
 
3.3.4.1 Range of Movement 
A reduction in dorsiflexion range of movement (ROM) can significantly impact 
on the ability to walk and on the quality of walking (Lehmann, 1993). A normal range 
of ankle dorsiflexion is 20 degrees (Norkin & Levange, 1992). Reductions in 
dorsiflexion ROM can contribute to alterations in walking performance in stroke 
(Lamontagne et al., 2000; Rydahl & Brouwer, 2004). 
 
3.3.4.2 Tone 
Spasticity is one of the impairments that follows an upper motor neuron lesion. 
Spasticity is characterized by a velocity dependent increase in tonic stretch reflexes. 
The Modified Tardieu Scale is used as a measurement of spasticity, which records 
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the degree of the muscle reaction and the velocity of the stretch at which it occurs 
(Mehrholz et al., 2005) (Table 3.5, Appendix E). The Tardieu Scale is a more 
accurate measure to differentiate spasticity from contracture compared to other 
clinical measures of tone (Patrick & Ada, 2006).  The Tardieu Scale is both a valid 
and reliable measure of spasticity (Mehrholz et al., 2005). Tone is a common 
occurrence following stroke and can negatively affect the ability to walk and the 
quality of walking (Hsu et al., 2003; Lamontagne, Malouin, & Richards, 2001; Lin et 
al., 2006).  
 
Table 3.5: Modified Tardieu Scale (Gracies et al., 2000) 
Test Score Description 
Velocity of 
stretch 
V1 Slow as possible (minimizing stretch reflex) 
V2 Speed of the limb segment falling under gravity 
V3 
As fast as possible (faster than the rate of the 





No resistance throughout the course of the passive 
movement 
1 
Slight resistance throughout the course of the 
passive movement, with no clear catch at a precise 
angle 
2 
Clear catch at a precise angle, interrupting the 
passive movement, followed by release 
3 
Fatigable clonus (<10 seconds when maintaining 
pressure) occurring at a precise angle 
4 
Infatigable clonus (>10 seconds when maintaining 
pressure) occurring at a precise angle 
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3.3.4.3 Active Motor Control 
The ability to produce voluntary movements can be impaired following stroke. 
These impairments can result in a reduced functional level. (Hsu et al., 2003; 
Lamontagne et al., 2002) The loss of the ability to produce movement is due to 
alterations in the neuromuscular unit as well as a reduction in muscular strength. 
Alterations to the neuromuscular unit occur due to changes at a cortical level 
eliminating or reducing the ability to initiate the movement required. The change in 
the ability to actively produce motor control is the impairment in this case. The 
manifestation of a loss of active motor control is a loss of strength. The Stroke 
Rehabilitation Assessment of Movement (STREAM) evaluates the quality and ability 
to produce basic movements and gait activities with an excellent degree of reliability 
(Daley, Mayo, & Wood-Dauphinee, 1999) (Table 3.6). The ankle subsection of 
STREAM was used to evaluate the degree of motor control impairment in the current 
study. Additionally, the strength of the participant was assessed using the Oxford 
Scale (Table 3.7).  The Oxford Scale has been used by a number of investigators 
(Florence et al., 1992; Savic, Bergstrom, Frankel, Jamous, & Jones, 2007). The  
reliability of the Oxford Scale is thought to be moderate to strong (Paternostro-Sluga 
et al., 2008; Savic et al., 2007; Wadsworth, Krishnan, Sear, Harrold, & Nielsen, 
1987), and has very strong reliability in relation to assessing movements with a score 
less than 3/5 (Florence et al., 1992). Strength of the ankle and knee was further 
assessed using a handheld dynamometer (Model 01163, Lafayette Muscle Tester, 
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Lafayette Instrument Company, Lafayette) to provide a quantitative assessment of 
the strength of the ankle.  
 
 
Table 3.6: STREAM. An outline of the scoring definitions for this scale. (Daley et al., 
1999) 
Score Description 
0 Unable to perform the movement through any appreciable range (includes 
flickers and slight movements) 
1a Able to perform only part of the movement, and with marked deviations from 
the normal pattern 
1b Able to perform only part of the movement, but in a manner comparable to 
the unaffected side 
1c Able complete the movement, but only with marked deviation from the 
normal pattern 












Table 3.7:  Oxford Scale. Examination of the dorsiflexion movement (Hislop, 
Montgomeroy, Connolly, Daniels, & Worthingham, 1995) 
Oxford Grading Muscle Activity 
0 No palpable contraction of the tibialis anterior tendon 
1 Palpable contraction or tendon will stand out as visualised by the 
investigator 
2 Only able to complete part of the range of movement 
3 Able to complete the full available ROM and can hold the end 
position without resistance from the investigator. 
4 Able to complete full range of movement against moderate 
resistance from the investigator 
5 Able to complete full range of movement and holds against maximal 
resistance from the investigator 
 
 
3.3.4.4 Sensation and Proprioception 
Alterations in sensation and proprioception can occur in stroke. This can affect 
the ability to walk due to reductions in balance due a lack of awareness of where that 









3.4 Interventions – AFO’s 
There were five different conditions (interventions) which each participant were 
assessed. : Nil orthosis (shoed), barefoot, spring leaf AFO, Push Aequi Brace (sports 
brace) and fibreglass cast. The three orthoses conditions are illustrated in Figure 3.2. 
The participants walked in their own shoes. These AFO’s were chosen as they 
represent AFO’s of varying rigidity and will have different biomechanical effects. It is 
intended that these differences in biomechanical action will allow representation of 
different walking performance.   
 
A         B    C 
  
Figure 3.2: A: Spring Leaf AFO; B: Push Aequei; C: Fibreglass Cast and plasterboot 
 
3.4.1 Push Aequi Brace (PAB) 
A Push Aequi brace (PCT/NL98/00002, Nea International, The Netherlands) is 
a sport brace used to stabilize the ankle via a rigid support on the medial side and a 
pre-formed foam lateral wall. It is secured by two velcro straps that wrap around the 
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ankle. There are three sizes of Push Aequi Brace (PAB) in left and right styles, 
measured by the circumference of the affected ankle. The PAB predominately 
stabilizes inversion and eversion of the ankle, but allow some dorsiflexion support 
though the swing phase of gait, particularly at the rear foot. During the stance phase 
the PAB provides minimal restriction to plantar flexion and dorsiflexion, thus allowing 
the normal kinematics of heel strike and rollover. 
 
3.4.2 Spring Leaf AFO (SLAFO) 
Spring Leaf AFOs (L2012, L2013, L2014, L2015, L2017, L2018, L2019, 
L2020, Grenace™, Australia) are mass produced polypropylene AFOs. They come in 
three different sizes for both men’s and women’s models. The Spring Leaf AFO 
(SLAFO) is fitted inside the patient’s shoe and is secured to the calf by a velcro strap. 
This AFO is designed to prevent plantar flexion during the swing phase of gait, but 
allows some plantar flexion and dorsiflexion during the stance phase due to the 
construction of the AFO. The degree of dorsiflexion available is dependent on the 
rigidity of the polypropylene.   
 
3.4.3 Fibreglass Cast (FGC) 
Each participant was cast in a below knee fibreglass cast (Dynacast® Extra 
4793 71362-00, BSN medical Ltd, England). The casting was undertaken whilst the 
patient was in a seated position with the ankle positioned in plantigrade (zero 
degrees dorsiflexion), or as close to plantigrade as the participants ankle allowed. 
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The method of casting is described in Table 3.7. Fibreglass casting is a commonly 
used assessment tool used by orthotists and physiotherapist’s to test the suitability of 
an individual to use a custom-made orthosis, particularly for a Ground Reaction Ankle 
Foot Orthosis (GRAFO).  
A GRAFO is an orthosis designed to utilize ground reaction forces and the 
muscle strength of the hip to provide a stabilization force around the knee. GRAFO’s 
are custom-made, taking many days or weeks to manufacture. The cost of 
manufacturing a GRAFO can also be significant.  Due to these practical 
considerations, a FGC was chosen to mimic the actions of a GRAFO.  
 
3.5 Procedures  
This section describes the methods for data collection for the physical 
assessment, and the gait assessment.   The assessment process was performed by 
the student investigator in the physiotherapy department of the large public hospital. 
A flow chart describing the process following recruitment is described in Figure 3.3 






Figure 3.3: Flowchart of examination and testing 
 
Recruitment: 
Does the participant meet the inclusion 
criteria? 
Yes.  
Eligible for recruitment 
No. 
Ineligible for recruitment 










3.5.1 Physical Assessment 
This section describes the procedure for the data collection of the physical 
assessment of the participants. It is divided into demographics, range of movement, 
tone, active motor control, sensation and proprioception. 
 
3.5.1.1 Demographics Assessment 
The participants’ height, body mass, and leg length were measured. Height 
was measured using a stadiometer fixed to the wall (SECA 206, SECA GMBH and 
Co, Hamburg, Germany), whilst body mass was measured using  scales accurate to 
0.05 kg (KW-11, @Weigh Pty Ltd, Moorabbin) The participant’s leg length was 
measured using a steel anthropometry tape (Alimed Measuring Tape 5560, Alimed, 
Dedham, MA). with the patient lying in a supine position on a bench (Neurological 
Bobath Table 50061, HealthTec, Yeerongpilly, Qld) from the anterior superior iliac 
spine (ASIS) to the medial malleolus of the ankle (Beattie, Isaacson, Riddle, & 
Rothstein, 1990; Gurney, 2002). 
 
3.5.1.2 Range of Movement 
 The degree of movement available at the ankle was assessed whilst barefoot 
in a prone position using a goniometer (Baseline plastic 3600 ISOM (STFR) 12-1000, 
Fabrication Enterprises, New York). Two measurements were taken; the first with the 
knee in full extension (Figure 3.4) and, the second, with the knee positioned with 90 
degrees of flexion (Figure 3.5) (Elveru, Rothstein, Lamb, & Riddle, 1988). The 
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researcher positioned the participants’ foot into the maximum degree of dorsiflexion 
range available. The goniometric measurement was with reference to the fifth 
metatarsal head (proximal goniometer arm), lateral malleolus (goniometer axis), and 
the line of the fibula (distal goniometer arm) (Figure 3.6). If the participant was not 
able to be positioned in a prone position, the measurements were then taken in a 
supine using the same reference points. 
 
 





Figure 3.5: ROM assessment in prone, knee flexed 
 
 








The participant was assessed whilst in the supine position with the hip and 
knee in a neutral position (00 of flexion) for gastrocnemius, and the knee positioned in 
90 degrees of flexion for soleus. The tone of the plantar flexors determined at the 
fastest stretch possible (V3 on the Tardieu Scale; Table 3.5) The ankle was stabilized 
over the joint line with one hand, and the other hand attempted to provide a rapid 
dorsiflexion movement to elicit a ”catch” in the range (Gracies et al., 2000)(Figure 
3.7). The point at which a catch occurs was noted, as was the degree of the catch. 
 
Figure 3.7: Assessment of spasticity  
 
3.5.1.4 Active motor control 
STREAM, the Oxford Scale and MMT were used to quantify active motor 
control and muscle strength of the tibialis anterior muscle. The Oxford Scale and 





The participant was positioned in supine on a plinth (Neurological Bobath 
Table 50061, HealthTec, Yeerongpilly, Qld). The knee was positioned in 30 degrees 
of flexion using a rolled towel to maintain the posture. For ease of assessment both 
the Oxford scaling and dynamometry occurred in this position. The femur was 
stabilised with one hand of the student researcher (depending which leg was 
assessed), with the other hand positioned over the distal tibia either with or without 
the dynamometer (Model 01163, Lafayette Muscle Tester, Lafayette Instrument 
Company, Lafayette) (Figure 3.8). The participant was asked to straighten their leg 
against the resistance. The student researcher continued to apply resistance until the 
participants effort was “broken” (Phillips, Lo, & Mastaglia, 2000). This was then 
scored as an Oxford scale level and recorded or the dynamometry result was record. 




Figure 3.8: Assessment of quadriceps strength 
 
3.5.1.4.2 Tibialis anterior 
The participant remained in supine following the quadriceps assessment. The 
participants distal tibia was stabilised by one hand of the student researcher, whilst 
the other provided resistance to the distal, dorsal aspect of the participants foot 
(Figure 3.9). This occurred both with and without a dynamometer. The participant was 
asked to dorsiflex with their maximal effort, with the student researcher providing 
resistance until the participant’s effort was “broken”. This was then scored as an 
Oxford scale level and recorded or the dynamometry result was record. Three trials 




Figure 3.9: Assessment of tibialis anterior strength 
 
To score STREAM the participant was positioned in sitting, with the foot being 
assessed slightly in front of the other and asked to “keep your heal on the ground and 
lift your toes of the ground as far as you can” (Daley et al., 1999) (Figure 3.10). The 





Figure 3.10: STREAM assessment, a visual observation of the ankle dorsiflexing 
whilst the participant is positioned in a chair 
 
3.5.1.5 Sensation and Proprioception 
Sensation to light tough of the foot and lower limb of the affected limb was 
tested. The sensation of the heel, first metatarsal head, dorsum of the foot, lateral 
and medial malleoli were tested with a light tissue touch, and were rated as either 
normal, impaired or absent (Carr & Shepherd, 1998).  
Testing of proprioception was also determined at the knee, ankle and great toe 
of the affected limb with the participant in a supine position. Participants were asked 
to determine the position of their joint after it had been passively positioned by the 
investigator. The investigator demonstrated the test on the participants’ unimpaired 
leg first to confirm understanding of the task. The knee, ankle and great toe was 
positioned by the investigator at the end of each available range (i.e. flexion or 
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extension). This was then described as either “up” or “down”. The participant was 
instructed to close their eyes whilst the investigator positioned the joint. The 
participant was then asked to indicate whether that position was either up or down. 
Five tests were completed at each joint. Proprioception was rated as normal for a 
score of five out of five, impaired for a score of one to four out of five, and absent for 
a score of zero out of five (Carr & Shepherd, 1998; School of Physiotherapy, 2009). 
This procedure of testing is the most common method of assessing sensation and 
proprioception in neurological patients (School of Physiotherapy, 2009). 
 
3.5.2 Gait assessment procedure 
The order of AFO conditions was randomised between participants in each 
group. Each participant walked over an electronic walkway.   For participants with a 
diagnosis of stroke the testing was conducted across three days to minimize the 
effect of fatigue. Whereas healthy participants were tested over one day. The leg 
which the healthy participants wore an AFO was matched to that of their age and 
gender matched stroke participant. This was considered the “matched leg” rather 
than affected leg. Before each test the participants with a diagnosis of stroke were 
provided with a 40 minute acclimatization period to become used to each new 
orthosis, during which they will spend no more than 15 minutes of actual walking. 
Healthy participants were provided with a 15 minutes acclimatisation period and a 
self-selected amount of rest following this. Once acclimatized to the orthosis 
condition, the participant performed four overground walking trials at a self-selected, 
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comfortable, pace under each orthotic condition along the walkway and force 
platform. The method of applying the fibreglass cast is outlined in Table 3.8 Patients 
were instructed to walk at a pace that felt comfortable and safe. Four trials were 
completed for each condition, resulting in twenty trials in total. Trials that result in 
poor or inaccurate data due to the participant’s performance, such as by stepping off 
the GaitRite® walkway, were excluded and repeated. A flowchart describing the 
testing procedure can be seen in Figure 3.11. 
Participants began walking 2m before the Gaitrite walkway and finished 2m 
after (Figure 3.11). This was to enable a stable walking pace prior to data collection 
(Goldie, et al., 2001). This allowed for a five metre walk test which has been found to 
be the most valid for assessing walking velocity in stroke patients (Salbach et al., 




Figure 3.11: Flowchart of testing procedure for participants with a diagnosis of stroke. 
 
 
Barefoot   gait assessment 
over GAITRite 
10 min rest 
 
15 minute 
acclimatisation to first 
orthosis within a 40 
minute period 
First orthotic gait 
assessment over 
GaitRite 











Second orthotic gait 
assessment over GaitRite 






Shod gait assessment over 
GAITRite 
Day Three 

















Table 3.8: Method of applying the FGC. 
Step Method of application 
1 Position the participant in sitting, with the affected limb exposed 
and the ankle positioned at plantigrade and neutral supination/ 
pronation 
2 Check the skin for any wounds or lesions that would preclude the 
individual from having a cast applied. 
3 Apply a stockinet from below the toes too above the knee 
4 Wrap the limb in an overlapping under-wrap to protect the skin 
from the metatarsal heads to below the knee 
5 Soak the DynaCast in cold water as per the manufacturer’s 
instructions 
6 Begin wrapping the affected limb with dynacast from the below the 
knee, down to the metatarsal heads with overlapping layers 
dynacast , ensuring the ankle is positioned in as much dorsiflexion 
range as available but not past plantigrade 
7 Whilst maintaining the dorsi flexion ROM allow the cast to cure 
8 A Plaster boot will be fitted over the cast for use in walking. Each 
participant will wear their own shoes on their non-hemiplegic foot 
9 Once cured the testing protocol will be completed. When the trials 
have been completed the fibreglass cast will be removed with an 
electrical saw by an experienced clinician. The skin will be 
checked for any areas of rubbing due to the cast or grazes due 





3.5.2.1 Reliability procedure 
 In order to establish the test retest reliability the kinematic data of the barefoot 
walks conducted on Days One and Three (Figure 3.11) were utilised. The student 
investigator and a senior physiotherapist each marked the anatomical landmarks of 
the lower limb on the videotaped knee angle on the computer screen at initial contact, 
midstance and terminal stance (as defined below) independently. To determine the 
interrater reliability the kinematic results of barefoot walk of day one and the 
kinematic results of the FGC on Day 1 were compared. Barefoot walking was chosen 
as there were data taken over multiple days and the FGC condition was chosen as it 
was the most rigid of the AFO’s and therefore has the potential to be more likely to 
have a negative kinematic effect.  
 
 
3.5.3 Spatiotemporal data  
 Results generated by GAITRite were downloaded into an Excel spreadsheet 
for further statistical analysis. 
  
3.5.4 Kinematic data  
The participants were videoed from the affected limb side whilst walking on the 
GAITRite® walkway.  A video camera (Sony HandyCam DCR-DVD 608e, Sony 
Corporation, Tokyo, 50Hz) was positioned on a tripod, perpendicular to the 






Figure 3.12: GAITRite and video camera set-up 
 
In this study a step is defined was from heel contact of one foot to the heel 
contact of the other foot that followed. Specifically for this study, the ground contact 
phase kinematics of the affected limb was of interest, therefore the video captured 
heel contact of the affected limb followed by heel contact of the unaffected limb. 
Participants were videoed for each walking condition. The resulting footage of all 
participants was compiled into one video in a random order, known only to the 
investigator. The Silicon Coach software was then utilised to assess the knee angle 
at three points during the stance (ground contact phase) of the affected limb at heel 
contact (initial contact), midstance (when the hip is vertically aligned over the ankle), 





knee joint line and the lateral malleolus were identified using visual analysis and 
measured using the software to generate the angle of the femur and tibia/fibula to 
indicate angle of the knee (Figure 3.13). To date the validity of the Silicon Coach 
software has yet to be established, to do so was beyond the scope of this study. 
 
Figure 3.13. Example of the output generated by SiliconCoach 
 
3.5 Data Analysis 
As this study was preliminary in nature there was no data available to perform 
an appropriate sample size calculation. Following data collection the data was 
exported from GAITRite to an Microsoft Excel spreadsheet, to allow the determination 
of the median, mean and standard deviation for each of the trials. The data was then 
exported from Microsoft Excel to the Statistical Package for the Social Sciences 
(SPSS, version 18, SPSS Inc., Chicago IL).  Data was analysed for normality via 
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established standards (Macellari, Giacomozzi, & Saggini, 1999; Portney & Watkins, 
2000). The assumptions of normality were that the participants were randomly 
selected and were representative of the population of interest. The distribution of the 
data scores of this population were considered normal where the homogeneity of 
variance is not violated, the data did not exceed ±2 for skewness and kurtosis and 
that the data is ordinal. The distribution of the data were viewed as histograms for 
spread and the presence of outliers. Normality calculations using Shapiro-Wilk 
indicated variation in the normality of distribution. In light of the small sample size 
involved and the variation in the normality of distribution the conservative option of 
non-parametric analysis was chosen. The data for outliers was kept in the analysis 
due to the small sample size and the statistical analyses chosen.  Descriptive 
statistics were calculated and displayed graphically. 
  Once normality was reviewed four separate analyses were performed: (1) the 
walking performance of the stroke participants were compared to the healthy 
participants, (2) the walking performance of the stroke group with AFO’s grouped 
together and under each different condition was performed, (3) the walking 
performance of the control group with AFO’s grouped together and under each 
different condition was performed. Post hoc analysis were used to detect the 
presence of differences for each group under each different walking condition.   (4) 
Individual analysis of participants occurred using Smallest Real Difference (SRD) 
methods to determine clinically relevant effects, if any. SRD was utilised as it was 
envisaged that the stroke patients responses might by varied and those responses 
109 
 
may not be reflected in the group analysis. Therefore to explore if individuals may 
benefit from an AFO SRD were used. Those that were considered to positively 
respond to AFO prescription were defined as thus; a change in gait performance 
greater than the SRD for at least one AFO in at least one gait parameter. Subsequent 
to this, the physical impairment characteristics of those that demonstrated changes 
greater than the SRD were examined. To limit the number of comparisons, ankle 
ROM, dorsiflexion strength and spasticity were categorised according to Table 3.9. 
Mean muscle activity of tibialis anterior and quadriceps muscles were reported 
according to MMT. Those individuals which responded to more than one AFO were 
further analysed, with differences greater than the SRD noted. Furthermore, following 
individual analysis using smallest real differences case studies will be presented to 




Table 3.9: Categorisation of ankle impairment for responders or non-responders 




Ankle ROM Less than 0 degrees 
dorsiflexion 




Score of less than 2/5 Score of 2/5 
Spasticity 
(Tardieu Scale) 





The data of the stroke group and the healthy participant group were analysed 
using non-parametric testing for dependent samples (Friedman’s Test), a significant 
finding resulting in post-hoc testing using Wilcoxon’s Test. The alpha level for these 
analyses was set at .05 (α = .05). Bonferroni corrections were not performed as the 
variables examined are closely related (Turk et al., 2008) increasing the risk of Type 
2 error. 
As the evidence from the literature suggests that the effect of AFO use is 
varied, and the range of results was large, the response of individuals to the 
application of AFO’s was of interest. Using the data from the shoe trials as a baseline 
to calculate SRD was calculated, with confidence levels set at 95%, using the 
following equation (Equation 3.2; (Stevenson, 2001; Stratford & Goldsmith, 1997): 
 
 
                                                    
where; SRD = Smallest Real Difference, SEM = Standard Error of the Mean 
 
In order to determine the reliability of the baseline (shod) data an Intraclass 
Correlation Coefficient (ICC) was calculated. Two way, mixed single measures (ICC 
3, 1) was used. To enable SRD to be calculated the four raw scores from each of the 
trials for each of the individual participants was exported from a Microsoft Excel 
spreadsheet onto SPSS. Using Equation 3.2 the values required were entered into an 
Microsoft Excel spreadsheet for the SRD calculation. Using median scores each 
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individuals’ difference in barefoot, PAB, SLAFO and FGC from their shod baseline 
was determined.  
 The difference of each individual’s performance from their baseline (shod walk) 
to barefoot, PAB, SLAFO and FGC were displayed graphically as bar graphs for 
velocity, cadence, double limb support, affected leg single support percentage of gait 
cycle, single support symmetry ratio, affected leg swing percentage of gait cycle and 
affected leg step length. The SRD indicator points were indicated on these graphs. 
Individual’s results were also displayed as box plots to indicate the spread of the 
results.  
 The reliability of the assessment of knee angle was assessed using an 
intraclass correlation coefficient (ICC). The ICC utilised was (2, 1), with results 
interpreted according the criteria of Altman (1999):  κ < 0.20 = poor, κ: 0.21–0.40 = 















The results of this study are presented in six sections related to the 
populations tested; the stroke participants and the healthy participants. Each 
section will compare the stroke participants with the healthy participants, and 
compare individual performance within each group of participants. The selected 
case studies will further examine the individual performance of certain stroke 
participants. The sections are divided according to the walking conditions 
compared. Prior to the main analyses, the sub-study to establish the reliability of 
the measure of knee kinematics is presented. 
 
1. Reliability sub-study 
2. General group characteristics comparison 
3. Shod walking compared to barefoot walking 
4. Shod walking compared to ankle foot orthoses (AFO) walking 
5. Shod walking compared to walking with specific types of AFO’s 
6. Individual analysis of the stroke participants 





The results are generally reported as means (standard deviations [SD]). 
Due to some measures breaching normality criteria, non-parametric testing was 
employed and therefore medians and inter-quartile ranges (IQR) will also be 
reported where appropriate. 
 
4.1 Reliability sub-study  
 This section reports the results of the test retest reliability and the 
interrater reliability for knee angle measures in participants with stroke. 
 
4.1.1 Test retest reliability 
 The test retest reliability of barefoot walking on Day 1 and Day 3 for the 
student investigator and a senior physiotherapist are reported in Table 4.1. Each 
of the three variables resulting in very good reliability according to the criteria of 











Table 4.1: Test retest reliability (Tester 1 = student investigator, Tester 2 = Senior 
Physiotherapist) 
Variable  Tester 1 Tester 2 




















4.1.2 Interrater reliability 
 The interater reliability of the student investigator and a senior 
physiotherapist is reported in Table 4.2. Three of the variables resulted in very 
good interrater reliability, one with good reliability and two variables with fair 
reliability according to the according to the criteria of Altmann (1999). 









Table 4.2: Interrater reliability between Tester 1 and Tester 2 (Tester 1 = student 
investigator, Tester 2 = Senior Physiotherapist) 
Variable  Reliability 


































4.2 General characteristics of stroke participants and healthy participants 
Analysis of the demographic data, as presented in Tables 4.3 and 4.4,  
indicated that there were no differences in age (Z= -0.026, p=0.980), stature (Z=-
0.540, p=0.589) or mass (Z=-0.359, p=0.719) between the stroke and healthy 
participants (Table 4.5). There were significant differences however in ankle 
range of motion (ROM) between the stroke and the healthy participants (Table 
4.6). Healthy participants had increased dorsiflexion ROM compared to stroke 
participants (Table 4.6), when assessed with their knee in flexion (Z=-3.461, 
p=0.001), or with their knee in extension (Z=-3.265, p=0.001). Healthy 
participants had stronger dorsiflexion movement, as evidenced by significantly 
greater scores when assessed using the Oxford Scale (Z=-4.693, p=0.0001), 
STREAM (Z=-4.668, p=0.0001) and manual muscle dynamometry (Z=   -4.284, 
p=0.0001). Healthy participants also had significantly stronger quadriceps muscle 
activation on assessment via the Oxford Scale (Z=-4.747, p=0.0001) and manual 
muscle dynamometry (Z=-3.513, p=0.0001). The stroke participants had a 
significantly increased amount of plantar flexor group muscle spasticity                
(Z= -2.4587, p=0.044). More specific examination of the differences in ankle 
impairment of the stroke participants is demonstrated in Table 4.7 and in Table 
4.8 for the healthy participants. 
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Table 4.3: A demographic description of the stroke group (Haem = Haemorrhagic 

















S1 Female 51 Haem Right 48 1.75 75.0 
S2 Male 23 Haem Left 68 1.81 76.5 
S3 Male 58 Haem Right 74 1.75 103.0 
S4 Male 61 Haem Right 91 1.73 107.5 
S5 Male 67 Isch Right 11 1.6 54.0 
S6 Female 42 Isch Right 34 1.74 94.0 
S7 Male 33 Haem Left 37 1.87 85.0 
S8 Female 54 Haem Right 100 1.60 84.0 
S9 Male 71 Isch Left 56 1.70 75.0 
S10 Male 57 Haem Left 9 1.80 76.5 
S11 Male 41 Haem Left 33 1.77 74.0 
S12 Male 57 Isch Left 58 1.68 55.4 




































H1 Female 51 1.64 74.0  
H2 Male 26 1.8 76.0  
H3 Male 58 1.75 110.0  
H4 Male 61 1.7 83.0  
H5 Male 65 1.75 87.0  
H6 Female 43 1.64 60.0  
H7 Male 32 1.73 77.0  
H8 Female 53 1.65 74.0  
H9 Male 70 1.71 71.0  
H10 Male 57 1.79 90.0  
H11 Male 42 1.79 90.0  
H12 Male 58 1.66 85.0  





















Table 4.5: A comparison between the demographics of the stroke and healthy 
participant groups (*p<0.05). 






























































Table 4.6: A comparison of the physical characteristics of the stroke and healthy participant groups; where ROM= 















































































































































Table 4.7: Results of the pre-testing screening assessment for the stroke group where; ROM= Range of Movement and 
MMT = Manual Muscle Test. 
 

























1 5 5 2 1b 0 V3 2.6 3 16.7 
2 1 10 0 0 3 V3 0.0 2 13.3 
3 -5 -4 1 1b 0 V3 2.6 2 15.6 
4 -5 -10 1 1a 1 V3 1.3 2 2.0 
5 10 10 1 0 2 V3 2.0 2 8.6 
6 15 10 2 1a 0 V3 3.8 2 16.8 
7 20 15 2 1b 1 V3 8.4 2 21.7 
8 15 5 2 1a 1 V3 5.5 2 7.9 
9 -10 -18 1 0 0 V3 0.2 3 8.6 
10 14 9 2 1a 1 V3 5.0 2 10.3 
11 24 20 2 1b 0 V3 6.7 4 17.6 
12 22 15 2 1b 1 V3 3.3 2 9.9 































Table 4.8: Results of the pre-testing screening assessment for the healthy group where; ROM= Range of Movement 


























1 20 10 5 2 0 18.8 5 22.1 
2 26 23 5 2 0 25.9 5 27.8 
3 12 10 5 2 0 12.2 5 23 
4 19 16 5 2 0 7.1 5 19.3 
5 18 15 5 2 0 11.1 5 11.9 
6 33 29 5 2 0 11.3 5 19.2 
7 35 25 5 2 0 27.6 5 27.5 
8 22 22 5 2 0 13.6 5 16.3 
9 25 25 5 2 0 13 5 18.8 
10 16 14 5 2 0 16.5 5 28.5 
11 26 19 5 2 0 24.4 5 19.4 
12 25 20 5 2 0 12.8 5 24.1 




(18.5 – 28) 
20.0 
(14.5-25) 





Mean(SD) 23.6 (6.7) 19.9 (6.6)    16.1 (6.3)  21.5 (4.8) 
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4.3 Shod walking compared to barefoot walking 
This section is divided into three components. Comparisons of the walking 
performance when shod (wearing shoes) and whilst barefoot for the stroke and 
the healthy participants. Then the differences between each condition for the 
stroke participants and the healthy participants are compared as individual 
groups. 
 
4.3.1 Stroke participants compared to healthy participants 
A comparison of barefoot walking between the stroke participants and 
healthy participants revealed that the healthy participants had a significantly 
faster walking velocity (Z=-3.180, p=0.0001). The healthy participants were 81.5 
cm/sec faster than the stroke participants (Table 4.9). Similarly, healthy 
participants demonstrated significantly improved performances, compared to the 
stroke participants having a faster cadence (Z=-3.180, p=0.001), reduced double 
limb support (Z=-3.180, p=0.001), increased affected leg step length (Z=-3.180, 
p=0.001) (Table 4.10), increased affected leg single support phase (Z=-3.180, 
p=0.001), and lower stance symmetry ratio (Z=-3.110, p=0.002; Table 4.11). 
There were no differences in performance between the stroke participants and 
the healthy participants for affected leg swing phase (Z=-1.853, p=0.064; Table 
4.11) or knee angles at initial ground contact (Z=-.890, p=0.373), mid stance (Z=-
.890, p=0.373); or terminal stance (Z=-1.112, p=0.266; Table 4.12) 
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Table 4.9: A comparison of velocity and, cadence, for the stroke and healthy participants walking in barefoot and shoes; 
and a comparison of barefoot walking and shod walking between the healthy and stroke participants (*p<0.05). 
 
 Stroke Normal Stroke vs Normal 
 Barefoot Shoe Barefoot Shoe Barefoot vs 
Barefoot 

























































































Table 4.10: A comparison of double limb support (DLS) and affected leg step length for the stroke and healthy 
participants walking in barefoot and shoes; and a comparison of barefoot walking and shod walking between the 
healthy and stroke participants (*p<0.05). 
 Stroke 
 
Normal Stroke vs Normal 
 Barefoot Shoe Barefoot Shoe Barefoot vs 
Barefoot 

























































































Table 4.11: A comparison of affected/matched leg single stance (%), affected/matched leg swing (%) and the single 
stance time symmetry for the stroke and healthy participants walking in barefoot and shoes; and a comparison of 
barefoot walking and shod walking between the healthy and stroke participants (*p<0.05).  
 Stroke Normal Stroke vs Normal 
 Barefoot Shoe Barefoot Shoe Barefoot vs 
Barefoot 

































































































































Z=-1.503,  p=0.133 Z=-.874, p=0.382 
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Table 4.12: A comparison of the knee angle at initial contact, midstance and terminal stance for the stroke and healthy 
participants walking in barefoot and shoes; and a comparison of barefoot walking and shod walking between the 
healthy and stroke participants (*p<0.05). 
 Stroke Normal Stroke vs Normal 
 Barefoot Shoe Barefoot Shoe Barefoot vs 
Barefoot 




































































































































 Z=-1.336,   p=0.182 Z=-0.937,   p=0.349 
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4.3.2 Shod walking compared to barefoot walking of stroke participants 
The walking velocity of the stroke participants was significantly faster 
when they wore shoes (47.1cm/sec) when compared to when barefoot (39.5 
cm/sec) (Z=-2.691, p=0.007), due to a significant increase in cadence of 5.7 
steps/min (Z=-2.201, p=0.028; Table 4.9), and a 4.1cm increase in affected leg 
step length (Z=-2.970, p=0.003; Table 4.10. There were no other differences 
between shod and barefoot walking.  
 
4.3.3 Shod walking compared to barefoot walking of healthy participants 
The walking velocity of the healthy participants was also significantly faster 
when they wore shoes (131.5 cm/sec) in comparison to barefoot (121.0 cm/sec) 
(Z=-2.900, p=0.004) due to an increased step length (Z=-3.180, p=0.001), but not 
cadence (Z=-0.664, p=0.507; Table 4.9). Healthy participants also demonstrated 
a significantly longer time in double limb support in shoes (25.9%) in comparison 
to barefoot (21.9%); (Z=-3.181, p=0.001; Table 4.10). Healthy participants also 
spent longer in matched leg single support phase (Z=-3.112, p=0.002) in barefoot 
and a longer matched leg swing phase (Z=-2.062, p=0.039) in barefoot in 
comparison to shod walking (Table 4.11). There were no differences in stance 
symmetry ratio (Z=-0.874, p=0.382; Table 4.11), or the knee angle at initial 
contact (Z=-1.222, p=0.222); midstance (Z=-0.315, p=0.753) or terminal stance 





4.4 Shod walking compared to all AFO’s 
This section is divided into three components. The walking performance in 
shoes and all of the AFO’s combined of the stroke participants and the healthy 
participants is compared, then the differences between each condition for the 
stroke participants and the healthy participants is compared as individual groups. 
 
4.4.1 Stroke participants compared to healthy participants  
The healthy participants’ walking velocity when wearing an AFO was 69.9 
cm/sec faster when compared to the stroke participants (Z=13.000, p=0.0001; 
Table 4.13). Further significant differences were found for cadence (Z=-9.308, 
p=0.0002; Table 4.13), double limb support (Z=-9.308, p=0.0002; Table 4.14), 
affected/matched leg step length (Z=13.000, p=0.0001; Table 4.14), 
affected/matched leg single support phase (Z=-3.180, p=0.001; Table 4.15) and 
stance symmetry ratio (Z=13.000, p=0.0001; Table 4.15). The healthy 
participants exceeding the stroke participants’ performance for each parameter 
(Tables 4.13, 4.14 and 4.15). There were no differences between the stroke 
participants and healthy participants in regards to affected leg swing phase (Z=-
0.943, p=0.345; Table 4.15) or the knee angle at initial contact (Z=0.091, 
p=0.763); midstance (Z=0.818, p=0.366); or terminal stance (Z=1.923, p=0.166; 





Table 4.13: A comparison of velocity and  cadence, for the stroke and healthy participants walking in shoes and all 




 Stroke Normal Stroke vs Normal 























































































Table 4.14: A comparison of double limb support (DLS) and affected/matched leg step length for the stroke and healthy 
participants walking in shoes and all AFO’s ; and a comparison of shod walking and  walking  in all AFO’s between the 
healthy and stroke participants (*p<0.05). 
 Stroke Normal Stroke vs Normal 























































































Table 4.15: A comparison of affected/matched leg single stance(%), affected/matched leg swing (%) and the single 
stance time symmetry for the stroke and healthy participants walking in shoes and all AFO’s ; and a comparison of 
shod walking and  walking  in all AFO’s between the healthy and stroke participants (*p<0.05). 
 Stroke Normal Stroke vs Normal 

















































































































Table 4.16: A comparison the knee angle at initial contact, midstance and terminal stance for the stroke and healthy 
participants walking in shoes and all AFO’s ; and a comparison of shod walking and  walking  in all AFO’s between the 
healthy and stroke participants (*p<0.05). 
 Stroke Normal Stroke vs Normal 
 Shoe All AFO Shoe All AFO All AFO vs All AFO 






















































































































 Z= 0.0001    p= 1.000 Z=-0.267    p=0.789 
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4.4.2 Shod walking compared to walking in all AFO’s of stroke participants 
In regards to the stroke participants no differences were identified for any 
of the parameters examined when walking in shoes was compared to walking in 
an AFO. Walking velocity was not significantly faster in an AFO when compared 
to shod walking (Z=-0.664, p=0.507; Table 4.13). None of the other gait 
parameters showed significant differences when shod walking was compared to 
walking in an AFO (Table 4.16). 
 
4.4.3 Shod walking compared to walking in all AFO’s of healthy participants 
The walking velocity of healthy participants was significantly slower (Z=-
3.040, p=0.002) when wearing an AFO (118.1cm/sec) in comparison to shod 
walking (131.5cm/sec) due to an significantly slower cadence (Z=-2.621, 
p=0.009) in an AFO (110.0 steps/minute) compared to shod (113.7 
steps/minute), and a significantly shorter (Z= -3.110, p= 0.002) affected/matched 
leg step length in an AFO (67.3cm) when compared to shod walking (68.4cm; 
Table 4.14). Affected/matched leg single support and swing phase were less 
(stance: Z=-2.621, p=0.009; swing: Z=-2.062, p= 0.039) in an AFO compared to 
shod walking. Single support stance time ratio was less symmetrical (Z=-2.900, 
p= 0.004) when using an AFO (-4.8), as opposed to shod walking (-0.97).  
Using an AFO caused the healthy participants to have a slightly flexed 
knee (3.3 degrees) at initial contact (Z=-1.969, p=.049) in comparison to shod 
walking (2.5 degrees). There were no differences at midstance (Z= -1.099, 
136 
 
p=0.272) or terminal stance (Z=-0.267, p=0.789) in regards to the same 
comparison (Table 4.16). 
 
4.5 Shod walking in comparison to AFO’s of varying rigidity 
This section is divided into three components. The walking performance in 
shoes and the PAB, SLAFO or FGC of the stroke participants and the healthy 
participants is compared, then the differences between each condition for the 
stroke participants and the healthy participants is compared as individual groups. 
 
 
4.5.1 Stroke participants compared to healthy participants 
As was similar to the earlier section, where the AFO’s of varying rigidity 
were considered as a group the healthy participants performance was superior to 
that of the stroke participants in regards to all but four parameters. The four 
parameters in which there were no differences are   affected/matched leg swing 
phase knee angle at initial contact, knee angle at midstance and knee angle at 
terminal stance.  For the participants with stroke, no significant differences were 
identified between the different types of AFO for any parameter tested, other than 
an increase in knee flexion at initial contact for the FGC condition. For healthy 
participants, significant differences were found between AFO’s for several 
parameters. In comparison to shod walking the use of an AFO caused a 
deterioration in velocity, cadence, matched leg single support phase, matched 
leg swing phase, matched leg step length, single support stance symmetry ratio 
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and knee angle at initial contact. There were no differences in performance 
regarding double limb support or knee angles at midstance or terminal stance. It 
is best to consider each AFO separately to elucidate the differences between the 
stroke and healthy participants. 
 
4.5.1.1 Comparison of the push aequi brace between stroke and healthy 
participants 
The healthy participants walked at a faster velocity than the stroke 
participants (Z=18.788, p=0.0001; Table 4.17) due to an increased cadence 
(Z=13.444, p=0.0001; Table 4.18) and longer affected/matched leg step length (Z 
=18.336, p=0.0001; Table 4.20). Healthy participants spent less time in double 
limb support (Z=14.207, p=0.0001; Table 4.19). The affected/matched leg single 
support phase was significantly greater for the healthy participants (Z=18.797, 
p=0.0001; Table 4.21) but not for the affected/matched leg swing phase (Z=-
0.513, p=0.614; Table 4.22). The symmetry of single leg stance time was more 
symmetrical (Z=13.444, p=0.0001) for the healthy participants (Table 4.23). 
There was no difference of the knee angle between the stroke participants and 
the healthy participants at initial contact (Z=0.409, p=0.522; Table 4.24) or 
terminal stance (Z=0.484, p=0.487; Table 4.26). However, at mid stance the 
healthy participants were in more flexed knee position (5.5 degrees) than the 
stroke participants (-1.0 degrees) who were in a slight hyperextended position 




4.5.1.2 Comparison of the spring leaf AFO between stroke and healthy 
participants 
As was determined for the PAB, the healthy participants walked at a faster 
velocity than the stroke participants when using a SLAFO (Z=18.778, p=0.0001) 
due to an increased cadence (Z=13.444, p=0.0001; Table 4.17) and a longer 
affected leg step length (Z=17.468, p= 0.0001; Table 4.20). Healthy participants 
spent less time in double limb support (Z=12.703, p=0.0001; Table 4.19) and 
spent longer in affected/matched leg single support (Z=18.784, p=0.0001; Table 
4.21) than stroke participants. No difference in affected/matched leg swing phase 
was found between the stroke and healthy participants when using a SLAFO (Z=-
0.744, p=0.479; Table 4.22). However, the single stance symmetry ratio between 
the stroke and healthy participants was significantly different (Z=18.336, 
p=0.0001) indicating the stroke group were more asymmetrical (Table 4.23). No 
differences were determined regarding the knee angle at initial contact (Z=1.274, 
p=0.259, Table 4.24), midstance (Z=1.344, p=0.246; Table 4.25) or terminal 










4.5.1.3 Comparison of the fibreglass cast between stroke and healthy 
participants 
When walking in a FGC healthy participants walked at a faster velocity 
that the stroke participants (Z=17.468, p=0.0001; Table 4.17), due to an 
increased cadence (Z=11.634, p=0.001; Table 4.18) and affected/matched leg 
step length (Z=16.621, p=0.0001; Table 4.20). When wearing a FGC healthy 
participants spent less time in double limb support (Z=11.283, p=0.001; Table 
4.19) and a shorter affected/matched leg step length (Z=15.391, p=0.0001; Table 
4.20). Healthy participants spent longer in affected/matched leg single stance 
(Z=18.778, p=0.001; Table 4.21) but not affected/matched leg swing phase (Z=-
0.924, p=0.362; Table 4.22) than the stroke participants. The healthy participants 
had a significantly more symmetrical stance ratio (Z=13.444, p=0.0001) when 
compared to stroke participants (Table 4.23). As was the case for spring leaf 
AFO’s there were no difference in the knee angle between stroke and healthy 
participants at initial contact (Z=3.779, p=0.052; Table 4.24), midstance 





Table 4.17: A comparison of the walking velocity (cm/sec) of the stroke participants and the healthy participants walking 
in shoes and each of push aequi brace (PAB), spring leaf AFO (SLAFO) and fibreglass cast (FGC); and comparison 
between the stroke and healthy participants in each of the orthotic conditions (*p<0.05). 
 Stroke Normal 
 
















































 PAB Z=-0.454 
p=0.650 
 
   Z=-1.623 
p=0.100 



























Stroke v Normal  
 


















Table 4.18: A comparison of the cadence (steps/minute) of the stroke participants and the healthy participants walking 
in shoes and each of push aequi brace (PAB), spring leaf AFO (SLAFO) and fibreglass cast (FGC); and comparison 
between the stroke and healthy participants in each of the orthotic conditions (*p<0.05). 
 Stroke Normal 















































 PAB Z=-0.559 
p=0.576 
 




























Stroke v Normal 
 
 
PAB x PAB Z=13.444 
p=0.0001* 
 







Table 4.19: A comparison of the double limb stance (DLS; %of gait cycles) of the stroke participants and the healthy 
participants walking in shoes and each of push aequi brace (PAB), spring leaf AFO (SLAFO) and fibreglass cast (FGC); 
and comparison between the stroke and healthy participants in each of the orthotic conditions (*p<0.05). 
 Stroke Normal 















































 PAB Z=-1.363 
p=0.173 
 
   Z=-0.594 
p=0.552 

























Stroke v Normal 
 
 
PAB x PAB Z=14.207 
p=0.0001* 
 








Table 4.20: A comparison of the affected/matched leg step length (cm) of the stroke participants and the healthy 
participants walking in shoes and each of push aequi brace (PAB), spring leaf AFO (SLAFO) and  cast (FGC); and 
comparison between the stroke and healthy participants in each of the orthotic conditions (*p<0.05). 
 Stroke Normal 














































 PAB Z=-0.664 
p=0.507 
   Z=-1.433 
p=0.152 
 

























Stroke v Normal  
PAB x PAB Z=18.336 
p=0.0001* 










Table 4.21: A comparison of the affected/matched leg single stance (%) of the stroke participants and the healthy 
participants walking in shoes and each of push aequi brace (PAB), spring leaf AFO (SLAFO) and fibreglass cast (FGC); 
and comparison between the stroke and healthy participants in each of the orthotic conditions (*p<0.05). 
 Stroke Normal 





































 PAB Z=-1.189 
p=0.235 
 
   Z=-1.785 
p=0.074 


























Stroke v Normal 
 
 
PAB x PAB Z=18.797 
p=0.0001* 
 









Table 4.22: A comparison of the affected/matched leg swing phase (%) of the stroke participants and the healthy 
participants walking in shoes and each of push aequi brace (PAB), spring leaf AFO (SLAFO) and fibreglass cast (FGC); 
and comparison between the stroke and healthy participants in each of the orthotic conditions (*p<0.05). 
 Stroke Normal 






































































Stroke v Normal 
 
 
PAB x PAB Z=-0.513 
p=0.614 
 








Table 4.23: A comparison of the single stance symmetry ratio of the stroke participants and the healthy participants 
walking in shoes and each of push aequi brace (PAB), spring leaf AFO (SLAFO) and fibreglass cast (FGC); and 
comparison between the stroke and healthy participants in each of the orthotic conditions (*p<0.05). 
 Stroke Normal 















































 PAB Z=-0.594 
p=0.552 
 




























Stroke v Normal 
 
 
PAB x PAB Z=13.444 
p=0.0001* 
 








Table 4.24: A comparison of the knee angle at initial contact (degrees) of the stroke participants and the healthy 
participants walking in shoes and each of push aequi brace (PAB), spring leaf AFO (SLAFO) and fibreglass cast (FGC); 
and comparison between the stroke and healthy participants in each of the orthotic conditions (*p<0.05). 
 Stroke Normal 















































 PAB Z=-0.792 
p=0.428 
 
   Z=-1.329 
p=0.184 

























Stroke v Normal 
 
 
PAB x PAB Z=0.409 
p=0.522 
 







Table 4.25: A comparison of the knee angle at midstance (degrees) of the stroke participants and the healthy 
participants walking in shoes and each of push aequi brace (PAB), spring leaf AFO (SLAFO) and fibreglass cast (FGC); 
and comparison between the stroke and healthy participants in each of the orthotic conditions (*p<0.05). 
 Stroke Normal 






































 PAB Z=-1.161 
p=0.246 
 
   Z=-1.476 
p=0.140 

























Stroke v Normal 
 
 
PAB x PAB Z=4.841 
p=0.028* 
 








Table 4.26: A comparison of the knee angle at terminal stance (degrees) of the stroke participants and the healthy 
participants walking in shoes and each of push aequi brace (PAB), spring leaf AFO (SLAFO) and fibreglass cast (FGC); 
and comparison between the stroke and healthy participants in each of the orthotic conditions (*p<0.05). 
 Stroke Normal 






































 PAB Z=-0.102 
p=0.919 
 
   Z=-0.315 
p=0.753 

























Stroke v Normal 
 
 
PAB x PAB Z=0.484 
p=0.487 
 








4.5.2 Comparison of shod walking and AFO’s of varying rigidity in stroke 
participants 
The study did not identify any significant differences in temporal spatial 
gait parameters between the four conditions of shoes and the three AFO options 
(Tables 4.17 – 4.23). The angle of the knee at initial contact was more flexed 
when walking in the more rigid fibreglass cast (8.5 degrees) when compared to 
shoes (4.0 degrees; Z=-2.585, p=0.010; Table 4.24) or the minimally rigid push 
aequi brace (4.0 degrees; Z=-2.233, p=0.026; Table 4.25). No other differences 
between AFO’s for knee angle were identified (Tables 4.24, 4.25, and 2.26).  
 
4.5.3 Comparison of shod walking and AFO’s of varying rigidity in healthy 
participants  
The effect of more rigid AFO’s was more marked in the healthy 
participants. There was no difference between shod walking velocity and that of 
the minimally rigid PAB (Z=-1.623, p=0.100). However, as the rigidity increased 
the walking velocity of the healthy participants decreased (Table 4.17). Walking 
velocity in the moderately rigid SLAFO was 119.9cm/sec in comparison to shod 
walking of 131.5 cm/sec (Z=-2.900, p=0.004); and even slower at 108.2cm/sec 
using the most rigid FGC (Z=-3.180, p=.001). This pattern continued when 
comparing the PAB (125.1cm/sec) to the SLAFO (Z=-2.551, p=0.011), or the 
FGC (Z=-2.900, p=0.004). SLAFO walking velocity was significantly slower in 
comparison to FGC (Z=-2.691, p=0.007) for healthy participants. These velocity 
changes were due to a decreased cadence (Table 4.18) using a FGC. There was 
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no difference between the cadence of SLAFO or the FGC (Z=-1.680, p=0.093). 
The velocity changes were also due to an increased affected leg step length, 
which demonstrated significant reductions in performance between conditions 
following the same pattern as for walking velocity (Table 4.17). The greater the 
rigidity of the AFO the worse the walking performance in regards to cadence and 
affected leg step length. Differences were also noted when double limb support 
was considered. Healthy participants spent more time in double limb stance 
when using a SLAFO (27.8%) in comparison to shoes (26.0%; Z=-3.040, 
p=0.002; Table 4.19). There were no significant differences between shoes and 
the other AFO’s for percentage time in double limb stance. Regarding affected 
leg single support phase there were no differences between shoes and PAB (Z=-
1.785, p=0.074), but there was a decrease in affected leg single support phase 
between shoes and SLAFO (Z=-2.204, p=0.028) and shoes and FGC (Z=-2.482, 
p=0.013).  
In comparison to shoes, the affected leg swing phase was significantly 
longer in FGC (Z=3.111, p=0.002), PAB (Z=-2.622, p=0.009) and SLAFO (Z=-
3.111, p=0.002) but not for any of the other comparisons. The most rigid 
fibreglass cast also caused single stance duration ratio to become more 
asymmetrical in comparison to shoes, PAB and SLAFO (Table 4.23). The 
difference was greatest between shoes (-0.975) and FGC (-7.57, Z=-3.180, 
p=0.001) and reduced as the rigidity of the comparison AFO increased. The ratio 
of the PAB (-2.10) was not significantly different to shoes (Z=-1.922, p0=.055) but 
was significantly different to fibreglass cast (Z=-3.110, p=0.002). Similarly there 
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was no difference between shoes and SLAFO (-3.27; Z=-1.503, p=0.133) but 
there was a difference between SLAFO and FGC (Z=-2.760, p=0.006). There 
was no difference between the single stance symmetry ratio of PAB and SLAFO 
(Z=-0.524, p=0.600). 
There were no differences in knee angle at initial contact (Table 4.24), 
midstance (Table 4.25) or terminal stance (Table 4.26) when comparing shoes to 
the orthotic conditions or the orthotic conditions to each other. 
 
4.6 Smallest real differences of the stroke group 
 
4.6.1 Stroke participants’ smallest real differences 
In order to examine the effects for AFO’s on each individual participant, a 
SRD was calculated. The SRD was used to determine changes in performance 
for each parameter in comparison to each individuals shod walking. The values 
representing the SRD, as calculated by using each individuals shoe trial, and the 











Table 4.27: Stroke participants’ values indicating the smallest real difference at a 
95% confidence level for each spatiotemporal parameter 
Variable Smallest Real Difference 
Value 
Baseline Reliability 
Velocity 6.3 cm/sec 0.99 
p<0.000 
DLS 7.8% 0.99 
p<0.000 




Stance Symmetry Ratio 18.35 0.98 
p<0.000 
Step Length 7.79cm 0.98 
p<0.000 
Affected leg swing  40.3% 0.97 
p<0.000 




Knee angle – initial 
contact 
19.3 degrees 0.943 
p<0.000 
Knee angle - midstance 20.1 degrees 0.979 
p< 0.000 
Knee angle – terminal 
stance 










4.6.2 Stroke participants’ Individual Responses 
Each participant’s difference in velocity when comparing their shod 
(baseline) walking to barefoot, PAB, SLAFO and FGC are described in Figure 4.1 
Individual descriptive results, in the form of box plots are displayed in Appendix 
F. Similarly, double limb support differences in performance are displayed in 
Figure 4.2; affected leg single support symmetry ratio differences in Figure 4.3, 
affected leg step length in Figure 4.4. As there were no individuals who exceeded 
by an amount greater than the SRD for cadence, affected leg single support 
phase or affected leg swing phase graphs for these results have also been 
displayed in the Appendices (Appendices H, L, and N). Individual descriptive 
results for all parameters can be found in Appendices G, I, J, K, M, O, P, Q, and 
R). Only changes greater than SRD are reported below.  
 
4.6.2.1 Shod versus barefoot for individual participants 
Five participants’ velocity decreased when walking barefoot. This was 
participants 1, 3, 5, 7 and 13.  Two of these participants’ also had shorter step 
lengths when barefoot (Participant 3 and 5). Participant 3’s knee angle at initial 
contact was more flexed than when walking with shoes, but more extended at 
terminal contact. Participant 4 was more extended at the knee in barefoot at 







4.6.2.2 Shod versus PAB 
Two participants’ walking velocity improved using a PAB (participants 6, 
by 17.65 cm/secs, and 7), and one participant’s velocity decreased using a PAB 
(participant 5). Regarding knee angles, participant 4 was more extended during 
midstance using the PAB.  
 
4.6.2.3 Shod versus SLAFO 
One participant’s velocity improved using a SLAFO (participant 6), 
Participant 13’s single stance time symmetry improved whilst participants 3, 8 
and 10 demonstrated deteriorations in single stance time symmetry. 
 
4.6.2.4 Shod versus FGC 
Three participants’ walking velocity improved using a FGC (participants 2, 
6 and 12, the latter by 24.05 cm/sec), with one participant (participant 7) walking 
16.95 cm/sec slower in FGC than in shoes. For participant 2, DLS percentage 
improved by 15.6% and step length also improved. Double limb support 
percentage worsened by 12.1% for participant 9 and step length shortened for 
two participants (Participant 3 and 5). Participant 4’s knee was more extended in 






4.6.2.5 Differences between AFO conditions 
Five of the 13 participant’s with stroke showed benefits for at least one 
condition of AFO greater than the SRD. Velocity improved in all AFO conditions 
for participant 6, and therefore the SRD was used to determine if one AFO was 
likely to be superior for the participant. When walking in the PAB participant 6’s 
velocity was faster than the FGC by an amount greater than the SRD. Six 
participants showed deterioration in at least one gait parameter. Participant 7 
demonstrated improved velocity with the PAB and reduced velocity with the FGC. 
Three participants (1, 4 & 11) did not show any differences. There were no 





Figure 4.1: Stroke group bar graph demonstrating mean difference of velocity from baseline (shoe result) under each 
testing condition. Values above or below lines indicate changes a result greater or less than the SRD (PAB – Push 





Figure 4.2: Stroke group bar graph demonstrating mean difference of double limb stance percentage from baseline 
(shoe result) under each testing condition. Values above or below lines indicate changes a result greater or less than 







Figure 4.3: Stroke group bar graph demonstrating mean difference of stance symmetry ratio from baseline (shoe result) 
under each testing condition. Values above or below lines indicate changes a result greater or less than the SRD (PAB 





Figure 4.4: Stroke group bar graph demonstrating mean difference of affected leg step length from baseline (shoe 
result) under each testing condition. Values above or below lines indicate changes a result greater or less than the SRD 







Figure 4.5: Stroke group bar graph demonstrating mean difference of knee angle at initial contact from baseline (shoe 
result) under each testing condition. Values above or below lines indicate changes a result greater or less than the SRD 






Figure 4.6: Stroke group bar graph demonstrating mean difference of knee angle at midstance from baseline (shoe 
result) under each testing condition. Values above or below lines indicate changes a result greater or less than the SRD 








Figure 4.7: Stroke group bar graph demonstrating mean difference of knee angle at terminal stance from baseline 
(shoe result) under each testing condition. Values above or below lines indicate changes a result greater or less than 
the SRD (PAB – Push Aequi Brace; SLAFO – Spring Leaf AFO; FGC – Fibreglass Cast). 
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4.6.3 Stroke participants’ identification of responders and non responders 
The characteristics of the stroke participants’ ankle impairments are 
described in Table 4.28. It is notable that the ages of the responders tended to be 
younger than the non-responders.  A description of the physical impairments of 
those participants who demonstrated a positive response and those who were 
non responders to an AFO are described in Table 4.8 Examination of this data 
does not yield any observable trends towards physical impairments common to 
responders versus non responders.  Of those who had a positive response, there 
were no participants who had a dorsiflexion range limitation. In comparison, the 
three participants with a dorsiflexion range limitation all failed to respond to AFO. 
One of whom (participant 4) walked with a more extended knee at midstance and 














Table 4.28: Categorisation of ankle impairments of stroke participants of those 
who demonstrated a positive response to at least one AFO and those that did not 
(non responder)  
 Impairment 
categorization 





















































4.6.4 Case Studies  
In order to further examine the physical characteristics of the ankle of the 
stroke participants who demonstrated a positive response in their walking 
performance in an AFO, individual case studies are now presented. Stroke 
participants were chosen for individual case analysis if they improved in one or 
more spatio-temporal parameter for one specific AFO, or if they improved in one 
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or more spatio-temporal parameter for multiple AFO’s (Table 4.28). As a 
consequence, participants’ two, six and thirteen are presented as case studies.  
 
4.6.4.1 Stroke Participant Two  
Participant Two was a 23 year old male who suffered a left parietal 
haemorrhage 68 days prior to day one of assessment for this study. He was   
1.81 m in stature with a mass of 76.5 kg. Physical assessment of his ankle 
indicated a dorsi flexion range of movement of 15 degrees with the knee 
extended, and ten degrees with the knee flexed. He had no palpable or 
identifiable dorsiflexion muscle activity when assessed using the Oxford Scale, 
STREAM or manual muscle dynamometry. He was able to exert 13.3 kg of force 
with his quadriceps muscle on assessment with manual muscle dynamometry 
and scored 2/5 using the Oxford Scale. Plantar flexor muscle spasticity was 
identified, scoring 3 at V3, indicating fatigable clonus occurring at a precise 
angle.   
Participant Two’s walking velocity at baseline of 20.0 cm/sec (+1.2) (Table 
4.30) was similar to the minimally rigid push aequi brace (20.5 cm/sec +1.5) and 
spring leaf AFO (23.3 cm/sec +2.0), but  walking in a fibreglass cast (32.0 cm/sec 
+2.9) was 60% faster than shod. Walking in a fibreglass cast improved double 
limb support (decreased by 39%), affected leg single stance time (increased by 
12%), and affected leg step length (increased by 35%) in comparison to shod 
walking. Whilst the other parameters did not change by an amount greater than 
the SRD value examination of the raw data indicated further trends suggesting 
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the fibreglass cast was of benefit to this individual. Cadence improved (increased 
by 20%) whilst the other parameters displayed marginal differences in 
performance between different AFO’s.  
 
4.6.4.2 Stroke Participant Six  
Participant Six was a 42 year old female with left sided deficits. Her stature 
was 1.74 m and body mass was 94 kg. She was 34 days post event at the 
commencement of this study. Her dorsiflexion range of movement was ten 
degrees beyond plantigrade with her knee extended and 15 degrees beyond 
plantigrade with her knee flexed. There was markedly abnormal dorsi flexor 
movement as represent by her STREAM score, and evidenced by an Oxford 
Scale grading of 1/5 and manual muscle test value of 3.8 kg. There was no 
evidence of plantar spasticity and her quadriceps muscle strength was graded as 
2/5 with a manual muscle test value of 16.8 kg. 
Using the SRD, Participant Six’s walking velocity increased in comparison 
to shod walking in all orthotic conditions (Table 4.31). The orthosis which resulted 
in the best walking velocity performance was the least rigid push aequi brace 
which improved by 16.1cm/sec in comparison to shod walking. The spring leaf 
AFO and fibreglass cast resulted in similar improvements to walking velocity. No 
other parameter improved due to walking in an AFO using either SRD or 




4.6.4.3 Stroke Participant 7  
Stroke Participant Seven was a 33 year old male who had a right sided 
haemorrhage resulting in left sided deficits. He was 1.87 m tall with a body mass 
of 85.0 kg. His walking was assessed 37 days following his stroke. He had 15 to 
20 degrees of dorsiflexion range of movement depending if his knee was flexed 
or extended. He scored 2/5 on the Oxford Scale for strength with moderately 
abnormal movement pattern as evidenced by his STREAM score. He was able to 
produce 8.4 kg of tibialis anterior strength on assessment by manual muscle 
dynamometry. He had mild plantar flexor spasticity. He scored 2/5 on the Oxford 
Scale for quadriceps strength and was able to produce 21.7 kg of quadriceps 
force on manual muscle dynamometry.  
Participants Seven’s responses to walking velocity performance, as 
assessed using SRD, unique. Using a PAB his velocity was faster than shod 
walking by 13.8 cm/sec. Yet in a FGC he was 20.3 cm/sec than shod walking. 
There is no indication from his ankle impairment characteristics above as to why 






4.7 Smallest real differences of the healthy participant group 
In order to examine the effects for AFO’s on each individual participant 
SRD was calculated and compared to actual performance for each parameter 
examined. Each individuals shod walking was used as the baseline for the 
comparison. The values representing the SRD and the reliability values are 

























Table 4.29: Healthy participants’ values indicating the smallest real difference at 
a 95% confidence level for each spatiotemporal parameter 
Variable Smallest Real Difference 
Value 
ICC (3,1) 
Velocity (cm/sec) 10.17cm/sec 0.99 
p<0 .000 
DLS 2.84% 0.96 
p<0.000 
Matched leg single support 12.6% 0.92 
p<0.000 
Stance Symmetry Ratio 6.65 0.79 
p<0.000 




25.1 steps/min 0.99 
p<0.000 
Matched leg swing 12.2% 0.97 
P<0.000 
Knee angle – initial contact 18.9 degrees 0.785 
p= 0.009 
Knee angle – midstance 14.6 degrees 0.898 
p< 0.000 
Knee angle – terminal 
stance 









4.7.1 Individual Responses 
Each participants difference in velocity when comparing their shod 
(baseline) walking to BF, PAB, SLAFO and FGC is described in Figure 4.8 
Individual descriptive results for velocity, in the form of box plots are displayed in 
Appendix S.. Similarly, double limb support differences in performance are 
displayed in Figure 4.9; matched leg single support phase differences in Figure 
4.10; matched leg step length in Figure 4.11 and matched leg knee angle at 
midstance in Figure 4.12. As there were no individuals who exceeded by an 
amount greater than the SRD for cadence, matched leg single support phase,  
matched leg swing phase or knee angles at initial contact or terminal stance 
graphs for these results have not been displayed below but as a appendices’ 
(Appendices U, Y, AA, AC, and AE). Individual descriptive graphical results for all 
parameters can be found in Appendices, T,  V, W, X, Z, AB, AD, AF and AG)..  
 
4.7.1.1 Shod vs Barefoot 
Five healthy participants walking velocity deteriorated when walking 
barefoot (participants 1, 2, 10, 11 and 13). Further no participants walking 
velocity increased in barefoot. The duration of the gait cycle spent in double limb 
support also deteriorated when barefoot. Ten of the thirteen healthy participants’ 
performance worsened (participants 1, 2, 3, 4, 5, 7, 9, 10, 11, 12). Similarly eight 
of participants’ matched leg step length reduced in barefoot (participants 1, 2, 4, 
7, 9, 11, 12, 13). Only one participant’s knee angle altered from baseline in 




4.7.1.2 Shod vs PAB 
Two participants walking velocity and affected leg step length reduced in 
the PAB (Participant 6 and 7). Whilst participant 6 increased in time spent in 
double limb support using the PAB. Participant 6 was more flexed in a PAB whilst 
participant 7 was more extended at the knee at terminal stance. 
 
4.7.1.3 Shod vs SLAFO 
Six healthy participants’ walking velocity deteriorated in the SLAFO 
(participants 2, 6, 7, 8, 10 and 13). Participants seven and eight both increased 
the time spent in double limb support and reduced their matched leg step length. 
Three participants’ single support stance symmetry ratio worsened (participants 
7, 8 and 13). Participant 7 was more extended in the SLAFO at terminal stance. 
 
4.7.1.4 Shod vs FGC 
Ten of the thirteen healthy participants’ walking velocity decreased in the 
FGC (participants 1, 2, 3, 4, 6, 7, 8, 9, 10 and 11) and also for matched leg step 
length (participants 1, 2, 4, 6, 7, 8, 9, 10, 11 and 13). Five participants single 
support stance symmetry ratio worsened (participants 3, 7, 8, 9, and 12). Two 
participants spent increased time in double limb support (participants’ 8 and 9) 
whilst one spent less time (participants 12). Participant Seven was more 




4.7.1.5 Differences between AFO conditions 
Two healthy participants’ walking velocities decreased in two AFO’s. 
Participants Two and Seven decreased in the SLAFO and the FGC. In both 
instances walking in the FGC was slower than the SLAFO by and amount greater 
than the SRD. Participant 7 also improved in the PAB but slower in the SLAFO 
by an amount greater than the SRD. Similarly, participant 7’s matched leg step 
length was less in the FGC compared to the SLAFO by an amount greater than 
the SRD. This was also the case when SLAFO compared to PAB. Regarding 
single support stance symmetry ratio the FGC was less symmetrical than the 
SLAFO by an amount greater than the SRD. Participant 7 had differences greater 





Figure 4.8: Healthy participant individual bar graph demonstrating difference of velocity from baseline (shoe result) 
under each testing condition. Values above or below lines indicate changes a result greater or less than the SRD (PAB 




Figure 4.9: Healthy participant individual bar graph demonstrating difference of double limb support from baseline (shoe 
result) under each testing condition. Values above or below lines indicate changes a result greater or less than the SRD 







Figure 4.10: Healthy participant individual bar graph demonstrating difference of stance symmetry ratio from baseline 
(shoe result) under each testing condition. Values above or below lines indicate changes a result greater or less than 





Figure 4.11: Healthy participant individual bar graph demonstrating difference of matched leg step length from baseline 
(shoe result) under each testing condition. Values above or below lines indicate changes a result greater or less than 









Figure 4.12: Healthy participant individual bar graph demonstrating difference of knee angle at terminal stance from 
baseline (shoe result) under each testing condition. Values above or below lines indicate changes a result greater or 




































This chapter addresses the aims of the study as outlined earlier in the 
introduction chapter. Principally topics that will be covered are: (1) the effects of 
walking in AFO’s in the early stages of walking recovery following stroke; (2) the 
effects walking in AFO’s of varying rigidity in the early stages of walking recovery 
following stroke; (3) the effects of AFO’s on the walking of healthy participants; 
the effects of walking in AFO’s of varying rigidity in healthy participants; (4) and 
how the walking, with and without AFO’s, of stroke and healthy participants 
compares. 
 
5.1 The effects of AFO’s on spatio temporal variables of gait following 
stroke 
The results of this study indicate that the routine prescription of AFO’s to 
individuals in the early stages of walking recovery following stroke with ankle 
impairments cannot be recommended. The application of the three AFO’s 
examined (PAB, SLAFO or FGC) did not demonstrate significant improvements 
in the group analysis for the parameters of velocity, cadence, double limb 
support, affected leg single stance support phase, affected leg swing phase, 
affected leg step length or single support symmetry were considered. No 
changes in knee angle at initial contact, midstance or terminal stance when using 
AFO’s were identified. However, individual analysis using SRD indicated that 
some individuals in the early stages of walking recovery following stroke may 
improve their walking performance when using an AFO, and that AFO’s of 
181 
 
differing rigidity can have different effects. Individual analysis also indicated that 
some stroke participants walking can deteriorate following AFO prescription. 
These results suggest that in certain cases an AFO may be of benefit, but not all, 
and that different AFO’s may have different effects. This finding is supported by 
Mulroy et al. (2010) who found that the presence of ankle contracture can 
influence which AFO will be of most benefit. 
There have been thirteen studies identified which have reported increased 
walking velocity when an AFO is prescribed (Table 5.1; (Abe et al., 2009; 
Churchill et al., 2003; Danielsson & Stibrant, 2004; de Wit et al., 2004; 
Franceschini et al., 2003; Gok et al., 2003; Hesse et al., 1996; Lehmann et al., 
1987; Mojica et al., 1988; Pavlik, 2008; Tyson & Thornton, 2001; Wang et al., 
2007; Wang et al., 2005). Four studies found an AFO made no difference to 
walking velocity (Burdett et al., 1988; Fatone & Hansen, 2007; Hesse et al., 












Table 5.1: Summary table of results for studies similar to this study 
 


























Slower velocity in 
barefoot 
AFO: no change to 
velocity, cadence, 
double limb support, 
single stance, swing, 
stance symmetry or 
knee angles 
Abe et al. 
(2009) 
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No change to velocity 
62.9cm/sec (27.4) 
 
Increased step length 
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AFO in 5 degrees 
dorsiflexion increased 
velocity – 49.3 cm/sec 
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Increased velocity – 
66.9cm/sec (29.5) 
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AFO’s considered by previous studies outline in Table 5.1 were different to 
those examined in this study, which may account for the differences to the results 
described earlier. Additionally, only one of the studies recruited participants with 
an acuity of stroke similar to this study (Gok et al., (2003). In Gok et al. (2003) 
participants were 67 days (30-270) post stroke in comparison to 51 (9-100) days 
of this study. They found a metallic AFO improved velocity in comparison to 
baseline, which was not defined as shoes or barefoot. This may account for the 
difference in findings, in that this study did find differences between shoes and 
barefoot, but not shoes and AFO’s. Conceivably, Gok et al. (2003) may have 
compared the differences between barefoot and AFO’s.  
Seven studies reported a similar baseline velocity to this study, six of 
which demonstrated improvement with AFO use. None of the seven considered 
similar AFO’s to those in this study, and six of the seven considered participants 
who were in the chronic phase of recovery in contrast to this study. The definition 
of ankle impairments was either not considered or not uniform. As such, 
comparison of results is difficult to interpret.  
Of the eighteen previous studies, only one compared an AFO with walking 
whilst barefoot or wearing shoes. Hesse et al., (1996), found walking in shoes 
faster than barefoot, and walking in an AFO faster than shoes. However, they 




As outlined in Table 5.1 six studies reported on cadence and affected leg 
step length: five described a longer step length and four reported improvements 
in cadence. The results of double limb support were mixed, one study finding an 
improvement and the other deterioration in this parameter. Additionally, only one 
study found an improvement in the swing phase. Similarly to velocity the 
differences in participant acuity, type of AFO examined, ankle impairment and 
baseline walking performances do not allow comparison to this study. Further 
discussion of the issues limiting the ability to compare studies will be found in 
later sections of this chapter. 
In this study each participant had deficits of foot and ankle function that 
could potentially be compensated for by wearing of an AFO. However, many 
participants did not show a benefit in the spatio temporal variables of gait. There 
are a number of reasons that may have contributed to this. AFO’s are 
hypothesised to increased foot and ankle stability (Wang, et al., 2007). However, 
the negative effects of AFO’s on gait shown in the healthy participants in this 
study may over ride this benefit.    In the current study, the participants had 
limited time to familiarise with the AFO’s, further experience with the AFO’s may 
have shown greater changes.  The results of this study are in accordance with 
the National Guidelines for stroke (National Stroke Foundation, 2005), in that 
routine prescription of AFO’s following stroke is not supported.  
The review of the literature has indicated that AFO’s can be of benefit to 
stroke patients and the use of AFO’s is common (Leung & Moseley, 2003). An 
assumption can be made that clinicians, such as physiotherapists, orthotists and 
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rehabilitation physicians, believe AFO’s to be useful, and that some patients 
share the same feelings as they continue to wear their AFO’s (de Wit et al., 2004; 
Tyson & Thornton, 2001).  It is also possible that AFO’s may have benefits that 
were not assessed in this study; such as improving a patient’s perception of their 
safety whilst walking, despite no identifiable change to their walking performance. 
Similarly, a physiotherapist may perceive a patient to walk more safely with an 
AFO, but on formative analysis or testing no discernible benefit was identified.  It 
is clear, however, that the prescription of AFO’s should include a thorough 
physical assessment and include assessment of gait parameters such as 
velocity, cadence, step length, stance and swing phases to ensure appropriate 
prescription to each individual patient (Condie, 2003; Tyson & Kent, 2009).  
 
 
5.2 The effect of AFO’s on healthy participants 
The careful consideration of prescription of AFO’s in the early stages of 
walking recovery following stroke was further supported by the effect that AFO’s 
have on healthy participants. When walking in an AFO the gait performance of 
healthy participants deteriorates. The findings of this study indicate that the more 
rigid the AFO, the greater the reduction in walking velocity, cadence, matched leg 
step length, and deterioration in matched leg swing time and the symmetry of 




The methodology of other investigations into the effect of AFO’s on the 
gait of healthy participants does not allow for easy comparison. Differences in the 
type of AFO examined and the age of the participants may account for 
differences in results.  Kitaoka et al., (2006) did not examine velocity but found 
differences in cadence comparing  shod walking to various AFO’s and 
differences in cadence when comparing AFO’s of differing construction. In this 
instance the least rigid AFO the PAB resulted in a cadence and velocity not 
differing significantly to shod walking and better than more restrictive AFO’s. 
Guillebastre, Calmels and Rougier (2009) demonstrated differences in velocity of 
AFO’s of varying construction, but not between AFO’s and barefoot walking;  less 
rigid AFO being faster than the more rigid AFO.  
The deterioration in walking of the healthy participants and the lack of 
improvement in walking of the stroke participants indicates that the effects of 
AFO prescription on gait may result in a negative outcome.  
 
5.3 The effects of AFO’s of varying rigidity 
The distinction in performance between AFO’s of varying rigidity is 
important. More rigid AFO’s, such as GRAFO’s (as represented by fibreglass 
casting) restrict the foot and ankle complex action resulting in reduced 
performance, as demonstrated by the deterioration in gait parameters seen in 
healthy participants in this study. This needs to be considered when prescribing 
AFO’s in pathologic situations.  Clinicians should have an understanding of how 
the brace being prescribed affects normal gait in order to ensure that their 
192 
 
prescription compensates in the desired manner. Differences in construction 
material and the inclusion of ankle articulations will alter the biomechanical 
effects of the AFO (Lehmann et al., 1987), namely less restrictive bracing will 
have different effects than more rigid AFO’s. No study has compared AFO’s of 
different modes of ankle control or rigidity (Table 5.1), and so comparison to this 
study is limited. The lack of a significant main effect in the stroke participants of 
this study, and the variability in response of participants, indicates that there can 
be no general recommendation from this study for prescribing AFO’s following 
stroke. The effect of reducing walking performance with increasing rigidity in 
healthy participants and the individual case differences suggests further 
examination is warranted.  This is further supported by Burdett et al. (1988) who 
found a minimally restrictive AFO sufficient to improve step length but not velocity 
in chronic stroke participants. Considering the results of the healthy participants, 
clinicians may consider prescribing the least rigid form of bracing that achieves 
improvement in gait parameters. However, more research in this area is needed 










5.4 Other considerations Knee analysis 
5.4.1 Reliability of the kinematic data 
 The reliability sub-study has indicated that in regards to the assessment of 
knee angle at initial contact, midstance has good interrater reliability and very 
good intrarater reliability. This result is similar to that of Cronin et al. (2006) who 
established similar reliability of knee angle in ten healthy males. Regarding 
terminal stance the interrater reliability could only be considered fair. However 
the clinical implication of lower reliability at terminal stance where the leg takes 
less body weight may reduce the clinical risk associated.  
 
5.4.2 Knee analysis of the stroke group 
A group analysis of the knee angle at initial contact, mid stance and 
terminal stance indicated that there was no difference under each AFO testing 
condition. With regard to differences between AFOs, a significant increase in 
knee flexion was seen at initial contact in the FGC condition compared to shod.    
The following section examines the effect of AFO use on knee angle at 
three points throughout the stance phase. It is divided into three points: initial 
contact, mid stance and terminal stance. Two studies have included the effect of 
AFO’s on knee angle (Fatone et al., 2009; Lehmann et al., 1987). Fatone et al. 
(2009) divided their participants into those who did or did not hyperextend and 
found that the design and construction of the AFO can influence the position of 
the knee through the stance phase. More specifically, for those that 
hyperextended, a more rigid design can assist in preventing that hyperextension. 
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Lehmann et al. (1987) also found that the angle the AFO was set at effects the 
angle of the knee through the stance phase, further emphasising the influence an 
AFO can have on knee angle. When the knee angles were considered, two 
individual stroke participants performance changed using an AFO. One 
participant improved using PAB and FGC. However, the small number of 
participants whose knee angles changed means that trends or conclusions 
cannot be drawn from these results.  Three of stroke participants who did not 
respond to an AFO were not able to achieve plantigrade due to either increased 
tone or reduced muscle length. These individuals may not have responded to an 
AFO as the limitation to their ankle range of movement would suggest the aim of 
achieving plantigrade in an AFO was not possible.  
The lack of definitive knee angle analysis from the use of motion capture 
technology (e.g. VICON), makes it difficult to interpret these results with 
confidence. However, the angle of the knee through the stance phase is of 
importance as it is believed that the knee can potentially be put at risk of 
structural damage if repeated hyperextension occurs. This must be considered if 
an AFO is being prescribed. Indeed the kinematics of the ankle, knee and hip 
through stance and swing phases when using an AFO is of interest and is yet to 







5.4.3 Knee analysis of the healthy group 
Similar to the stroke group, the angle of the knee at three points of the gait 
cycle were examined; initial contact, mid stance and terminal stance. No 
differences were detected at each of these points when comparing the five 
testing conditions. Individual analysis found that one participants’ knee angle 
changed at terminal stance in each of the three AFO’s. Having such a small 
number of responders does not allow any conclusions to be drawn. Considering 
that AFO’s can be designed to deliberately alter the position of the knee through 
the stance phase (Lehmann, Warren, & DeLateur, 1970) the lack of a clear effect 
on the knee angle of healthy participants indicates that; healthy participants can 
modulate their walking in some way to compensate for the altered kinematics of 














5.5 Potential indicators of responders to AFO’s 
The characteristics of individuals who are likely to benefit from AFO’s were 
unable to be determined from this study as there was no clear pattern regarding 
ROM, strength or spasticity that indicated that an AFO may be of benefit. It was 
noted that those with a dorsiflexion range less than plantigrade did not benefit 
from an AFO. The area of ankle impairment characteristics as a potential 
indicator for AFO prescription is one that needs to be considered in further 
studies. There was an indication of the responders being younger than the non-
responders, as indicated by Table 4.26. However the disparate and small sample 
sizes did not allow for relevant statistical analyses. 
 
5.6 Issues regarding variability in study design in the AFO literature  
As demonstrated in Table 5.1 there is wide variation in the studies to date, 
making comparison of outcomes difficult.  Study design is a factor that may 
influence these outcomes. The issues regarding the study design are considered 
in this section. 
 
5.6.1 Inclusion/ Exclusion criteria 
As has already been identified, the lack of similarity participant 
characteristics in studies similar to this may have resulted in different outcomes. 
Whilst not allowing easy comparison the differences in these characteristics may 
suggest they are of importance when considering AFO prescription. These 
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influences can be considered as: walking ability, ankle impairments, previous use 
of an AFO and duration since stroke.  
 
5.6.1.1 Walking ability  
Each of the stroke group participants’ was able to walk either with 
supervision or independently to be eligible for this study. Six participants walked 
for one or more condition with a velocity less than 0.4 m/sec which is indicative of 
being a household ambulator only (Perry et al., 1995) and only two participants 
were able to walk faster than 0.8 m/sec, indicating the ability to walk in the 
community (Perry et al., 1995). For eleven of the thirteen participants their 
walking velocity was limited to such a degree that could limit their abilities to 
engage in community activity.  Of the studies identified in Table 5.1 the baseline 
velocities had a wide range of response (18cm/sec – 61 cm/sec) indicating that 
there is little homogeneity in participant groups studied and that little 
comparisons can be drawn. 
 To be eligible for this study an ankle impairment that may lend itself to the 
prescription was present. As each participant was able to walk without an AFO, 
their ankle impairments may have not been the primary factor limiting their ability 
to walk. They may have already learnt to compensate for their impairment 
thereby reducing its functional influence. These factors may explain the limited 












5.6.1.2 Ankle Impairment 
There is little conformity between each study identified in Table 5.1 as to 
the nature or degree of ankle impairment of the participants. Only four studies 
identify or quantify muscle strength. Eleven studies indicated the presence of 
spasticity or ankle range of movement. Eight studies did not include any 
information about ankle impairments. Due to limitations in reporting ankle 
impairment characteristics it is difficult to determine similarities or differences 
between participants assessed. Further studies should consider better defining 
ankle characteristics in order to allow better definitions of those individuals with 
stroke who may benefit from an AFO. 
 
5.6.1.3 Previous AFO use  
Eight studies identified in Table 5.1 required use of an AFO for at least 
one month prior. This suggests that because an AFO had been previously 
prescribed it had already been determined that an AFO was of benefit and that 
the individual had ample opportunity to practice with their AFO. There was also 
the potential that the AFO had been prescribed to assist the individual to regain 
the ability to walk. Then, following achieving the ability to walk with an AFO, the 
individual learnt the ability to walk without and AFO. Under those circumstances 
the assumption is that walking with an AFO is the preferred option. In those 
cases, the results cannot be generalised to patients with stroke who have not 
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used an AFO previously and, therefore, it is likely that the effectiveness of AFO’s 
may be overstated.  
Two previous studies included patients who had not been prescribed an 
AFO (Gok et al., 2003; Wang et al., 2007). In both instances, significant 
differences were found for velocity, but not cadence. Wang et al. (2007) also 
found differences for step length, stride length and stance width. In each of these 
instances clinical relevance of the demonstrated difference was questionable, 
such as improvement in walking velocity of 4.45cm/sec in an AFO compared to 
without. The participants’ characteristics or protocol of each study were such that 
comparison would not yield relevant discussion regarding this study. Wang et al. 
(2007) included participants who did not have ankle impairment as demonstrated 
by mean tibialis anterior strength of the stroke patients of 22 pounds of force. 
Gok et al. (2003) examined different AFO’s to this study, primarily comparing 
metallic and plastic AFO’s. Whilst Gok et al. (2003) compared AFO’s of varying 
rigidity the differences may not have been as marked, such as is the case in this 
study.   
 
5.6.1.4 Duration of stroke  
The studies describing AFO use in stroke (Table 5.1) describe participants 
at varied points of their recovery.  Ten studies were of patients only in the chronic 
phase and six included patients in the subacute and chronic. The subacute 
phase and chronic phase post stroke are different stages in rehabilitation and it is 
likely that these phases should be investigated separately (Kreisel et al., 2007).  
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This study aimed to assess those participants in the early stages of 
walking recovery following stroke, once they had attained the ability to walk and 
in the presence of ankle impairment. Ten of the eighteen studies reported in 
Table 5.1 assessed participants who were at least six months post stroke, many 
of who had used an AFO for many months prior to assessment (as discussed 
above). The individuals in the chronic phase of their recovery or whose functional 
performance has stabilised will respond differently to those who are in the early 
stages of walking recovery for whom improvements in performance are still 
expected. Those who are in the acute phase of recovery may improve in their 
function due to practice, rehabilitation or natural recovery in addition to any 
adaptive device prescribed. Additionally, the findings of this study, in that an AFO 
may not be of benefit and that the healthy participants walking performance 
deteriorates raises the question of the use of AFO’s during the acute and 
subacute phases of stroke recovery. In that the prescription of an AFO may be  
detrimental due to inhibiting movement (Boake et al., 2007; Levy et al., 2007) 
when the brains ability to recover due to neuroplasticity is at its greatest (Nudo, 
2007; Ward, 2004). However, and AFO may provide benefit  as an AFO may 
improve mobility in circumstances more difficult than walking indoors on a level 
surface, such as indicated in improved stair climbing in the study of De Wit et al.  












5.7 Limitations of the Study 
This study did not control for neglect or perceptual changes affecting 
balance, other than participants being able to walk without hands-on assistance. 
The presence of a neglect or perceptual change may influence an individual’s 
gait performance. As perception or neglect was not measured the influence of 
those factors cannot be accurately assessed. Therefore any influence, positive or 
negative, that an AFO has on these impairments cannot be commented on. This 
raises the possibility that other factors that influence gait performance were not 
measured or controlled for which may have also influence the results of this 
study.  
A number of methodological limitations influenced the results of this study. 
Some of these have been commented on earlier in this chapter. The main 
limitation of the study is the characteristics of the stroke group. Survivors of 
stroke can display a wide range of characteristics. Any conclusions made using 
the results of this study as support should only be applied to those with similar 
characteristics.  Perhaps the weakest element of this is the exclusion of those 
who could only walk with assistance of a therapist as these individuals may 
benefit most from being prescribed an AFO.  Tyson and Thornton (2001) 
endeavoured to include these participants but by doing so their results for gait 
velocity may have been influenced by the effect of the person assisting the 
participant and not the intrinsic gait performance of the participant.  
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To spend a total of fifteen minutes acclimatizing to a new orthosis for 
individuals who had only recently begun to walk following stroke may have also 
affected the results. Further experience and practice with the AFO’s may have 
had stronger effects on the gait variables. However, allowing more experience 
with each AFO would have required extending the assessments over a number 
of days to limit fatigue. Results may then have been affected by recovery, as the 
participants were engaged in a comprehensive rehabilitation programme in the 
subacute stage of stroke where recovery is considerable.   
Further limiting the study is the small sample size of each group and the 
lack of a power calculation to establish the appropriate sample size. The sample 
sizes weakened the statistical analysis and limited the ability to make 
conclusions regarding a wider group of patients.  A larger sample size may have 
allowed for parametric statistical analysis to be performed.  
The measurement tools used also limited the depth to which any results 
could be explained however provided measures that may be more commonly 
available in specialist rehabilitation centres that commonly treat stroke patients. 
Spatio-temporal parameters of walking can be significantly supplemented and 
explained by kinematic analysis, ground reaction force results and 
electromyographic (EMG) data. Such data would help to explain why the results 
occurred, and not just a description of what results occurred. Particularly, the 
results of the angle of the knee through the stance phase should be regarded 
with caution. The Silicon Coach software was not available during data collection, 
thus markers were not attached to the greater trochanter, knee joint line or lateral 
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malleolus (in keeping with SiliconCoach protocol), however use of markers may 
have facilitated better identification of the knee angle. The decision to use Silicon 
Coach was made because only one of the studies reviewed in Table 5.1 (Fatone 
et al, 2009) considered the knee angle in a group of stroke participants.  In an 
ideal methodology, laboratory based measures would be included. Measurement 
tools which record the parameters identified above were not co-located with the 
participants. This limitation is mitigated to a certain extent by the good inter-rater 
reliability regarding initial contact and midstance but not in regards to terminal 
stance.  This study was limited in it assessed the effect of AFO’s on 
spatiotemporal parameters such as velocity and step length and knee angle. An 
AFO may also improve the energy cost of walking, perception of safety and 
reduce falls.  
Further limiting this study was that participants from a single rehabilitation 
unit were recruited. The philosophy and work practices of that unit may have 
influenced when a participant was eligible for recruitment. Particularly that the 
patients’ therapist may limit a patients walking until they have adequate lower 
limb control or balance to not be at risk of musculoskeletal injury such as via 
knee hyperextension. The study did not include walking on uneven or outdoors 
environments when an AFO may have brought about greater advantage. The 
varied use of gait aids by the stroke participants may have also influenced the 
results. 
The inclusion of a follow-up component to the analysis would have 
strengthened the study. To re-assess the stroke participant three or six months 
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following their initial assessment would have indicated how people with stroke 
recover and the number of who continued to use an AFO. Differences in 
performance of those that continued to use an AFO to their baseline data could 
also be enlightening.  
It is hoped, that as a preliminary study, the limitations identified in this 
study can utilised to develop better controlled studies and the methods improved 
to allow a greater understanding of the effects of AFO’s on the gait of stroke 
survivors and of healthy participants.  These can be summarised succinctly. 
Greater sample sizes are required, preferably via a multicentre trial as suggested 
by Condie (2003). A methodology that identifies spatiotemporal parameters of 
stroke survivors who require assistance to walk with reliability and validity would 
allow analysis of individuals for who an AFO may provide most benefit.  Analysis 
of impairments at the trunk, pelvis, hip, knee and ankle as well gait performance 
should be considered in order to potentially develop a tool which better identifies 
those individuals best suited to AFO prescription. Particular attention could be 
made to those who are prescribed AFO’s, assessing how their gait progresses 
and how, or if, their orthotic requirements change. 
In regards to the healthy participants similar methods should be applied. 
The most important advancement of the effect of AFO’s on healthy gait would be 
to assess spatiotemporal, kinematic, ground reaction force and EMG data in a 







5.8 Implications for further research 
 As has been demonstrated the benefit of AFO’s following stroke is varied. 
There is the potential for improvements to walking following AFO prescription, but 
equally there is the potential of no benefit. Further research is required to attempt 
to better identify who will benefit most and to which type of AFO will be most 
appropriate. Multicentre trials should be considered to control for local clinical 
practices and multiple AFO’s should be compared to determine their effects in 
stroke participants of differing abilities. These trials should include AFO’s of 
different design and construction materials to ensure broad variety of AFO type is 
considered, including articulated AFO’s. The ankle impairments of participants 
should be thoroughly assessed and reported to allow better comparison between 
studies and deeper understanding of the effect that ankle characteristics have on 
AFO response. 
 The reliability of Silicon Coach software in the assessment of kinematics in 
stroke also requires further attention including a larger number of participants 
and any influence of marking key anatomical points may have. 
Electromyographic assessment may be used to examine muscle activity when 
walking in an AFO. 
 Broader aspects of the benefits of AFO prescription should also be 
considered, including energy cost, patients perceived benefits, the effects on 
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AFO’s of reducing falls and the potential of AFO’s to improve walking on uneven 
ground or outdoors may be of interest. 
 It is hoped that the suggestions made above will allow greater 




5.9 Conclusion  
This study examined the effect of five different walking conditions 
(barefoot, shoes and three different AFO’s) on various spatiotemporal 
parameters of gait on thirteen people following a stroke who had recently begun 
to walk without assistance had specific impairment of ankle function. Thirteen 
healthy individual were also assessed in the same manner. The group of stroke 
participants and the group of healthy participants were examined in isolation of 
the other and comparatively. An analysis of individuals was also applied. 
The analysis of the data of the stroke group demonstrated that overall, 
AFO’s did not improve gait performance in relation to the parameters measured.  
Thus the initial hypotheses were not supported. Individual analyses 
demonstrated differential responses to AFO’s, both in terms of whether there was 
a benefit, and the type of AFO providing the benefit.   This study demonstrated 
that some individuals who respond to AFO use with improvements in gait 
parameters greater than the SRD. This was counterbalanced by individuals 
whose performance deteriorated when using an AFO by an amount greater than 
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the SRD. This indicates that AFO’s may be of benefit but also have the potential 
to negatively affect walking. The design of the study was such that the 
hypotheses could not be well tested due to the small sample size. Attempts to 
clarify physical characteristics of ankle impairments which may indicate that the 
prescription of an AFO is warranted were not able to establish any clinical 
markers for AFO prescription.  
Larger sample sizes may allow these questions to be elucidated. The 
analysis of the data of the healthy individuals was more conclusive. The findings 
were that the more rigid the AFO, as demonstrated by the results for FGC, 
brought about deterioration to the gait parameters.  
In summary, this study adds further evidence to the literature regarding the 
effect of AFO’s on the gait of people with stroke in the early stages of their 
walking recovery; and the effect of AFO’s on the gait of healthy individuals. 
Despite no clear trend regarding the effect of differing AFO’s there is an 
indication that AFO’s can be of benefit to the gait of some stroke survivors. 
However, clinicians should be aware of potential negative effects of AFO use and 
ensure individualised prescription of an AFO and careful, ongoing, assessment of 
the effects of the AFO. Further research into the immediate and long term effects 
of AFO’s on walking of stroke survivors and to the effects of AFO use on the gait 
of healthy individuals is warranted. Research into identifying which individuals 
would benefit most from an AFO following stroke is required.  It is necessary to 
consider this research in order to best optimise recovery from stroke to allow 
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Appendix C – Stroke Participant’s Consent Form 
 
PARTICIPANT INFORMATION AND CONSENT FORM  
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St Vincent’s Hospital, Melbourne, Australian Catholic University 
 
Version 7: Dated 8/10/2010 
Site: St Vincent’s Hospital and St George’s Hospital in association with 
Australian Catholic University 
 
Full Project Title: A preliminary study into the effectiveness of various foot orthoses 
on gait parameters in early stroke patients with varying ankle impairments. 
 
Principal Researcher:  Dr Elizabeth Bradshaw 
Associate Researchers: Dr Vanessa Rice (Australian Catholic University) 
    Kim Brock (St Vincent’s) 




This Participant Information and Consent Form is 5 pages long. Please make sure 
you have all the pages.  
You are invited to take part in this research project, which looks at the effect on 
walking of multiple types of ankle splints. Your physiotherapist has suggested you as 
a possible participant because you are having difficulty controlling your foot when 
walking following your stroke. The research project aims to investigate the different 
ankle splints available and determine the most appropriate splint for the different 
foot control problems that can occur following stroke.  
This Participant Information and Consent Form tells you about the research project. 
It explains what is involved to help you decide if you want to take part. 
Please read this information carefully. Ask questions about anything that you don’t 
understand or want to know more about. Before deciding whether or not to take part, you 
might want to talk about it with a relative, friend or your local health worker. 
Participation in this research is voluntary. If you don’t wish to take part, you don’t have 
to.  
If you decide you want to take part in the research project, you may be asked to sign the 
consent section. By signing it you are telling us that you: 
 understand what you have read;  
 consent to take part in the research project; 
 consent to be involved in the procedures described; 
 consent to the use of your personal and health information as described. 
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You will be given a copy of this Participant Information and Consent Form to keep. 
2. What is the purpose of this research project? 
The purpose of this project is to look for differences in the way people walk in the 
early stages following stroke whilst wearing different ankle splints. There is very little 
research into what happens to people’s walking in the early stages following stroke 
whilst wearing ankle splints, even though these splints are commonly used. This 
project will measure walking ability while wearing different types of splints, and 
compare this with the level of control the person has over their foot and ankle.  
Thirty people who are currently receiving rehabilitation will be invited to participate 
in this project. Each participant will be involved in testing each type of ankle splint. 
Participants will be divided into two groups depending on how their stroke has 
affected their foot and ankle function. Healthy, aged matched, participants will also 
be recruited to enable further comparison. 
The results of this research will be used by the researcher, Robert Mehan, to obtain a 
Masters of Exercise Science (Research) Degree, at Australian Catholic University. 
This research has been funded by the St. Vincent’s Research Endowment Fund. 
3. What does participation in this research project involve? 
Participation in this project will involve a testing protocol over three  consecutive 
days, for about 1.5hours on each occasion. Twelve weeks following your initial 
testing you will be followed up for further testing on one day only for approximately 
1.5 hours. The testing will occur at the Physiotherapy Department, St Vincent’s 
Hospital, Fitzroy Campus as it houses the necessary equipment to record the 
information required.  
Your first assessment will involve the physiotherapist assessing the strength and 
flexibility of your foot and ankle while you are sitting comfortably in a chair and lying 
on a bed. The walking tests will involve walking along a 10.5m runway which records 
the way in which you walk and walking over a second runway with a plate embedded 
which records pressure (approximately 5m). You will i walk along the runway in 
barefoot with no splint. You will then be tested wearing the ankle splints. Two of the 
ankle splints are ready made and sit inside your shoe. The third splint is a light 
fibreglass plaster cast which will be applied to your lower leg and then removed as 
soon as the test is over. The cast is removed using a vibrating plaster saw. Should 
you not have appropriate footwear, then it will be provided. When wearing the 
fiberglass cast special plaster boots will be provided. Your relative will be videotaped 
from side on to examine what movement is occurring at the knee joint under each 
testing condition. 
You will have time to practice walking and get used to each splint before the test is 
carried out. There are rest times built into the testing procedure so that you do not 
become tired. If you are tired, the testing can be stopped for a rest at any time. A 
physiotherapist will supervise your walking at all times and provide you with 
assistance if you require it. You can use any walking aid that you are currently using. 
The testing will take place over 3 days, 2 tests on the first day, 2 tests on the second 
day and one test on the third day.  The assessment of your ankle will be repeated 






You will be contacted approximately 12 weeks after your testing to arrange your 
follow-up. On this day the initial physiotherapy assessment will be repeated and you 
will walk on the walkway in your shoes without a splint. If you are wearing an ankle 
splint at this time, we will ask you to walk with your usual splint.  Again, a 
physiotherapist will supervise your walking at all times and provide you with 
assistance if you require it. 
 Reimbursement 
You will not be paid for your participation in this project. If required, reimbursement 
of taxi fares for the follow up visit can be provided. 
4. What are the possible benefits? 
The results of your tests will be provided to your physiotherapist and the in 
depth analysis may assist in deciding the suitability of ankle splints for you. 
However, we can not guarantee that you will receive any benefit from 
participating in the study. If the project is successful we hope it will allow the 
identification of patients who will benefit from ankle splints in the early stages 
following stroke. 
5. What are the possible risks? 
There are very few risks associated with participation in this project. Each aspect of 
intervention could reasonably occur in your normal physiotherapy treatment. 
There is a very small risk of a plaster saw grazing the skin when the fibreglass cast if 
removed with a plaster saw. The risks are minimised by using a large amount of 
padding beneath the plaster cast. The researcher who applies the fibreglass cast will 
be an experienced physiotherapist who has at least 5 years experience of applying 
fibreglass casts to individuals who have suffered strokes. 
On occasions the other ankle splints can be uncomfortable to wear. The discomfort 
can usually be eliminated by reapplication of the splint. 
There is a risk of losing balance and falling whilst walking. Your physiotherapist is 
trained in assessing the suitability you to be able to participate safely. 
6. Do I have to take part in this research project? 
Participation in any research project is voluntary. If you do not wish to take part, you 
do not have to. If you decide to take part and later change your mind, you are free 
to withdraw from the project at a later stage. 
Your decision whether or not to take part and then withdraw, will not affect your 
routine treatment, your relationship with those treating you or your relationship with 
St Vincent’s Hospital.  
7. How will I be informed of the final results of this research project? 
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If you wish to find out about the results of the study please let your physiotherapist 
know and we will forward a brief summary of the results to you, when the project is 
complete. 
8. What will happen to information about me? 
The information we gather regarding your stroke, the movement in your leg and 
your walking will be recorded. After the data collection is finished, we will allocate a 
code number to your data and no details that identify you will be stored. The data 
will be stored in a locked filing cabinet or in password protected computer files for 
seven years. After this period, the data will be destroyed.  
Any information obtained in connection with this project and that can identify you 
will remain confidential. It will only be disclosed with your permission, except as 
required by law. If you give us your permission by signing the Consent Form, we 
plan to publish the results of the study in a thesis and in a physiotherapy journal. In 
any publication, information will be provided in such a way that you cannot be 
identified.   
9. Can I access research information kept about me? 
In accordance with relevant Australian and/or Victorian privacy and other relevant 
laws, you have the right to access the information collected and stored by the 
researchers about you. Please contact one of the researchers named at the end of 
this document if you would like to access your information. 
In addition, in accordance with regulatory guidelines, the information collected in this 
research project will be kept for at least seven years. You must be aware that the 
information collected about you will not be able to be identified as outlined in point 8.  
Access to information about you at this point will not be possible. 
10. Is this research project approved? 
The ethical aspects of this research project have been approved by the Human 
Research Ethics Committee of St Vincent’s Hospital and by the Human Research 
Ethics Committee of Australian Catholic University. 
This project will be carried out according to the National Statement on Ethical 
Conduct in Human Research (2007) produced by the National Health and Medical 
Research Council of Australia. This statement has been developed to protect the 
interests of people who agree to participate in human research studies. 
11. Consent 
I have read, or have had this document read to me in a language that I understand, 
and I understand the purposes, procedures and risks of this research project as 
described within it. 
I have had an opportunity to ask questions and I am satisfied with the answers I 
have received. 
I freely agree to participate in this research project, as described.  
I understand that I will be given a signed copy of this document to keep. 
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Participant’s name (printed) …………………………………………………… 
Signature        Date 
Name of witness to participants signature (printed) ……………………………………………… 
Signature        Date 
Declaration by researcher*: I have given a verbal explanation of the research 
project, its procedures and risks and I believe that the participant has understood 
that explanation. 
Researcher’s name (printed) …………………………………………………… 
Signature        Date 
Note: All parties signing the consent section must date their own signature. 
12. Who can I contact? 
The person you may need to contact will depend on the nature of your query. 
Therefore, please note the following: 
 
For further information or appointments: 
If you want any further information concerning this project or if you have any 
problems which may be related to your involvement in the project (for example, 
feelings of distress), you can contact the principal researcher (Dr Elizabeth Bradshaw 






If you have any complaints about any aspect of the study or the way in which it is being 
conducted you may contact the Patient Liaison Officer at St Vincent’s Hospital 
(Melbourne) on Telephone: (03) 9288 3108. You will need to tell the Patient Liaison 
Officer the name of the person who is noted above as principal investigator. 
 
Alternatively you are able to contact the Chair of the Human Research and Ethics 
Committee, Australian Catholic University via the contact details below. The Patient 
Liaison Officer at St Vincent’s should be contacted in the first instance. 
VIC:Chair, HREC 
C/o Research Services 
Australian Catholic University 
Melbourne Campus 
Locked Bag 4115 
FITZROY VIC 3065 
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Tel: 03 9953 3158 
Fax: 03 9953 3315 
 
 
Research Participants Rights 
If you have any questions about your rights as a research participant, then you may 
contact the Executive Officer Research at St. Vincent’s Health on Telephone: 9288 3930 



















Appendix D – Healthy Participant Consent Form 
 
PARTICIPANT INFORMATION and consent form (Control) 




Version 1: Dated 8/10/2010 
Site: St Vincent’s Hospital and St George’s Hospital in association with Australian Catholic University 
 
Full Project Title: A preliminary study into the effectiveness of various foot orthoses 
on gait parameters in early stroke patients with varying ankle impairments. 
 
Principal Researcher:  Dr Elizabeth Bradshaw 
Associate Researchers: Dr Vanessa Rice  (Australian Catholic University) 
    Kim Brock (St Vincent’s) 
Student Researcher: Robert Mehan (St Vincent’s) 
_____________________________________________________________________ 
This Participant Information and Consent Form is 5 pages long. Please make sure 
you have all the pages.  
You are invited to take part in this research project, which looks at the effect on walking of multiple types 
of ankle splints. You have received initial information regarding this project via email seeking volunteers 
for healthy participants. The research project aims to investigate the different ankle splints available and 
determine the most appropriate splint for the different foot control problems that can occur following 
stroke.  
This Participant Information and Consent Form tells you about the research project. It 
explains what is involved to help you decide if you want to take part. 
Please read this information carefully. Ask questions about anything that you don’t 
understand or want to know more about. Before deciding whether or not to take part, you 
might want to talk about it with a relative, friend or your local health worker. 
Participation in this research is voluntary. If you don’t wish to take part, you don’t have 
to.  
If you decide you want to take part in the research project, you may be asked to sign the 
consent section. By signing it you are telling us that you: 
 understand what you have read;  
 consent to take part in the research project; 
consent to be involved in the procedures described; 
consent to the use of your personal and health information as described. 
You will be given a copy of this Participant Information and Consent Form to keep. 
2. What is the purpose of this research project? 
The purpose of this project is to look for differences in the way people walk whilst wearing different ankle 
splints. Then compare that to how similarly aged people walk in ankle splints following a stroke. There is 
very little research into what happens to people’s walking in the early stages following stroke whilst 
wearing ankle splints, even though these splints are commonly used. This project will measure walking 
ability while wearing different types of splints.   Each participant will be involved in testing each type of 
ankle splint. The results of this research will be used by the researcher, Robert Mehan, to obtain a Masters 
of Exercise Science (Research) Degree, at Australian Catholic University. 
This research has been funded by the St. Vincent’s Research Endowment Fund. 
3. What does participation in this research project involve? 
Participation in this project will involve a testing protocol over a single day, for about 1.5 hours. The 
testing will occur at the Physiotherapy Department, St Vincent’s Hospital, Fitzroy Campus as it houses the 
necessary equipment to record the information required.  
Your first assessment will involve the physiotherapist assessing the strength and flexibility of your foot and 
ankle while you are sitting comfortably in a chair and lying on a bed. The walking tests will involve 
walking along a 10.5m runway which records the way in which you walk and walking over a second 
runway with a plate embedded which records pressure (approximately 5m). You will walk along the 
runway in barefoot with no splint. You will then be tested wearing the ankle splints and in shoes. Two of 
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the ankle splints are ready made and sit inside your shoe. The third splint is a light fibreglass plaster cast 
which will be applied to your lower leg and then removed as soon as the test is over. The cast is removed 
using a vibrating plaster saw. Should you not have appropriate footwear, then it will be provided. When 
wearing the fiberglass cast special plaster boots will be provided. Your relative will be videotaped from 
side on to examine what movement is occurring at the knee joint under each testing condition. 
You will have time to practice walking and get used to each splint before the test is carried out. There are 
rest times built into the testing procedure so that you do not become tired. If you are tired, the testing can be 
stopped for a rest at any time. A physiotherapist will supervise your walking at all times and provide you 




You will not be paid for your participation in this project. If required, reimbursement of taxi fares for the 
follow up visit can be provided. 
4. What are the possible benefits? 
The results of your tests will be provided to your physiotherapist and the in depth 
analysis may assist in deciding the suitability of ankle splints for you. However, we can 
not guarantee that you will receive any benefit from participating in the study. If the 
project is successful we hope it will allow the identification of patients who will benefit 
from ankle splints in the early stages following stroke. 
5. What are the possible risks? 
There are very few risks associated with participation in this project. Each aspect of intervention could 
reasonably occur in your normal physiotherapy treatment. 
There is a very small risk of a plaster saw grazing the skin when the fibreglass cast if removed with a 
plaster saw. The risks are minimised by using a large amount of padding beneath the plaster cast. The 
researcher who applies the fibreglass cast will be an experienced physiotherapist who has at least 5 years 
experience of applying fibreglass casts to individuals who have suffered strokes. 
On occasions the other ankle splints can be uncomfortable to wear. The discomfort can usually be 
eliminated by reapplication of the splint. 
There is a risk of losing balance and falling whilst walking. Your physiotherapist is trained in assessing the 
suitability you to be able to participate safely. 
6. Do I have to take part in this research project? 
Participation in any research project is voluntary. If you do not wish to take part, you do not have to. If you 
decide to take part and later change your mind, you are free to withdraw from the project at a later stage. 
Your decision whether or not to take part and then withdraw, will not affect your routine treatment, your 
relationship with those treating you or your relationship with St Vincent’s Hospital.  
7. How will I be informed of the final results of this research project? 
If you wish to find out about the results of the study please let your physiotherapist know and we will 
forward a brief summary of the results to you, when the project is complete. 
8. What will happen to information about me? 
The information we gather, the movement in your leg and your walking will be recorded. After the data 
collection is finished, we will allocate a code number to your data and no details that identify you will be 
stored. The data will be stored in a locked filing cabinet or in password protected computer files for seven 
years. After this period, the data will be destroyed.  
Any information obtained in connection with this project and that can identify you will remain confidential. 
It will only be disclosed with your permission, except as required by law. If you give us your permission by 
signing the Consent Form, we plan to publish the results of the study in a thesis and in a physiotherapy 
journal. In any publication, information will be provided in such a way that you cannot be identified.   
9. Can I access research information kept about me? 
In accordance with relevant Australian and/or Victorian privacy and other relevant laws, you have the right 
to access the information collected and stored by the researchers about you. Please contact one of the 
researchers named at the end of this document if you would like to access your information. 
In addition, in accordance with regulatory guidelines, the information collected in this research project will 
be kept for at least seven years. You must be aware that the information collected about you will not be 
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10. Is this research project approved? 
The ethical aspects of this research project have been approved by the Human Research Ethics Committee 
of St Vincent’s Hospital and by the Human Research Ethics Committee of Australian Catholic University. 
This project will be carried out according to the National Statement on Ethical Conduct in Human 
Research (2007) produced by the National Health and Medical Research Council of Australia. This 
statement has been developed to protect the interests of people who agree to participate in human research 
studies. 
11. Consent 
I have read, or have had this document read to me in a language that I understand, and I understand the 
purposes, procedures and risks of this research project as described within it. 
I have had an opportunity to ask questions and I am satisfied with the answers I have received. 
I freely agree to participate in this research project, as described.  
I understand that I will be given a signed copy of this document to keep. 
Participant’s name (printed) …………………………………………………… 
Signature        Date 
Name of witness to participants signature (printed) ……………………………………………… 
Signature        Date 
Declaration by researcher*: I have given a verbal explanation of the research project, its procedures and 
risks and I believe that the participant has understood that explanation. 
Researcher’s name (printed) …………………………………………………… 
Signature        Date 
Note: All parties signing the consent section must date their own signature. 
12. Who can I contact? 
The person you may need to contact will depend on the nature of your query. Therefore, please note the 
following: 
 
For further information or appointments: 
If you want any further information concerning this project or if you have any problems which may be 
related to your involvement in the project (for example, feelings of distress), you can contact the principal 







If you have any complaints about any aspect of the study or the way in which it is being conducted you 
may contact the Patient Liaison Officer at St Vincent’s Hospital (Melbourne) on Telephone: (03) 9288 
3108. You will need to tell the Patient Liaison Officer the name of the person who is noted above as 
principal investigator. 
 
Alternatively you are able to contact the Chair of the Human Research and Ethics Committee, Australian 
Catholic University via the contact details below. The Patient Liaison Officer at St Vincent’s should be 
contacted in the first instance. 
VIC:Chair, HREC 
C/o Research Services 
Australian Catholic University 
Melbourne Campus 
Locked Bag 4115 
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FITZROY VIC 3065 
Tel: 03 9953 3158 
Fax: 03 9953 3315 
 
 
Research Participants Rights 
If you have any questions about your rights as a research participant, then you may contact the Executive 
Officer Research at St. Vincent’s Health on Telephone: 9288 3930 or the Chair of the Human Research and 


































Appendix E – Summary of the Tardieu Scale 
 
Tardieu Scale – from (Gracies, et al., 2000) 
Grading is always performed at the same time of the day, in a constant position 
of the body for a given limb. Other joint, particularly the neck, must also remain in 
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a constant position throughout the test and between tests. For each muscle 
group, reaction to stretch is rated at a specified stretch velocity with 2 
parameters, X and Y. 
Velocity of stretch: 
 V1: As slow as possible (minimizing stretch reflex). 
 V2: Speed of the limb segment falling under gravity. 
V3: As fast as possible (faster than the rate of the natural drop of the limb 
segment under gravity). 
Quality of muscle reaction (X): 
0: No resistance throughout the course of the passive movement. 
1: Slight resistance throughout the course of the passive movement, with 
no clear catch at a precise angle. 
2: Clear catch at a precise angle, interrupting the passive movement, 
followed by release. 
3: Fatigable clonus (<10 seconds when maintaining pressure) occurring at 
a precise angle. 
4: Infatigable clonus (>10 seconds when maintaining pressure) occurring 
at a precise angle. 
Angle of muscle reaction (Y): measured relative to the position of minimal stretch 
of the muscle (corresponding to angle 0) for all joints except hip, where it is 






Appendix F Box Plot – Individual stroke group velocity 
 
 
Stroke group box plot (median, IQR) – individual velocity results of each participant under each testing condition (PAB – 







Appendix G Box Plot – Individual stroke group double limb support  
 
Stroke group box plot (median, IQR) – individual double limb support percentage results of each participant under each 






Appendix H: Smallest Real difference bar graph– Individual stroke group affected leg single support phase 
 
 
Stroke participant individual bar graph demonstrating difference of affected leg single support phase from baseline 
(shoe result) under each testing condition. Values above or below lines indicate changes a result greater or less than 








Appendix I Box Plot – Individual stroke group affected leg single support phase 
 
 
Stroke group box plot (median, IQR) – individual affect leg single stance percentage results of each participant under 







Appendix J Box Plot – Individual stroke group stance symmetry ratio 
 
Stroke group box plot (median, IQR) – individual stance symmetry ratio results of each participant under each testing 






Appendix K Box Plot – Individual stroke group affected leg step length 
 
Stroke group box plot (median, IQR) – individual affected leg step length results of each participant under each testing 










Stroke participant individual bar graph demonstrating difference of affected leg swing phase from baseline (shoe result) 
under each testing condition. Values above or below lines indicate changes a result greater or less than the smallest 
real difference (PAB – Push Aequi Brace; SLAFO – Spring Leaf AFO; FGC – Fibreglass Cast) 
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Stroke group box plot (median, IQR) – individual affected leg swing results of each participant under each testing 








Stroke participant individual bar graph demonstrating difference of cadence from baseline (shoe result) under each 
testing condition. Values above or below lines indicate changes a result greater or less than the smallest real difference 




Appendix O Box Plot – Individual stroke group cadence 
 
 
Stroke group box plot (median, IQR) – individual cadence results of each participant under each testing condition (PAB 













Stroke group box plot (median, IQR) – individual knee angle at initial contact results of each participant under each 









Stroke group box plot (median, IQR) – individual knee angle at midstance results of each participant under each testing 













Stroke group box plot (median, IQR) – individual knee angle at terminal stance results of each participant under each 






Appendix S Box Plot – Individual healthy group velocity 
 
 
Healthy Participant individual box plot (median, IQR) – individual velocity results of each participant under each testing 








Appendix T Box Plot – Individual healthy group double limb support 
 
 
Participant individual box plot (median, IQR) – individual double limb support percentage results of each participant 











Healthy participant individual bar graph demonstrating difference of affected leg single support phase from baseline 
(shoe result) under each testing condition. Values above or below lines indicate changes a result greater or less than 






Appendix V Box Plot – Individual healthy group matched leg single support phase 
 
Healthy Participant individual box plot (median, IQR) – individual matched leg single support percentage results of each 












Appendix W Box Plot – Individual healthy group stance symmetry ratio 
 
Healthy Participant individual box plot (median, IQR) – individual stance symmetry ratio results of each participant 










Appendix X Box Plot – Individual healthy group matched leg step length 
 
 
Healthy participant individual box plot (median, IQR) – individual matched leg step length results of each participant 













Healthy participant individual bar graph demonstrating difference of matched leg swing phase from baseline (shoe 
result) under each testing condition. Values above or below lines indicate changes a result greater or less than the 






Appendix Z Box Plot – Individual healthy group matched leg swing phase 
 
 
Healthy Participant individual box plot (median, IQR) – individual matched leg swing phase results of each participant 











Healthy participant individual bar graph demonstrating difference of cadence from baseline (shoe result) under each 
testing condition. Values above or below lines indicate changes a result greater or less than the smallest real difference 








Healthy Participant individual box plot (median, IQR) – individual cadence results of each participant under each testing 





Appendix AC Smallest Real difference bar graph– Individual healthy group knee angle at initial contact 
 
Healthy participant individual bar graph demonstrating difference of knee angle at initial contact from baseline (shoe 
result) under each testing condition. Values above or below lines indicate changes a result greater or less than the 









Healthy Participant individual box plot (median, IQR) – individual knee angle at initial contact results of each participant 





Appendix AE Smallest Real difference bar graph– Individual healthy knee angle at midstance 
 
Healthy participant individual bar graph demonstrating difference of knee angle at midstance from baseline (shoe 
result) under each testing condition. Values above or below lines indicate changes a result greater or less than the 










Healthy Participant individual box plot (median, IQR) – individual knee angle at midstance results of each participant 




Appendix AG Box Plot – Individual healthy group knee angle at terminal stance 
 
 
Healthy Participant individual box plot (median, IQR) – individual knee angle at terminal stance results of each 
participant under each testing condition (PAB – Push Aequi Brace; SLAFO – Spring Leaf AFO; FGC – Fibreglass Cast) 
